



**CHAMPAIGN COUNTY BOARD
OPIOID SETTLEMENT TASK FORCE**

County of Champaign, Urbana, Illinois
Tuesday, May 20, 2025 - 6:30 p.m.

Shields-Carter Meeting Room
Brookens Administrative Center
1776 E. Washington St., Urbana

Committee Members:

Aaron Esry

John Farney

Jennifer Locke - Chair

Brett Peugh

Emily Rodriguez

Ed Sexton – Vice-Chair

Chris Stohr

Agenda Items

Page #'s

- I. Call to Order**
- II. Roll Call**
- III. Approval of Agenda/Addendum**
- IV. Approval of Minutes**
 - A. February 24, 2025 1-3
- V. Public Input**
- VI. Communications**
- VII. New Business**
 - A. Probation & Court Services
 - 1. Intergovernmental Agreement with the Probation & Court Services Department for transportation to treatment 4-19
 - 2. Master Agreement for Transportation Services 20-22
 - B. Coroner
 - 1. Request for Radox Evidence MultiSTAT Analyzer (*discussion only*) 23-34
 - 2. Intergovernmental Agreement with the Coroner's Office for a Radox Evidence MultiSTAT Analyzer 35-62
 - C. Champaign-Urbana Public Health Department
 - 1. Request to Expand Harm Reduction Services (*discussion only*) 63-81
 - 2. Agreement with CUPHD for the Purchase of Harm Reduction Equipment & Supplies 82-103
 - D. Next steps (*discussion only*)
- VIII. Other Business**
 - A. Date of next meeting
- IX. Chair's Report**
- X. Adjournment**

All meetings are at Brookens Administrative Center – 1776 E Washington Street in Urbana – unless otherwise noted. To enter Brookens after 4:30 p.m., enter at the north (rear) entrance located off Lierman Avenue. Champaign County will generally, upon request, provide appropriate aids and services leading to effective communication for qualified persons with disabilities. Please contact Administrative Services, 217-384-3776, as soon as possible but no later than 48 hours before the scheduled meeting.



CHAMPAIGN COUNTY BOARD
OPIOID SETTLEMENT TASK FORCE
County of Champaign, Urbana, Illinois

MINUTES – Subject to Approval

DATE: Monday, February 24, 2025
TIME: 6:30 p.m.
PLACE: Shields-Carter Meeting Room
Brookens Administrative Center
1776 E. Washington St., Urbana, IL 61802

Committee Members:

Present	Absent
Aaron Esry	
John Farney	
Brett Peugh	
Emily Rodriguez	
Ed Sexton (Vice-Chair)	
Chris Stohr	
Jennifer Locke (Chair)	

Others Present: Kait Kuzio (Grant Coordinator), and Megan Robison (Recording Secretary)

Agenda Items

I. Call to Order

Chair Locke called the meeting to order at 6:32 p.m.

II. Roll Call

A verbal roll call was taken, and a quorum was declared present.

III. Approval of Agenda/Addendum

MOTION by Mr. Sexton to approve the agenda; seconded by Ms. Rodriguez. Upon vote, the **MOTION CARRIED** unanimously.

IV. Approval of Minutes

A. November 13, 2024

MOTION by Mr. Esry to approve the minutes of November 13, 2024; seconded by Mr. Stohr. Upon vote, the **MOTION CARRIED** unanimously.

V. Public Participation

None

45 VI. Communications

46
47 Ms. Locke shared what other communities have are doing with their settlement funds. Peoria County
48 used funds to purchase an app for all of their drug court clients. The Florida Governor used settlement
49 funds to oppose a ballot measure to legalize marijuana. McLean County is using funds to pay an
50 employee at Chestnut Health Systems. She asked that everyone use their own personal judgment when
51 making decisions on ways to spend these funds.

52
53 VII. New Business

54 A. Contract with CU at Home for dedicated beds for opioid impacted individuals

55
56 Ms. Locke noted the changes in the agreement pointing out that CU at Home will be allocating ten beds
57 to be used exclusively for opioid impacted individuals. Ms. Kuzio mentioned that there is not a definition
58 of "opioid impacted" but rather it is dictated by the approved uses list in attachment D. They have
59 identified Drug Court, the County Jail and the Probation Department as being the prioritized clients for
60 the designated rooms.

61
62 Cedar King, Project Manager, joined the conversation and explained that they currently have eleven out
63 of twenty-seven clients that are impacted by opioids. He believes they will see even more opioid
64 impacted individuals as they add more beds. Ms. Rodriguez asked about the screening at intake. Mr.
65 King explained how their screening gives priority to certain groups. Mr. Peugh asked if they expect these
66 rooms to be underutilized and Mr. King does not believe and thinks they will continue to be at full
67 capacity.

68
69 **MOTION** by Mr. Stohr to recommend County Board approval of a resolution amending the contract with
70 CU at Home to include dedicated beds for opioid impacted individuals; seconded by Mr. Sexton. Upon
71 vote, the **MOTION CARRIED** unanimously.

72
73 B. Funding Request for Harm Reduction Program at CUPHD

74
75 Joe Trotter, Harm Reduction Program Coordinator, introduced himself and how his program helps
76 people that use drugs. Currently, they only receive partial funding for the number of syringes that they
77 disburse. They have a funding gap of \$12,000 for syringes. Board members continued to discuss details
78 of this program and how it works.

79
80 **MOTION** by Ms. Rodriguez to recommend County Board approval of a resolution authorizing a contract
81 for \$15,000 with the Harm Reduction Program at CUPHD; seconded by Mr. Stohr. Upon vote, the
82 **MOTION CARRIED** unanimously.

83
84 C. Next steps

85
86 Chair Locke had a meeting with the Mental Health Board Director about incorporating requests for
87 funding into their current process. She will be continuing those conversations. They will also be getting a
88 request from the County Coroner in the near future.

89
90 Ms. Rodriguez mentioned that they might be hearing from the Greater Aids Community Project.

91
92 Mr. Peugh will be reaching out to veteran groups to see if they have a need in their community

- 93 **VIII. Other Business**
- 94 A. Date of next meeting
- 95
- 96 None
- 97
- 98 **IX. Chair's Report**
- 99
- 100 None
- 101
- 102 **X. Adjournment**
- 103
- 104 Chair Locke adjourned the meeting at 7:15 p.m.
- 105
- 106
- 107
- 108

**INTERGOVERNMENTAL AGREEMENT BY AND BETWEEN THE COUNTY OF CHAMPAIGN,
ILLINOIS AND CHAMPAIGN COUNTY DEPARTMENT OF PROBATION AND COURT
SERVICES REGARDING THE USE OF OPIOID SETTLEMENT FUNDS FOR TRANSPORTATION**

This **AGREEMENT** is entered into by and between the County of Champaign, Illinois ("County"); and Champaign County Department of Probation and Court Services ("Probation") hereinafter collectively referred to as "the Parties", regarding funding for transportation of Department-involved individuals effective on the last date signed by a Party hereto.

Witnesseth:

WHEREAS, units of local government have conferred upon them the following powers by Article VII, Section 10, of the 1970 Illinois Constitution:

"(A) Units of local government and school districts may contract or otherwise associate themselves, with the State, with other States and their units of local government and school districts, and with the United States to obtain or share services and to exercise, combine or transfer any power or function, in any manner not prohibited by law or ordinance. Units of local government and school districts may contract and otherwise associate with individuals, associations, and corporations in any manner not prohibited by law or by ordinance. Participating units of government may use their credit, revenues and other resources to pay costs and to service debt related to intergovernmental activities"; and

WHEREAS, the County is a unit of local government within the meaning of Article VII, Section 1 of the Illinois Constitution of 1970 and is authorized to enter into contracts with individuals, associations, and corporations in any manner not prohibited by law or by ordinance; and

WHEREAS, County has received funds from the National Opioid Settlements to be used for opioid remediation purposes; and

WHEREAS, County has established a process to allocate those funds in accordance with applicable settlement requirements and local priorities; and

WHEREAS, Probation has requested funding to support opioid-impacted, department-involved individuals with transportation to and from treatment, recovery services, court-ordered programming, or related supportive services, the location of which can vary depending on availability; and

WHEREAS, both Parties agree that this funding will enhance community health outcomes and align with the intended use of Opioid Settlement Funds per Attachments C and D, List of Opioid Remediation Uses and Approved Uses of Opioid Settlement Funds as follows:

- Treat Opioid Use Disorder

- Support People in Treatment and Recovery
- Connect People Who Need Help to the Help They Need (Connections to Care)
- Address the Needs of the Criminal Justice-Involved Persons; and

WHEREAS, treatment facilities can range from within five miles to forty-five miles, the location is dependent on availability, and the County wishes to reduce transportation barriers to getting justice-involved individuals to treatment; and

WHEREAS, such provision of Opioid Settlement funding shall be construed as a subaward, with Probation as the subrecipient, and this Agreement construed as a subrecipient agreement; and

NOW, THEREFORE, in consideration of the premises and the mutual covenants hereafter set forth, the Parties agree as follows:

Section 1. PREAMBLE

The foregoing preambles are hereby incorporated into this Agreement as if fully restated in this Section 1.

Section 2. COUNTY agrees to the following:

- a. County shall provide Probation a one-time payment of \$2,000.00 in opioid settlement funding to assist with transportation which will support the County's response to the opioid crisis, particularly as it relates to justice-involved individuals. Probation acknowledges that this is a one-time payment and that future funding must be formally requested.
- b. County shall provide Probation a copy of Final Distributor Settlement Agreement (Schedules A and B of Exhibit E of the Opioid Settlement Agreement, attached hereto and) incorporated by reference herein as Attachment B and/or C, and shall provide Probation with updates as to any additional terms, conditions, or related communications from the Illinois Department of Human Services and by the Illinois Office of Opioid Settlement Administration within.
- c. County shall issue a one-time payment in the amount of \$2,000.00 to Probation no later than June 15, 2025, upon execution of this AGREEMENT.

Section 3. Probation agrees to the following:

- a. Probation agrees to utilize the \$2,000.00 in opioid settlement funding from the County to provide transportation of opioid-impacted individuals.

- b. Probation agrees to comply with all applicable federal, state, and local statutes, rules, regulations, and guidelines governing the use, management, and reporting of opioid settlement funds, including all requirements set forth in Attachments C and D by the Illinois Department of Human Services and by the Illinois Office of Opioid Settlement Administration within.
- c. Probation agrees to submit outcome or usage data upon request by the County. This may include the number individuals transported and the locations. Data may be shared in aggregate form and is not required to include personal identifiers.
- d. Probation certifies that it is not debarred, suspended, proposed for debarment or permanent inclusion on the Illinois Stop Payment List, declared ineligible, or voluntarily excluded from participation in the award as set forth in Attachments C and D or in this Agreement by any federal department or agency, or by the State of Illinois.

Section 4. Terms & Conditions:

a) Compliance

Probation shall ensure that the transportation services provided to individuals with this funding are specifically opioid-impacted, per the requirements set forth in Attachments C and D by the Illinois Department of Human Services.

b) Record-Keeping

Probation shall maintain record of the payments made with the provided funds for a minimum of 3 years and shall make such records available to the County upon request. The County may conduct a financial or programmatic review to verify the appropriate use of provided funds.

c) Amendments

This AGREEMENT may be amended only by writing signed by both parties.

d) Duration; Termination

The AGREEMENT shall become effective upon execution by both parties and shall remain in effect until the completion of the equipment purchase and confirmation of payment, unless otherwise terminated in accordance with the terms herein.

e) Repayment and Misuse of Funds

If Probation is found to have used funds for unauthorized purposes, fails to provide the required requested data for three years from the date of payment, the County reserves the right to request repayment of funds in whole or in part.

SIGNATURE PAGE

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly authorized officers on the date(s) below.

The County of Champaign, Illinois

Approved: _____

Steve Summers
County Executive
Champaign County

Date: _____

Approved: _____

Jennifer Locke
Board Chair
Champaign County

Date: _____

Champaign County – Department of Probation and Court Services

Approved: _____

Shannon Siders
Director
Champaign County Department of Probation and Court Services

Date: _____



Attachment C: List of Opioid Remediation Uses

Final Distributor Settlement Agreement – Exhibit E

Schedule A Core Strategies

Settling States and Exhibit G Participants may choose from among the abatement strategies listed in Schedule B. However, priority may be given to the following core abatement strategies (“*Core Strategies*”).¹

¹ As used in this Schedule A, words like “expand,” “fund,” “provide” or the like shall not indicate a preference for new or existing programs.

NALOXONE OR OTHER FDA-APPROVED DRUG TO REVERSE OPIOID OVERDOSES

Expand training for first responders, schools, community support groups and families; and

Increase distribution to individuals who are uninsured or whose insurance does not cover the needed service.

MEDICATION-ASSISTED TREATMENT (“MAT”) DISTRIBUTION AND OTHER OPIOID-RELATED TREATMENT

Increase distribution of MAT to individuals who are uninsured or whose insurance does not cover the needed service;

Provide education to school-based and youth-focused programs that discourage or prevent misuse;

Provide MAT education and awareness training to healthcare providers, EMTs, law enforcement, and other first responders; and

Provide treatment and recovery support services such as residential and inpatient treatment, intensive outpatient treatment, outpatient therapy or counseling, and recovery housing that allow or integrate medication and with other support services.

PREGNANT & POSTPARTUM WOMEN

Expand Screening, Brief Intervention, and Referral to Treatment (“*SBIRT*”) services to non-Medicaid eligible or uninsured pregnant women;

Expand comprehensive evidence-based treatment and recovery services, including MAT, for women with co- occurring Opioid Use Disorder (“*OUD*”) and other

Substance Use Disorder (“*SUD*”)/Mental Health disorders for uninsured individuals for up to 12 months postpartum; and

Provide comprehensive wrap-around services to individuals with OUD, including housing, transportation, job placement/training, and childcare.

□ EXPANDING TREATMENT FOR NEONATAL ABSTINENCE SYNDROME (“NAS”)

Expand comprehensive evidence-based and recovery support for NAS babies;

Expand services for better continuum of care with infant- need dyad; and

Expand long-term treatment and services for medical monitoring of NAS babies and their families.

□ EXPANSION OF WARM HAND-OFF PROGRAMS AND RECOVERY SERVICES

Expand services such as navigators and on-call teams to begin MAT in hospital emergency departments;

Expand warm hand-off services to transition to recovery services;

Broaden scope of recovery services to include co-occurring SUD or mental health conditions;

Provide comprehensive wrap-around services to individuals in recovery, including housing, transportation, job placement/training, and childcare; and

Hire additional social workers or other behavioral health workers to facilitate expansions above.

□ TREATMENT FOR INCARCERATED POPULATION

Provide evidence-based treatment and recovery support, including MAT for persons with OUD and co-occurring SUD/MH disorders within and transitioning out of the criminal justice system; and

Increase funding for jails to provide treatment to inmates with OUD.

□ PREVENTION PROGRAMS

Funding for media campaigns to prevent opioid use (similar to the FDA’s “Real Cost” campaign to prevent youth from misusing tobacco);

Funding for evidence-based prevention programs in schools;

Funding for medical provider education and outreach regarding best prescribing practices for opioids consistent with CDC guidelines, including providers at hospitals (academic detailing);

Funding for community drug disposal programs; and

Funding and training for first responders to participate in pre-arrest diversion programs, post-overdose response teams, or similar strategies that connect at-risk individuals to behavioral health services and supports.

□ EXPANDING SYRINGE SERVICE PROGRAMS

Provide comprehensive syringe services programs with more wrap-around services, including linkage to OUD treatment, access to sterile syringes and linkage to care and treatment of infectious diseases.

□ EVIDENCE-BASED DATA COLLECTION AND RESEARCH ANALYZING THE EFFECTIVENESS OF THE ABATEMENT STRATEGIES WITHIN THE STATE

Attachment D: Approved Uses of Opioid Settlement Funds

Final Distributor Settlement Agreement – Exhibit E

Schedule B Approved Uses

² As used in this Schedule B, words like “expand,” “fund,” “provide” or the like shall not indicate a preference for new or existing programs.

Support treatment of Opioid Use Disorder (OUD) and any co-occurring Substance Use Disorder or Mental Health (SUD/MH) conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

□ TREAT OPIOID USE DISORDER (OUD)

Support treatment of Opioid Use Disorder (“OUD”) and any co-occurring Substance Use Disorder or Mental Health (“SUD/MH”) conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, those that:²

Expand availability of treatment for OUD and any co-occurring SUD/MH conditions, including all forms of Medication-Assisted Treatment (“MAT”) approved by the U.S. Food and Drug Administration.

Support and reimburse evidence-based services that adhere to the American Society of Addiction Medicine (“ASAM”) continuum of care for OUD and any co-occurring SUD/MH conditions.

Expand telehealth to increase access to treatment for OUD and any co-occurring SUD/MH conditions, including MAT, as well as counseling, psychiatric support, and other treatment and recovery support services.

Improve oversight of Opioid Treatment Programs (“OTPs”) to assure evidence-based or evidence-informed practices such as adequate methadone dosing and low threshold approaches to treatment.

Support mobile intervention, treatment, and recovery services, offered by qualified professionals and service providers, such as peer recovery coaches, for persons with OUD and any co-occurring SUD/MH conditions and for persons who have experienced an opioid overdose.

Provide treatment of trauma for individuals with OUD (*e.g.*, violence, sexual assault, human trafficking, or adverse childhood experiences) and family members (*e.g.*, surviving family members after an overdose or overdose fatality), and training of health care personnel to identify and address such trauma.

Support evidence-based withdrawal management services for people with OUD and any co-occurring mental health conditions.

Provide training on MAT for health care providers, first responders, students, or other supporting professionals, such as peer recovery coaches or recovery outreach specialists, including telementoring to assist community-based providers in rural or underserved areas.

Support workforce development for addiction professionals who work with persons with OUD and any co-occurring SUD/MH conditions.

Offer fellowships for addiction medicine specialists for direct patient care, instructors, and clinical research for treatments.

Offer scholarships and supports for behavioral health practitioners or workers involved in addressing OUD and any co-occurring SUD/MH or mental health conditions, including, but not limited to, training, scholarships, fellowships, loan repayment programs, or other incentives for providers to work in rural or underserved areas.

Provide funding and training for clinicians to obtain a waiver under the federal Drug Addiction Treatment Act of 2000 (“DATA 2000”) to prescribe MAT for OUD, and provide technical assistance and professional support to clinicians who have obtained a DATA 2000 waiver.

Disseminate web-based training curricula, such as the American Academy of Addiction Psychiatry’s Provider Clinical Support Service–Opioids web-based training curriculum and motivational interviewing.

Develop and disseminate new curricula, such as the American Academy of Addiction Psychiatry’s Provider Clinical Support Service for Medication–Assisted Treatment.

□ SUPPORT PEOPLE IN TREATMENT AND RECOVERY

Support people in recovery from OUD and any co-occurring SUD/MH conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the programs or strategies that:

Provide comprehensive wrap-around services to individuals with OUD and any co-occurring SUD/MH conditions, including housing, transportation, education, job placement, job training, or childcare.

Provide the full continuum of care of treatment and recovery services for OUD and any co-occurring SUD/MH conditions, including supportive housing, peer support services and counseling, community navigators, case management, and connections to community-based services.

Provide counseling, peer-support, recovery case management and residential treatment with access to medications for those who need it to persons with OUD and any co-occurring SUD/MH conditions.

Provide access to housing for people with OUD and any co-occurring SUD/MH conditions, including supportive housing, recovery housing, housing assistance programs, training for housing providers, or recovery housing programs that allow or integrate FDA-approved medication with other support services.

Provide community support services, including social and legal services, to assist in deinstitutionalizing persons with OUD and any co-occurring SUD/MH conditions.

Support or expand peer-recovery centers, which may include support groups, social events, computer access, or other services for persons with OUD and any co-occurring SUD/MH conditions.

Provide or support transportation to treatment or recovery programs or services for persons with OUD and any co-occurring SUD/MH conditions.

Provide employment training or educational services for persons in treatment for or recovery from OUD and any co-occurring SUD/MH conditions.

Identify successful recovery programs such as physician, pilot, and college recovery programs, and provide support and technical assistance to increase the number and capacity of high-quality programs to help those in recovery.

Engage non-profits, faith-based communities, and community coalitions to support people in treatment and recovery and to support family members in their efforts to support the person with OUD in the family.

Provide training and development of procedures for government staff to appropriately interact and provide social and other services to individuals with or in recovery from OUD, including reducing stigma.

Support stigma reduction efforts regarding treatment and support for persons with OUD, including reducing the stigma on effective treatment.

Create or support culturally appropriate services and programs for persons with OUD and any co-occurring SUD/MH conditions, including new Americans.

Create and/or support recovery high schools.

Hire or train behavioral health workers to provide or expand any of the services or supports listed above.

CONNECT PEOPLE WHO NEED HELP TO THE HELP THEY NEED (CONNECTIONS TO CARE)

Provide connections to care for people who have—or are at risk of developing—OUD and any co-occurring SUD/MH conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, those that:

Ensure that health care providers are screening for OUD and other risk factors and know how to appropriately counsel and treat (or refer if necessary) a patient for OUD treatment.

Fund SBIRT programs to reduce the transition from use to disorders, including SBIRT services to pregnant women who are uninsured or not eligible for Medicaid.

Provide training and long-term implementation of SBIRT in key systems (health, schools, colleges, criminal justice, and probation), with a focus on youth and young adults when transition from misuse to opioid disorder is common.

Purchase automated versions of SBIRT and support ongoing costs of the technology.

Expand services such as navigators and on-call teams to begin MAT in hospital emergency departments.

Provide training for emergency room personnel treating opioid overdose patients on post-discharge planning, including community referrals for MAT, recovery case management or support services.

Support hospital programs that transition persons with OUD and any co-occurring SUD/MH conditions, or persons who have experienced an opioid overdose, into clinically appropriate follow-up care through a bridge clinic or similar approach.

Support crisis stabilization centers that serve as an alternative to hospital emergency departments for persons with OUD and any co-occurring SUD/MH conditions or persons that have experienced an opioid overdose.

Support the work of Emergency Medical Systems, including peer support specialists, to connect individuals to treatment or other appropriate services following an opioid overdose or other opioid-related adverse event.

Provide funding for peer support specialists or recovery coaches in emergency departments, detox facilities, recovery centers, recovery housing, or similar settings; offer services, supports, or connections to care to persons with OUD and any co-occurring SUD/MH conditions or to persons who have experienced an opioid overdose.

Expand warm hand-off services to transition to recovery services.

Create or support school-based contacts that parents can engage with to seek immediate treatment services for their child; and support prevention, intervention, treatment, and recovery programs focused on young people.

Develop and support best practices on addressing OUD in the workplace.

Support assistance programs for health care providers with OUD.

Engage non-profits and the faith community as a system to support outreach for treatment.

Support centralized call centers that provide information and connections to appropriate services and supports for persons with OUD and any co-occurring SUD/MH conditions.

□ ADDRESS THE NEEDS OF CRIMINAL JUSTICE-INVOLVED PERSONS

Address the needs of persons with OUD and any co-occurring SUD/MH conditions who are involved in, are at risk of becoming involved in, or are transitioning out of the criminal justice system through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, those that:

Support pre-arrest or pre-arraignment diversion and deflection strategies for persons with OUD and any co-occurring SUD/MH conditions, including established strategies such as:

Self-referral strategies such as the Angel Programs or the Police Assisted Addiction Recovery Initiative (“PAARI”);

Active outreach strategies such as the Drug Abuse Response Team (“DART”) model;

“Naloxone Plus” strategies, which work to ensure that individuals who have received naloxone to reverse the effects of an overdose are then linked to treatment programs or other appropriate services;

Officer prevention strategies, such as the Law Enforcement Assisted Diversion (“LEAD”) model;

Officer intervention strategies such as the Leon County, Florida Adult Civil Citation Network or the Chicago Westside Narcotics Diversion to Treatment Initiative; or

Co-responder and/or alternative responder models to address OUD-related 911 calls with greater SUD expertise.

Support pre-trial services that connect individuals with OUD and any co-occurring SUD/MH conditions to evidence-informed treatment, including MAT, and related services.

Support treatment and recovery courts that provide evidence-based options for persons with OUD and any co-occurring SUD/MH conditions.

Provide evidence-informed treatment, including MAT, recovery support, harm reduction, or other appropriate services to individuals with OUD and any co-occurring SUD/MH conditions who are incarcerated in jail or prison.

Provide evidence-informed treatment, including MAT, recovery support, harm reduction, or other appropriate services to individuals with OUD and any co-occurring SUD/MH conditions who are leaving jail or prison or have recently left jail or prison, are on probation or parole, are under community corrections supervision, or are in re-entry programs or facilities.

Support critical time interventions (“CTI”), particularly for individuals living with dual-diagnosis OUD/serious mental illness, and services for individuals who face immediate risks and service needs and risks upon release from correctional settings.

Provide training on best practices for addressing the needs of criminal justice-involved persons with OUD and any co-occurring SUD/MH conditions to law enforcement, correctional, or judicial personnel or to providers of treatment, recovery, harm reduction, case management, or other services offered in connection with any of the strategies described in this section.

□ ADDRESS THE NEEDS OF PREGNANT OR PARENTING WOMEN AND THEIR FAMILIES, INCLUDING BABIES WITH NEONATAL ABSTINENCE SYNDROME

Address the needs of pregnant or parenting women with OUD and any co-occurring SUD/MH conditions, and the needs of their families, including babies with neonatal

abstinence syndrome (“NAS”), through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, those that:

Support evidence-based or evidence-informed treatment, including MAT, recovery services and supports, and prevention services for pregnant women—or women who could become pregnant—who have OUD and any co-occurring SUD/MH conditions, and other measures to educate and provide support to families affected by Neonatal Abstinence Syndrome.

Expand comprehensive evidence-based treatment and recovery services, including MAT, for uninsured women with OUD and any co-occurring SUD/MH conditions for up to 12 months postpartum.

Provide training for obstetricians or other healthcare personnel who work with pregnant women and their families regarding treatment of OUD and any co-occurring SUD/MH conditions.

Expand comprehensive evidence-based treatment and recovery support for NAS babies; expand services for better continuum of care with infant-need dyad; and expand long-term treatment and services for medical monitoring of NAS babies and their families.

Provide training to health care providers who work with pregnant or parenting women on best practices for compliance with federal requirements that children born with NAS get referred to appropriate services and receive a plan of safe care.

Provide child and family supports for parenting women with OUD and any co-occurring SUD/MH conditions.

Provide enhanced family support and childcare services for parents with OUD and any co-occurring SUD/MH conditions.

Provide enhanced support for children and family members suffering trauma as a result of addiction in the family; and offer trauma-informed behavioral health treatment for adverse childhood events.

Offer home-based wrap-around services to persons with OUD and any co-occurring SUD/MH conditions, including, but not limited to, parent skills training.

Provide support for Children’s Services—Fund additional positions and services, including supportive housing and other residential services, relating to children being removed from the home and/or placed in foster care due to custodial opioid use.

□ PREVENT OVER-PRESCRIBING AND ENSURE APPROPRIATE PRESCRIBING AND DISPENSING OF OPIOIDS

Support efforts to prevent over-prescribing and ensure appropriate prescribing and dispensing of opioids through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

Funding medical provider education and outreach regarding best prescribing practices for opioids consistent with the Guidelines for Prescribing Opioids for Chronic Pain from the U.S. Centers for Disease Control and Prevention, including providers at hospitals (academic detailing).

Training for health care providers regarding safe and responsible opioid prescribing, dosing, and tapering patients off opioids.

Continuing Medical Education (CME) on appropriate prescribing of opioids.

Providing Support for non-opioid pain treatment alternatives, including training providers to offer or refer to multi-modal, evidence-informed treatment of pain.

Supporting enhancements or improvements to Prescription Drug Monitoring Programs (“PDMPs”), including, but not limited to, improvements that:

Increase the number of prescribers using PDMPs;

Improve point-of-care decision-making by increasing the quantity, quality, or format of data available to prescribers using PDMPs, by improving the interface that prescribers use to access PDMP data, or both; or

Enable states to use PDMP data in support of surveillance or intervention strategies, including MAT referrals and follow-up for individuals identified within PDMP data as likely to experience OUD in a manner that complies with all relevant privacy and security laws and rules.

Ensuring PDMPs incorporate available overdose/naloxone deployment data, including the United States Department of Transportation’s Emergency Medical Technician overdose database in a manner that complies with all relevant privacy and security laws and rules.

Increasing electronic prescribing to prevent diversion or forgery.

Educating dispensers on appropriate opioid dispensing.

□ PREVENT MISUSE OF OPIOIDS

Support efforts to discourage or prevent misuse of opioids through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

Funding media campaigns to prevent opioid misuse.

Corrective advertising or affirmative public education campaigns based on evidence.

Public education relating to drug disposal.

Drug take-back disposal or destruction programs.

Funding community anti-drug coalitions that engage in drug prevention efforts.

Supporting community coalitions in implementing evidence-informed prevention, such as reduced social access and physical access, stigma reduction—including staffing, educational campaigns, support for people in treatment or recovery, or training of coalitions in evidence-informed implementation, including the Strategic Prevention Framework developed by the U.S. Substance Abuse and Mental Health Services Administration (“SAMHSA”).

Engaging non-profits and faith-based communities as systems to support prevention.

Funding evidence-based prevention programs in schools or evidence-informed school and community education programs and campaigns for students, families, school employees, school athletic programs, parent-teacher and student associations, and others.

School-based or youth-focused programs or strategies that have demonstrated effectiveness in preventing drug misuse and seem likely to be effective in preventing the uptake and use of opioids.

Create or support community-based education or intervention services for families, youth, and adolescents at risk for OUD and any co-occurring SUD/MH conditions.

Support evidence-informed programs or curricula to address mental health needs of young people who may be at risk of misusing opioids or other drugs, including emotional modulation and resilience skills.

Support greater access to mental health services and supports for young people, including services and supports provided by school nurses, behavioral health workers or other school staff, to address mental health needs in young people that (when not properly addressed) increase the risk of opioid or another drug misuse.

□ PREVENT OVERDOSE DEATHS AND OTHER HARMS (HARM REDUCTION)

Support efforts to prevent or reduce overdose deaths or other opioid-related harms through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

Increased availability and distribution of naloxone and other drugs that treat overdoses for first responders, overdose patients, individuals with OUD and their friends and family members, schools, community navigators and outreach workers, persons being released from jail or prison, or other members of the general public.

Public health entities providing free naloxone to anyone in the community.

Training and education regarding naloxone and other drugs that treat overdoses for first responders, overdose patients, patients taking opioids, families, schools, community support groups, and other members of the general public.

Enabling school nurses and other school staff to respond to opioid overdoses, and provide them with naloxone, training, and support.

Expanding, improving, or developing data tracking software and applications for overdoses/naloxone revivals.

Public education relating to emergency responses to overdoses.

Public education relating to immunity and Good Samaritan laws.

Educating first responders regarding the existence and operation of immunity and Good Samaritan laws.

Syringe service programs and other evidence-informed programs to reduce harms associated with intravenous drug use, including supplies, staffing, space, peer support services, referrals to treatment, fentanyl checking, connections to care, and the full range of harm reduction and treatment services provided by these programs.

Expanding access to testing and treatment for infectious diseases such as HIV and Hepatitis C resulting from intravenous opioid use.

Supporting mobile units that offer or provide referrals to harm reduction services, treatment, recovery supports, health care, or other appropriate services to persons that use opioids or persons with OUD and any co-occurring SUD/MH conditions.

Providing training in harm reduction strategies to health care providers, students, peer recovery coaches, recovery outreach specialists, or other professionals that provide care to persons who use opioids or persons with OUD and any co-occurring SUD/MH conditions.

Supporting screening for fentanyl in routine clinical toxicology testing.

□ FIRST RESPONDERS

In addition to items in section C, D and H relating to first responders, support the following:

Education of law enforcement or other first responders regarding appropriate practices and precautions when dealing with fentanyl or other drugs.

Provision of wellness and support services for first responders and others who experience secondary trauma associated with opioid-related emergency events.

□ LEADERSHIP, PLANNING AND COORDINATION

Support efforts to provide leadership, planning, coordination, facilitations, training and technical assistance to abate the opioid epidemic through activities, programs, or strategies that may include, but are not limited to, the following:

Statewide, regional, local or community regional planning to identify root causes of addiction and overdose, goals for reducing harms related to the opioid epidemic, and areas and populations with the

greatest needs for treatment intervention services, and to support training and technical assistance and other strategies to abate the opioid epidemic described in this opioid abatement strategy list.

A dashboard to (a) share reports, recommendations, or plans to spend opioid settlement funds; (b) to show how opioid settlement funds have been spent; (c) to report program or strategy outcomes; or (d) to track, share or visualize key opioid- or health-related indicators and supports as identified through collaborative statewide, regional, local or community processes.

Invest in infrastructure or staffing at government or not-for-profit agencies to support collaborative, cross-system coordination with the purpose of preventing overprescribing, opioid misuse, or opioid overdoses, treating those with OUD and any co-occurring SUD/MH conditions, supporting them in treatment or recovery, connecting them to care, or implementing other strategies to abate the opioid epidemic described in this opioid abatement strategy list.

Provide resources to staff government oversight and management of opioid abatement programs.

□ TRAINING

In addition to the training referred to throughout this document, support training to abate the opioid epidemic through activities, programs, or strategies that may include, but are not limited to, those that:

Provide funding for staff training or networking programs and services to improve the capability of government, community, and not-for-profit entities to abate the opioid crisis.

Support infrastructure and staffing for collaborative cross-system coordination to prevent opioid misuse, prevent overdoses, and treat those with OUD and any co-occurring SUD/MH conditions, or implement other strategies to abate the opioid epidemic described in this opioid abatement strategy list (*e.g.*, health care, primary care, pharmacies, PDMPs, etc.).

□ RESEARCH

Support opioid abatement research that may include, but is not limited to, the following:

Monitoring, surveillance, data collection and evaluation of programs and strategies described in this opioid abatement strategy list.

Research non-opioid treatment of chronic pain.

Research on improved service delivery for modalities such as SBIRT that demonstrate promising but mixed results in populations vulnerable to opioid use disorders.

Research on novel harm reduction and prevention efforts such as the provision of fentanyl test strips.

Research on innovative supply-side enforcement efforts such as improved detection of mail-based delivery of synthetic opioids.

Expanded research on swift/certain/fair models to reduce and deter opioid misuse within criminal justice populations that build upon promising approaches used to address other substances (*e.g.*, Hawaii HOPE and Dakota 24/7).

Epidemiological surveillance of OUD-related behaviors in critical populations, including individuals entering the criminal justice system, including, but not limited to approaches modeled on the Arrestee Drug Abuse Monitoring (“ADAM”) system.

Qualitative and quantitative research regarding public health risks and harm reduction opportunities within illicit drug markets, including surveys of market participants who sell or distribute illicit opioids.

Geospatial analysis of access barriers to MAT and their association with treatment engagement and treatment outcomes.

Agreement for Transportation Services

Between County of Champaign Department of Probation and Court Services and [INSERT NAME]

This Agreement (“Agreement”) is made as of the date of final signature, by and between County of Champaign Department of Probation and Court Services (“Department”), a department of County of Champaign, Illinois, and [TRANSPORT COMPANY NAME] (“Provider”).

1. Purpose

The Department seeks transportation services from Provider on an as-needed basis. This Agreement outlines the general terms under which Provider may be called upon to deliver individuals to and from Department-specified locations.

2. Scope of Services

Provider agrees to:

- Provide timely and safe point-to-point transportation for individuals as requested by the Department;
- Follow all pick-up and drop-off instructions provided;
- Notify the Department immediately of any delays, service disruptions, or incidents during transport.

Provider is responsible only for transportation and is not responsible for supervision or monitoring of individuals transported.

3. Payment

Provider shall charge the Department’s authorized credit card at the time of service or in accordance with a schedule mutually agreed upon by both parties.

Rates shall be as follows: [\$_____] per trip/per mile/per hour (specify).

No invoices will be submitted or required.

4. Insurance

Provider shall maintain:

- Commercial automobile liability insurance with coverage of no less than \$1,000,000 per occurrence;

- Any additional insurance required under applicable law.

Proof of insurance shall be provided to the Department upon execution of this Agreement and upon renewal.

5. Term and Termination

This Agreement shall be effective from [Start Date] through [End Date], unless terminated earlier.

Either party may terminate this Agreement at any time with ten (10) days' written notice.

The Department will terminate immediately for cause.

6. Legal Compliance

Provider shall comply with all applicable federal, state, and local laws and regulations governing its operations.

7. Confidentiality

Provider shall maintain the confidentiality of any non-public information obtained in the course of providing services under this Agreement and shall not disclose any personal information about individuals transported, except as required by law.

8. Independent Contractor

Provider is an independent contractor and not an employee, agent, or representative of County of Champaign or the Department.

9. Indemnification

Provider agrees to indemnify, defend, and hold harmless Champaign County, including its employees and the Department of Probation and Court Services, from any claims, damages, or losses resulting from Provider's actions while providing transportation services under this Agreement.

10. Entire Agreement

This Agreement constitutes the entire understanding between the parties. Any amendments must be made in writing and signed by both parties.

Remainder of page left intentionally blank.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date below.

County of Champaign, Illinois Department of Probation and Court Services

Approved: _____ Date: _____
Shannon Siders
Director
Champaign County Department of Probation and Court Services

[Transport Company Name]

Approved: _____ Date: _____
[name]
[title]

From: Laurie A. Brauer <lbrauer@champaigncountyil.gov>
Sent: Tuesday, March 4, 2025 3:55 PM
To: Kaitlyn M. Kuzio <kaitlyn.kuzio@champaigncountyil.gov>
Subject: RE: Follow up about Randox

Hi Kaitlyn,

Thank you so much for meeting with me regarding the Randox Analyzer. The Randox Evidence Multistat Analyzer is \$79,244. The invoice includes the analyzer, shipping, accessory package and 12 quantitative kits.

MultiSTAT Benefits to Champaign County Coroner's Office

- **Results in under 30 Minutes** – greatly reduces the wait time for results.
- **Semi-Quantitative Results** – the biochip allows for the identification of substances and metabolites present in a post-mortem sample.
- **Multiplexing Technology** – our test menu can detect over 600 drugs and drug metabolites
- **Reduced False Positives** – specific antibodies on the biochip enable the separation of drugs with the same parent type. Example, Amphetamines, Benzodiazepines, Oxycodone, fentanyl and 6-MAM.

The Savings for Champaign County Coroner's Office

- Champaign County has roughly 205,000 people in population.
- As per the most recent annual report, toxicology was performed on approximately 250 cases in 2023.
- As per the most recent annual report, autopsies were performed in approximately 30% of death investigations.
- The current toxicology process ranges from \$300 -\$600 for screen and confirmation results.

By utilizing the MultiSTAT, we would spend about **\$40-50** per decedent. Plus, we would gain the benefit of a greatly reduced result time allowing us to provide faster answers to the families of our decedents and local law enforcement and public health agencies.

How can Champaign County use the MultiSTAT?

- Everyday use for any case where toxicology is warranted.
- Can be used for Drug Court.
- Testing in Blood, Urine, Oral Fluids and, Saliva samples.
- Employment Screening.
- Drug Testing for the Jails.
- Can be used to alert local authorities to the prevalence or rise in dangerous drugs in the community.

- Can decrease the need for full autopsies – saving the county money when performing Randox toxicology only is an alternative.
- Signing of death certificates more expeditiously in toxicology only cases.
- Assisting in expediting arrest warrants (prevention usage).

Having the positive quantitative results that Randox would provide in real time will also benefit the Overdose fatality review board. The overdose fatality review boards are multidisciplinary teams that are established on the state, city, or county level to examine and understand the circumstances surrounding fatal drug overdoses. These teams review fatal drug overdose cases via decedent reviews within their jurisdictions in order to determine what factors and characteristics may lead to a possible overdose, and to identify missed opportunities and system gaps in hopes of preventing future overdose deaths.

Please let me know if you have any other questions.



Laurie Brauer | Coroner
Champaign County Coroner's Office
p. (217) 384-3888 f. (217) 384-1209
lbrauer@champaigncountyil.gov

From: Kaitlyn M. Kuzio <kaitlyn.kuzio@champaigncountyil.gov>
Sent: Wednesday, March 5, 2025 08:23
To: Laurie A. Brauer <lbrauer@champaigncountyil.gov>
Subject: RE: Follow up about Randox

Hi Laurie,

Is this \$79,244 is the total you're requesting or are there additional related expenses. For instance, you'd talked about warranty, etc.

Best,
Kait

Good morning,

Yes the \$79,244 is the total, the warranty cost will be after the first year and each year after that so I didn't include it.



Laurie Brauer | Coroner
Champaign County Coroner's Office
p. (217) 384-3888 f. (217) 384-1209
lbrauer@champaigncountyil.gov

Evidence MULTISTAT proposal

Our Reference: rdxtox/usa-IN10

Dear **Laurie Brauer**,


Randox Toxicology is pleased to offer this proposal for the purchase of the Multistat analyzer for toxicology drug screening and testing in the medical examiner's office. This analyzer is an excellent analyzer for fast and accurate screening of drugs in the postmortem workflow process.

The Evidence Multistat analyzer and Biochip Array Technology will allow for reliable analysis of toxicology specimen in blood, urine, or oral fluid.

Fully automated bench top analyzer

- 3 samples per hour
- Results in 17 minutes
- 1,000 patient data storage capability
- LIS compatible
- CV less than 10%
- Touch screen color monitor

We are excited at the possibility of the analyzer being considered for procurement in your lab and we look forward to working with the lab.



Randox Laboratories-US Limited, 515 Industrial Boulevard, Bardane Industrial Park, Kearneysville, WV, 25430
T +1 304 728 2890 Toll Free: 866 4 RANDOX F +304 728 1890 Toll Free: 866 RANDOX I

Randox Toxicology Limited is a company registered within Northern Ireland. Company number: NI 606013 VAT Registered Number: GB 151682708



FINANCIAL PROPOSAL

Name	Laurie Brauer
Organization	Champaign County Coroner Office
Address	202 Art Bartell Rd, Urbana, IL 61802

Ref. No. rdxtox/usa- ILCHMS1	Randox Contact Curtis Miller	Date January 31, 2025
Contract Type Outright Purchase	Contract Period N/A	Minimum Purchase none

Evidence Multistat Analyzer **\$60,000.00**

Cat. No. EV4115

Consisting of: Analyzer; Equipment Installation; Training of two operators; Operator's manual; One year's analyzer warranty

Shipping **\$ 2,500**

Accessory Package **\$ 5,500**

Consisting of: Roller mixer, MicroCentrifuge, 2ml centrifuge tubes, Tube rack, (20), 200ul pipette, (20) 300ul tip reloads, (100) 1000ul pipette, (50) 1250ul tip reloads

Evidence MultiSTAT – ToxPlex Quant Kit **\$937/kit**

Cat. No. EV4156 (Blood)

Expected Annual Testing Expense (1 ToxPlex per month) **\$11,244/yr**

*Consisting of: 24 Biochips x 29 tests per Biochip = 696 tests (two samples per cartridge)
Multi-analyte reagents and consumables.*

Total Purchase Order **\$79,244**

Order includes; Multistat analyzer, Shipping, Accessory package, 12 ToxPlex Quantitative kits



ToxPlex Quantitative Drug Panel
Cat. No. EV4156 (Blood)

1. Acetaminophen	16. Meprobamate
2. Amphetamines	17. Methamphetamine
3. Barbiturates	18. Methadone
4. Benzodiazepines I (Oxazepam)	19. Methaqualone
5. Benzodiazepines II(Clonazepam)	20. Opiate
6. Cocaine (Benzoylecgonine)	21. Oxycodone
7. Buprenorphine	22. Phencyclidine (PCP)
8. Cannabinoids (THC)	23. Pregabalin
9. Xylazine	24. Propoxyphene
10. Dextromethorphan	25. Salicylate
11. Ethyl Glucuronide (ETG)	26. Tramadol
12. Fentanyl	27. Tricyclic Antidepressants
13. Haloperidol	28. Zolpidem
14. Ketamine	29. 6-MAM(Heroin)
15. MDMA	

Accessory Package Components

VWR Item #	Item Description
75838-336	CENTRIFUGE MICRO 16100 X G 15000 RPM
76462-034	ROLLER-MIXER VACUUM TUBE 36RPM 1
20170-170	TUBE PP CAP NAT 2ML PK500
76337-380	RACK 96 PLACE ASSORTED W/O LID PK5
76627-798	UHP 1 CHANNEL 20-200 µL
76627-770	UHP 1 CHANNEL 100-1000 µL

QUOTATION TERMS AND CONDITIONS

Delivery

The analyzer and other products delivered within six (6) weeks of receipt of confirmed purchase order.

Installation and Training

Installation will take place at the customer premises as soon as requested after delivery of the analyzer. A technical specialist shall conduct the training course, which will take the form of a three-day course for as three operators.

Payment and Credit Terms

Credit terms of 30 days from product delivery.

Warranty Period and Service

The analyzer will be covered by a comprehensive warranty for the period of 12 months from the date of installation. This warranty covers all costs of parts, travel and labor.

Customer and Technical Support

Immediate technical support provided by telephone, with 48-hour turnaround onsite technical support.

ALL PRICES QUOTED ARE EXCLUSIVE OF TAX AND FREIGHT.

F.O.B. Kearneysville, WV

Evaluation of “Real-Time” Fatal Drug Overdose Surveillance by King County Medical Examiner's Office, Seattle, Washington

Richard Harruff, MD, PhD, Celia M. Simpson, BS, Amy L. Gifford, BS, Nicole Yarid, MD,
William L. Barbour, BS, and Catherine Heidere, MSW

Abstract: To address the challenges in monitoring the continuously accelerating drug overdose epidemic, the King County Medical Examiner's Office in Seattle, Washington, instituted a “real-time” fatal drug overdose surveillance project, depending on scene investigations, autopsy findings, and in-house testing of blood, urine, and drug evidence collected from death scenes. Validation of the project's rapid death certification methodology from 2019 through 2021 was performed at the following 3 levels: blood testing, urine testing, and death certification, and for the following 4 drugs: fentanyl, opiate, methamphetamine, and cocaine. For blood testing, sensitivity ranged from 90% to 99%, and specificity ranged from 86% to 97%. For urine testing, sensitivity ranged from 91% to 92%, and specificity ranged from 87% to 97%. The positive predictive value for cocaine was poor for both blood testing (57%) and urine testing (72%). Of 1034 deaths, 807 were certified as overdose by rapid methodology, and 803 (99.5%) were confirmed by formal toxicology results. Manners of death were changed from accident to natural in 3 of 1034 cases (0.29%). Results of this study indicate that the rapid overdose surveillance methodology described in this study offers benefits to families and provides useful, timely information for responding law enforcement and public health agencies.

Key Words: forensic pathology, drug overdose surveillance, toxicology, drug evidence testing, validation

(*Am J Forensic Med Pathol* 2023;44: 11–16)

As the overdose epidemic continues to accelerate throughout the United States,^{1–4} the goal of achieving an effective surveillance strategy by rapidly identifying the appearance and identity of specific drugs has become increasingly important.^{5–12} National, regional, and local trends are all important for monitoring the impact on our communities as manifestations of the epidemic vary temporally and regionally, especially with respect to the appearance of novel synthetic drugs and seemingly limitless supplies of fentanyl and inexpensive methamphetamine.^{13–20} The COVID-19 pandemic superimposed further complications that remain largely uncharted.^{21,22} Monitoring the drug overdose epidemic is crucial to informing public health and criminal justice responses and guiding rational drug policies. Chief among the metrics for monitoring the crisis are mortality data derived from death certificates generated by medical examiner and coroner offices relying on analyses from toxicology laboratories. Because of the burgeoning caseload of overdose deaths relative to limited resources, crucial death investigation systems have been overwhelmed, resulting in long delays in completing death certificates.^{5–7,12,16,19,21}

As the escalating overdose epidemic overwhelmed resources in the Pacific Northwest, the King County Medical Examiner's Office (KCMEO) in Seattle, Washington, an agency of Public Health–Seattle and King County, created a rapid fatal overdose surveillance system with the goal of rapidly certifying drug overdose deaths and identifying the specific drugs involved.^{11,12} This project involved dedicated personnel, specialized testing instruments, development of methodologies, and multiagency collaborations. In many instances, rapid death certification (RDC) reduced delays in death certification from weeks or months to hours or days and provided information critical for timely law enforcement and public health responses. The purposes of this report are to evaluate RDC and to validate the methods employed.

METHODS AND MATERIALS

The KCMEO serves a population of approximately 2.3 million in a mixed urban and rural population in a geographic area of 2307 square miles. Seattle is the largest city with population of approximately 0.74 million. During the 3 years of this study, the KCMEO had from 10 to 12 medicolegal death investigators who responded to death scenes, gathered information, examined decedents for evidence relative to cause and manner of death, and collected items of suspicious drugs and paraphernalia. Items of drug evidence were transported along with decedents to the KCMEO facility. In-house testing was performed on deaths due to probable overdose, identified using an algorithm described, and validated previously.¹¹ This study found the algorithm alone to be accurate in identifying probable overdose deaths, with a sensitivity of 83% and a positive predictive value (PPV) of 89%. The median time between death and identification as a probable overdose was 1 day, and the interquartile range was 1 to 2 days.¹¹

In-house testing for RDC comprised the following 3 parts: (1) testing of urine collected at autopsy using BTNX Rapid Response fentanyl-specific dipsticks and 1-Step Detect MultiDrug Rapid Test Cups, which hold an array of 14 different drug test strips (Table 1); (2) testing of autopsy blood using Randox Evidence MultiSTAT chemiluminescence immunoanalyzer with an array of 20 different drugs (Table 1); and (3) testing of drug evidence collected at scenes such as pills, powders, crystals, pipes, straws, syringes, scorched foil, and other paraphernalia, using 2 Raman spectrometers (ThermoFisher TruNarc and Rigaku ResQ), MX908 high-pressure mass spectrometer, and BTNX Rapid Response fentanyl-specific urine dipsticks on evidence samples appropriately diluted into water. Blood samples were submitted to the Washington State Patrol (WSP) Toxicology Laboratory for comprehensive testing. The WSP Toxicology Laboratory, in turn, used NMS Labs (Horsham, Pa) to manage backlogged cases. Both toxicology laboratories used immunoassay screening for the common drug categories, gas chromatography–mass spectrometry for confirmation and quantitation of cocaine, and liquid chromatography–tandem mass spectrometry for confirmation and quantitation of fentanyl, methamphetamine, and opiate. After in-house testing

Manuscript received July 27, 2022; accepted August 25, 2022.

From the King County Medical Examiner's Office, Seattle, WA. The authors report no conflict of interest.

Reprints: Richard C. Harruff, MD, PhD, King County Medical Examiner's Office, 325 Ninth Ave, HMC Box 359792, Seattle, WA 98104. E-mail: richard.harruff@kingcounty.gov.

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

ISSN: 0195-7910/23/4401-0011

DOI: 10.1097/PAF.0000000000000798

TABLE 1. Analytes in Blood and Urine Testing Used for Rapid Death Certification

Analytes in Blood and Urine Screening Methods	1-Step Detect MultiDrug Rapid Test Cups
Randox Evidence MultiSTAT	
ABCHMINACA	Amphetamine
ABPINACA	Benzodiazepine
ALPHAPVP	Buprenorphine
Amphetamine	Carfentanyl
Barbiturate	Cocaine
Benzodiazepine	Ethyl glucuronide
Benzoyllecgonine	Fentanyl
Buprenorphine	Methadone
Ethyl glucuronide	Methamphetamine
Fentanyl	Morphine
Methadone	Oxycodone
Methamphetamine	Synthetic marijuana
6-Monoacetylmorphine	Tetrahydrocannabinol
Opiate	Tramadol
Oxycodone	
PCP	
Pregabalin	
Tetrahydrocannabinol	
Tramadol	
Tricyclic antidepressants	

of drug evidence collected at scenes, using the instruments described previously, these items were submitted to the WSP Crime Laboratory, Materials Analysis Section, for confirmatory testing by gas chromatography–mass spectrometry and infrared spectroscopy.

Rapid death certification for individual deaths was based on concurrence of scene investigations, autopsy findings, and in-house testing. A specific drug was listed on the death certificate if at least 2 independent tests of the 3 (blood testing, urine testing, and drug evidence testing) were positive for the same drug. By these combined methodologies, overdose deaths were certified within hours or few days. For those certified by RDC, the cause of death used the wording, “Acute (combination) drug intoxication including <specific drug(s) identified>”; this wording carries the implication that additional drugs may be added to the death certificate after receiving results of formal toxicology analysis. At the time of certification, to indicate specific cases in which RDC methodology was used to certify the death, whether as an overdose or to exclude overdose, the certifying pathologist would “flag” the case in a special database field. After results from the WSP Toxicology Laboratory were received, the results were used to confirm the initial death certificates based on RDC methodology or to amend them by affidavit, if necessary, adding drugs that were not identified by in-house testing or removing drugs that were not identified by WSP results.

The KCMEO developed and maintains a surveillance database structure specific for the in-house testing and other activities generating data related to fatal overdose surveillance. The surveillance database is linked by case number to KCMEO's case management system (CME Case Management Software; VertiQ Software LLC, Morgan Hill, Calif). CME is likewise linked to the Washington Department of Health Electronic Death Registration System (EDRS). After the death certificate is filed with the Washington Department of Health, the EDRS record is permanent and remains unchanged, while the CME record is updated with results from the WSP Toxicology Laboratory.

Evaluation and validation of RDC were performed for the following 4 major drugs: opiate, fentanyl, methamphetamine, and cocaine. As described earlier²³ and used in this report, “opiate” in contrast to the general drug category, “opioid,” refers to heroin or probable heroin because morphine, with or without 6-monoacetylmorphine, is reported in toxicology analyses. With in-house urine and blood testing, “cocaine” refers to cocaine or benzoyllecgonine. Validation was performed at the following 3 levels: blood testing, urine testing, and death certification. The WSP Toxicology Laboratory results served as the “criterion standard” for validation at all levels. Validation at the death certificate level was accomplished by comparing the initial death certificates filed in EDRS with the final death certificate in CME, identified by the RDC flag described previously. Data queries using tools of Microsoft SQL Server Management Studio, Visual Studio, Access, and Excel generated the tables for this report. Sensitivity, specificity, PPV and negative predictive value (NPV), and accuracy were computed using standard methods.²⁴ The Venn diagram in the Figure 1 was constructed using R/RStudio with the *VennDiagram* package. Because this study used only deidentified, aggregate data from decedents, institutional review by University of Washington, Human Subjects Division, were not required.

RESULTS

Over the 3 years of this study, 2019 through 2021, there were a total of 47,778 deaths in King County, of which KCMEO took jurisdiction in 11,080. A total of 1797 deaths (3.8% of all King County deaths and 16% of KCMEO jurisdictional cases) were certified as overdose deaths; 1710 were certified as overdose as a primary cause, and the others listed overdose as other significant condition (OSC). The RDC methods allowed rapid certification of 1005 overdose deaths (56% of all overdose deaths in the same period). In these 3 years, blood testing was performed on 1915 decedents, urine testing was performed in 1992, and drug evidence testing was done on 6047 items collected from 1213




FIGURE 1. Diagram showing extent of in-house testing. BT, blood testing; UT, urine testing; DT, drug evidence testing.

death scenes. A subset of these were used to calculate performance metrics of 1507 in-house blood testing results (Table 2) and 1172 in-house urine testing results (Table 3).

There were 1034 death certificate records that were initially certified by RDC methodology, flagged as described earlier, with which to compare the final death certificates completed after receiving WSP toxicology results. Table 4A shows that of the 1034 initial deaths certificates based on RDC methodology, 807 had overdose as the primary cause of death, 19 listed overdose as a contributing condition, 10 were certified with causes other than overdose, and 198 certificates remained pending, awaiting toxicology results from WSP. After the toxicology results were received, the pending cases were updated. In the final death certificates, shown in Table 4B, overdose as a primary cause accounted for 989; of these 652 (66%) were due to a combination of drugs. Of the 807 overdose deaths initially certified as the primary cause by RDC testing, 803 (99.5%) were confirmed as overdose after obtaining formal toxicology results. Table 5 compares initial death certification, based on

RDC methodology, with final certification, based on WSP toxicology results, and the agreement between the two, for each of the 4 drugs independently. In this analysis, the false-negative rates ranged from 2.9% for cocaine to 15% for methamphetamine, and the false-positive rates ranged from 0.29% for methamphetamine to 1.6% for cocaine. Death certificates were amended accordingly; that is, drugs were added to the amended death certificates for the false negatives and removed from the false positives. Tables 6 to 9 provide more extensive performance metrics of RDC relative to the extent of the individual in-house testing modalities: 991 cases of blood testing only, 730 cases of blood and urine testing, 656 cases of blood and drug evidence testing, and 504 cases having all 3 in-house testing modalities—blood, urine, and drug evidence. Overall, blood testing was most important, with 991 of the 1034 cases certified using blood testing in concurrence with urine and/or drug testing. The Venn diagram in the Figure 1 further illustrates the relative extent of testing among the 3 modalities. As expected, as the extent of testing increased, fewer cases were in each category.

TABLE 2. Sensitivity, PPV, Specificity, NPV, and Accuracy for In-House Blood Testing of 1507 Decedent Samples Compared With WSP Toxicology Results of Blood Testing

Drug	Sensitivity, %	PPV, %	Specificity, %	NPV, %	Accuracy, %
Fentanyl	97	90	94	98	95
Methamphetamine	90	95	97	93	94
Opiate/morphine	92	89	95	97	95
Cocaine	99	57	86	100	88

TABLE 3. Sensitivity, PPV, Specificity, NPV, and Accuracy for In-House Urine Testing of 1172 Decedent Samples Compared With WSP Toxicology Results of Blood Testing

Drug	Sensitivity, PPV, Specificity, NPV, Accuracy,				
	%	%	%	%	%
Fentanyl	92	79	87	95	88
Methamphetamine	91	94	97	95	94
Opiate/morphine	91	75	92	97	92
Cocaine	92	72	95	99	94

In addition, specificity increased with the extent of testing while sensitivity decreased. With respect to manner of death, of the 813 deaths initially certified accident by RDC methodology (Table 4A), 5 were amended otherwise: 3 deaths initially certified accident (overdose) were amended to natural (2 heart disease and 1 alcoholic liver disease with an OSC of chronic drug use), one was amended to suicide (overdose), and one was amended to undetermined (overdose). Taking amendment from an unnatural manner to a natural manner as the most serious false positive, the overall error rate in manner certification was 0.29% (3/1034).

DISCUSSION

Guidelines for certification of overdose deaths published by the National Association of Medical Examiners²⁵ recommend against using screening methods to certify deaths because of the inherent false-positive rates of these tests.^{26,27} While this study certainly supports this recommendation, the results also indicate that RDC can be achieved in many cases by the RDC methodology described herein, adhering to a strict protocol relying on concurrence of information gathered from scene investigation, autopsy findings, screening autopsy blood and urine, and testing drug evidence collected from scenes. Over the 3-year period KCMEO certified 56% of 1797 overdose deaths within 1 to 3 days. Using formal toxicology testing as the “criterion standard” for comparison, both the sensitivities and negative predictive values of blood and urine screenings were greater than 90% for all 4 drugs, indicating that these screening tests were fairly good in detecting the presence or absence of drugs. The specificities and PPVs for 3 of the 4 were 89% or greater, indicating that the blood and urine screening tests

TABLE 5. Drugs Present in 1034 Death Certificates Based on RDC Methodology (Initial DC) Compared With Certification Following WSP Results (Final DC) and Agreement Between the Initial and Final Certification (Both) Along With Calculated FN and FP Rates

Drug	Initial	Final	Both, n	FN, %	FP, %
	DC, n	DC, n			
Fentanyl	406	493	393	8.4	1.3
Methamphetamine	363	514	360	15	0.29
Opiate/morphine	254	341	240	8.4	1.4
Cocaine	187	217	170	2.9	1.6

FN, false negative; FP, false positive.

were also fairly good in excluding the presence or absence of drugs. The exception was for cocaine because of a high false-positive rate; only 57% of positive blood screening tests were correct, and only 72% of urine screening tests were correct. Accuracy, the overall probability that the screening test gave a correct result, positive or negative, ranged from 88% to 95% for the 4 drugs evaluated.

For death certification, the most important considerations are correctly classifying overdose as the cause of death and, even more importantly, correctly classifying the manner of death. By RDC methodology, certification relied on a combination of the following 3 independent means: blood testing, urine testing, and drug evidence testing. The probability of error in certification was reduced by adhering to the “2-test” rule: a drug was listed on the death certificate only if 2 independent tests found the same drug. Comparing initial death certificates based on RDC methodology with final death certificates based on WSP toxicology results and taking the latter as the “criterion standard” for comparison found that adding an additional test to blood screening, although reducing sensitivity, substantially enhanced the specificity of certification for all drugs, even for cocaine; specificities ranged from 98% to 100% if all 3 tests were employed. Although certain death certificates were amended after receiving WSP results, either adding or removing drugs, as indicated in Table 5, this was considered a relatively minor error because the cause of death remained overdose and the manner remained accident. Because most overdose deaths (66%) in this study were due to a combination of drugs, the probability of

TABLE 4. (A) Death Certification Based on Rapid Death Certification Compared With (B) Certification Completed After Receiving WSP Toxicology Results

A. Death Certified by RDC Methodology	Manner of Death					Total
	Accident	Suicide	Natural	Undetermined	Pending/Blank	
Drug OD primary	791	10	0	6	0	807
Drug OD (OSC)*	19	0	0	0	0	19
Not drug OD	3	1	6	0	NA	10
Total	813	11	6	6	198	1034

B. Death Certified After WSP Results	Manner of Death					Total
	Accident	Suicide	Natural	Undetermined	Homicide	
Drug OD primary	965	14	0	9	1	989
Drug OD (OSC)*	21	0	0	0	0	21
Not drug OD	4	0	19	1	0	24
Total	990	14	19	10	1	1034

*Other significant conditions.

TABLE 6. Sensitivity, PPV, Specificity, NPV, and Accuracy of In-House Blood Testing of 991 Cases Compared With Final Death Certification

Drug	Sensitivity, PPV, Specificity, NPV, Accuracy,				
	%	%	%	%	%
Fentanyl	99	93	93	99	96
Methamphetamine	92	98	98	92	95
Opiate/morphine	96	90	94	98	95
Cocaine	100	70	87	100	90

correctly classifying an overdose death was very high (essentially 100%) even if some of the drugs listed on the initial death certificate were not confirmed by the toxicology laboratory results. On the other hand, changing the manner of death from accident to natural constituted a major error; this occurred in 3 of 1034 cases. Nevertheless, the overall probability of correctly classifying the manner of death was very high (99.7%).

There are definite reasons to certify overdose deaths rapidly: to benefit families who want to understand the reason for their loved ones' deaths and need death certificates for settling insurance and other business matters; to facilitate timely responses by law enforcement and public health agencies; to quickly identify emergence of novel drugs in a community; and to expedite collection of mortality data. Testing of drug evidence offers another dimension of surveillance. Although testing of drug evidence is rarely performed by medical examiner and coroner offices, this added dimension of overdose surveillance allows rapid identification of novel drugs, formulations, and routes of administrations occurring in the local community.^{28,29} Furthermore, the collaboration in this project, between KCMEO and the WSP Crime Laboratory, represents a notable example of uniting resources of public health and criminal justice agencies in surveillance of illicit drugs.

There are disadvantages in RDC. It is resource intensive, requiring personnel, equipment, and funding not usually part of a medical examiner or coroner office. To deploy RDC methodology, the KCMEO made use of federal grants for purchase of instruments and supplies and to fund key positions; student interns from local colleges were found to be reliable and cost-effective. Data management was especially challenging in maintaining consistency and updating death certificates after receiving WSP toxicology results. Affidavits were often required to amend the official Certification of Death. However, another challenge was discovered when the Washington Department of Health compared data for entry into the State Unintentional Drug Overdose Reporting System; the death certificate affidavits were not making their way into the data stream for State Unintentional Drug Overdose Reporting System entry. This problem is currently being resolved and represents a growing need for data science in exploiting the valuable information collected by medical examiners and coroners.³⁰

TABLE 7. Sensitivity, PPV, Specificity, NPV, and Accuracy for In-House Blood Testing Combined With Urine Testing of 730 Cases, Compared With Final Death Certification

Drug	Sensitivity, PPV, Specificity, NPV, Accuracy,				
	%	%	%	%	%
Fentanyl	93	97	97	92	95
Methamphetamine	88	99	99	90	94
Opiate/morphine	93	93	97	97	96
Cocaine	94	89	97	98	96

TABLE 8. Sensitivity, PPV, Specificity, NPV, and Accuracy for In-House Blood Testing Combined With Drug Evidence Testing of 656 Cases, Compared With Final Death Certification

Drug	Sensitivity, PPV, Specificity, NPV, Accuracy,				
	%	%	%	%	%
Fentanyl	73	99	99	78	86
Methamphetamine	75	100	100	78	86
Opiate/morphine	75	95	98	97	89
Cocaine	58	82	96	88	87

Limitations of this study and RDC methodology were largely due to the separation of KCMEO from the testing laboratories and the length of time between postmortem examination and final certification. Although excellent collaboration existed between KCMEO and WSP for the period of study, the WSP toxicology laboratory depended heavily on NMS Labs to manage their backlog. Thus, there were long delays, weeks to months, between specimen collection and receipt of final toxicology results. Furthermore, discrepancies between RDC testing and final toxicology results were difficult to resolve, requiring communications with 2 different laboratories, both external to KCMEO. This limitation was especially challenging in resolving discrepancies in results for cocaine. Part of cocaine's discrepancy seemed to be due to higher levels of reporting positive results by the toxicology laboratories compared with in-house blood testing for RDC; the higher threshold of the toxicology laboratory may have resulted in false-negative results. For example, in certain cases, scene investigation, blood testing, urine testing, and drug evidence testing all indicated cocaine's involvement in the overdose in the absence of a positive toxicology laboratory result; communicating directly with the toxicology laboratory analysts confirmed the presence of cocaine or benzoylecgonine but at levels below their reporting limit. On the other hand, relying on RDC data in the face of conflicting toxicology laboratory results jeopardized the concept of the "criterion standard." This problem deserves further study. Another limitation was due to the way death certificates were identified for analysis in this study; this depended on the certifying pathologist remembering to flag the case as described earlier. Thus, some cases initially certified by RDC may have been missed in the present analysis. On the other hand, over the course of the 3 years encompassed by this study, KCMEO pathologists became more familiar and confident with the processes, leading to a gradual maturation in using RDC methodology.

In summary, this study shows that the methods described offer a reasonable means of rapidly issuing death certificates, for the benefit of families and facilitating responses by agencies of law enforcement and public health. Because of concerted efforts in "real-time" fatal drug overdose surveillance, the KCMEO has become the center of overdose information collection and dissemination

TABLE 9. Sensitivity, PPV, Specificity, NPV, and Accuracy for In-House Blood Testing Combined With Urine and Drug Evidence Testing of 504 Cases, Compared With Final Death Certification

Drug	Sensitivity, PPV, Specificity, NPV, Accuracy,				
	%	%	%	%	%
Fentanyl	68	100	100	69	82
Methamphetamine	71	99	100	77	85
Opiate/morphine	70	97	99	87	89
Cocaine	52	91	98	87	88

for both King County and State of Washington. Accepting a low risk of misclassifying deaths, at least for KCMEO and its partner agencies, the advantages of RDC far outweigh its disadvantages.

ACKNOWLEDGMENTS

The authors thank the Washington State Patrol Toxicology Laboratory and Crime Laboratory, Materials Analysis Section, for the collaboration.

REFERENCES

- Wilson N, Kariisa M, Seth P, et al. Drug and opioid-involved overdose deaths—United States, 2017–2018. *MMWR Morb Mortal Wkly Rep*. 2020; 69(11):290–297.
- Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2019. *NCHS Data Brief*. 2020;394:1–8.
- Mattson CL, Tanz LJ, Quinn K, et al. Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. *MMWR Morb Mortal Wkly Rpt*. 2021;70:202–207.
- National Institutes of Health. Opioid overdose crisis. March 11, 2021. Available at: <https://nida.nih.gov/drug-topics/opioids/opioid-overdose-crisis>. Accessed July 8, 2022.
- Friedman LS. Real-time surveillance of illicit drug overdoses using poison center data. *Clin Toxicol*. 2009;47:573–579.
- Horon IL, Singal P, Fowler DR, et al. Standard death certificate versus enhanced surveillance to identify heroin overdose-related deaths. *Am J Public Health*. 2018;108:777–781.
- Morrow JB, Roper-Miller JD, Catlin ML, et al. The opioid epidemic: moving toward an integrated, holistic analytical response. *J Anal Toxicol*. 2019;43:1–9.
- Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. OD2A: Surveillance. March 9, 2022. Available at: <https://www.cdc.gov/drugoverdose/od2a/surveillance.html>. Accessed July 8, 2022.
- Hoots BE. Opioid overdose surveillance: improving data to inform action. *Public Health Rep*. 2021;136:5S–8S.
- O'Donnell J, Gladden RM, Kariisa M, et al. Using death scene and toxicology evidence to define involvement of heroin, pharmaceutical morphine, illicitly manufactured fentanyl and pharmaceutical fentanyl in opioid overdose deaths, 38 states and the District of Columbia. *Addiction*. 2022;117:1483–1490.
- Vannice K, Hood J, Yarid N, et al. Accuracy of medical examiner's assessment for near-real-time surveillance of fatal drug overdoses, King County, Washington, March 2017–February 2018. *Public Health Rep*. 2022;137:463–470.
- Shute R, Bollinger K, Tucker M, et al. Use of rapid toxicology screening tools in medical examiner/coroner offices. *U.S. Department of Justice, National Institute of Justice, Office of Investigative and Forensic Sciences*. 2021;1–9.
- Baldwin N, Gray R, Goel A, et al. Fentanyl and heroin contained in seized illicit drugs and overdose-related deaths in British Columbia, Canada: an observational analysis. *Drug Alcohol Depend*. 2018;185:322–327.
- Hedegaard H, Bastian BA, Trinidad JP, et al. Regional differences in the drugs most frequently involved in drug overdose deaths: United States, 2017. *Natl Vital Stat Rep*. 2019;68:1–12.
- Lovrecic B, Lovrecic M, Gabrovec B, et al. Non-medical use of novel synthetic opioids: a new challenge to public health. *Int J Environ Res Public Health*. 2019;16:177.
- Shover CL, Falasinnu TO, Dwyer CL, et al. Steep increases in fentanyl-related mortality west of the Mississippi River: recent evidence from county and state surveillance. *Drug Alcohol Depend*. 2020; 216:108314.
- Thombs RP, Thombs DL, Jorgenson AK. What is driving the drug overdose epidemic in the United States? *J Health Soc Behav*. 2020;61: 275–289.
- Baldwin GT, Seth P, Noonan RK. Continued increases in overdose deaths related to synthetic opioids: implications for clinical practice. *JAMA*. 2021; 325:1151–1152.
- O'Donnell J, Tanz LJ, Gladden RM, et al. Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls—United States, 2019–2020. *MMWR Morb Mortal Wkly Rep*. 2021;70:1740–1746.
- Ministry of Public Safety & Solicitor General. Illicit drug toxicity deaths in BC January 1, 2011–December 31, 2021. *BC Coroners Service*. 2022; 1–26.
- DiGennaro C, Garcia GP, Stringfellow EJ, et al. Changes in characteristics of drug overdose death trends during the COVID-19 pandemic. *Int J Drug Policy*. 2021;98:103392.
- Imtiaz S, Nafeh F, Russell C, et al. The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data. *Subst Abuse Treat Prev Policy*. 2021;16:1–14.
- Harruff RC, Couper FJ, Banta-Green CJ. Tracking the opioid drug overdose epidemic in King County, Washington using an improved methodology for certifying heroin related deaths. *Acad Forensic Pathol*. 2015;5:499–506.
- Zhou XH, Obuchowski NA, McClish DK. *Statistical Methods in Diagnostic Medicine*. 2nd ed. Hoben, NJ: John Wiley & Sons; 2011.
- Davis GG, Cadwallader AB, Fligner CL, et al. Position paper: recommendations for the investigation, diagnosis, and certification of deaths related to opioid and other drugs. *Am J Forensic Med Pathol*. 2020; 41:152–159.
- McMillin GA, Johnson-Davis KL, Kelly BN, et al. Impact of the opioid epidemic on drug testing. *Ther Drug Monit*. 2021;43:14–24.
- Kerensky T, LaRochelle M, Fan SL, et al. Non-prescription fentanyl positive toxicology: prevalence, positive predictive value of fentanyl immunoassay screening, and description of co-substance use. *J Addict Med*. 2021;15:150–154.
- Fiorentin TR, Krotulski AJ, Martin DM, et al. Detection of cutting agents in drug-positive seized exhibits within the United States. *J Forensic Sci*. 2019; 64:888–896.
- Fiorentin TR, Logan BK. Analytical findings in used syringes from a syringe exchange program. *Int J Drug Policy*. 2020;81:102770.
- Berry SD, Edgar HJH. Extracting and standardizing medical examiner data to improve health. *AMIA Jt Summits Transl Sci Proc*. 2020;2020:63–70.

**INTERGOVERNMENTAL AGREEMENT BY AND BETWEEN THE COUNTY OF CHAMPAIGN,
ILLINOIS AND CHAMPAIGN COUNTY CORONER'S OFFICE REGARDING THE USE OF
OPIOID SETTLEMENT FUNDS FOR THE PURCHASE OF A RANDOX ANALYZER**

This **AGREEMENT** is entered into by and between the County of Champaign, Illinois ("County"); and Champaign County Coroner's Office ("Coroner's Office") hereinafter collectively referred to as "the Parties", regarding funding for diagnostic equipment to perform automated biochemical testing effective on the last date signed by a Party hereto.

Witnesseth:

WHEREAS, units of local government have conferred upon them the following powers by Article VII, Section 10, of the 1970 Illinois Constitution:

"(A) Units of local government and school districts may contract or otherwise associate themselves, with the State, with other States and their units of local government and school districts, and with the United States to obtain or share services and to exercise, combine or transfer any power or function, in any manner not prohibited by law or ordinance. Units of local government and school districts may contract and otherwise associate with individuals, associations, and corporations in any manner not prohibited by law or by ordinance. Participating units of government may use their credit, revenues and other resources to pay costs and to service debt related to intergovernmental activities"; and

WHEREAS, the County is a unit of local government within the meaning of Article VII, Section 1 of the Illinois Constitution of 1970 and is authorized to enter into contracts with individuals, associations, and corporations in any manner not prohibited by law or by ordinance; and

WHEREAS, County has received funds from the National Opioid Settlements to be used for opioid remediation purposes; and

WHEREAS, County has established a process to allocate those funds in accordance with applicable settlement requirements and local priorities; and

WHEREAS, Coroner's Office has requested funding to purchase a forensic analyzer to improve detection and analysis of opioids and other substances in post-mortem, but also in ante-mortem, examinations; and

WHEREAS, the use of such equipment aligns with the permissible uses of opioid settlement funds and supports timely, accurate cause-of-death determinations that can guide public health and law enforcement interventions; and

WHEREAS, reduced toxicology results can help to identify potentially bad batches within the County and increase response time to prevent further overdoses; and

WHEREAS, the use of an on-site analyzer is expected to reduce County’s reliance on third-party laboratories, decrease turnaround time for results, and potentially lower overall testing costs; and

WHEREAS, timely and reliable toxicology results from Coroner’s Office contribute essential data to help the County allocate resources, shape prevention strategies, and monitor the effectiveness of intervention efforts; and

WHEREAS, both Parties agree that this funding will enhance community health outcomes and align with the intended use of Opioid Settlement Funds per Attachments C and D, List of Opioid Remediation Uses and Approved Uses of Opioid Settlement Funds; and

WHEREAS, such provision of Opioid Settlement funding shall be construed as a subaward, with Coroner’s Office as the subrecipient, and this Agreement construed as a subrecipient agreement; and

NOW, THEREFORE, in consideration of the premises and the mutual covenants hereafter set forth, the Parties agree as follows:

Section 1. PREAMBLE

The foregoing preambles are hereby incorporated into this Agreement as if fully restated in this Section 1.

Section 2. COUNTY agrees to the following:

- a. County shall provide Coroner’s Office a one-time payment of \$79,244.00 in opioid settlement funding to assist with purchasing a Randox Evidence Multistat Analyzer which will support the County’s response to the opioid crisis, particularly as it relates to identifying opioid-related fatalities. Coroner’s Office acknowledges that this is a one-time payment and that future funding must be formally requested.
- b. County shall provide Coroner’s Office a copy of Final Distributor Settlement Agreement (Schedules A and B of Exhibit E of the Opioid Settlement Agreement, attached hereto and) incorporated by reference herein as Attachment B and/or C, and shall provide Coroner’s Office with updates as to any additional terms, conditions, or related communications from the Illinois Department of Human Services and by the Illinois Office of Opioid Settlement Administration within.
- c. County shall issue a one-time payment in the amount of \$79,244.00 to Coroner’s Office no later than June 1, 2025, upon execution of this AGREEMENT.

Section 3. Coroner's Office agrees to the following:

- a. Coroner's Office agrees to utilize the \$79,244.00 in opioid settlement funding from the County to purchase a Randox Evidence Multistat Analyzer device for on-site toxicology testing.
- b. Coroner's Office agrees to comply with all applicable federal, state, and local statutes, rules, regulations, and guidelines governing the use, management, and reporting of opioid settlement funds, including all requirements set forth in Attachments C and D by the Illinois Department of Human Services and by the Illinois Office of Opioid Settlement Administration within.
- c. Coroner's Office agrees to submit outcome or usage data upon request by the County. This may include the number of opioid-related toxicological screenings performed using the purchased equipment and other relevant programmatic information. Data may be shared in aggregate form and is not required to include personal identifiers. The Champaign County Board or any of its committees may request an in-person review of the equipment and permissible data provided by Coroner's Office at any point during for three years from the date of payment.
- d. Coroner's Office certifies that it is not debarred, suspended, proposed for debarment or permanent inclusion on the Illinois Stop Payment List, declared ineligible, or voluntarily excluded from participation in the award as set forth in Attachments C and D or in this Agreement by any federal department or agency, or by the State of Illinois.

Section 4. Terms & Conditions:

a) Compliance

Coroner's Office shall ensure that the equipment purchased under this AGREEMENT is used primarily for opioid-related forensic and toxicological analysis, in alignment with approved opioid abatement strategies.

b) Record-Keeping

Coroner's Office shall maintain record of the purchase made with the provided funds for a minimum of 3 years and shall make such records available to the County upon request. The County may conduct a financial or programmatic review to verify the appropriate use of provided funds.

c) Amendments

This AGREEMENT may be amended only by writing signed by both parties.

d) Duration; Termination

The AGREEMENT shall become effective upon execution by both parties and shall remain in effect until the completion of the equipment purchase and confirmation of payment, unless otherwise terminated in accordance with the terms herein.

e) Repayment and Misuse of Funds

If Coroner's Office is found to have used funds for unauthorized purposes, fails to provide the required requested data for three years from the date of payment, the County reserves the right to request repayment of funds in whole or in part.

SIGNATURE PAGE

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly authorized officers on the date(s) below.

The County of Champaign, Illinois

Approved: _____

Steve Summers
County Executive
Champaign County

Date: _____

Approved: _____

Jennifer Locke
Board Chair
Champaign County

Date: _____

Champaign County Coroner

Approved: _____

Laurie Brauer
Coroner
Champaign County

Date: _____

Attachment A: Coroner's Office's Request

From: Laurie A. Brauer <lbrauer@champaigncountyil.gov>
Sent: Tuesday, March 4, 2025 3:55 PM
To: Kaitlyn M. Kuzio <kaitlyn.kuzio@champaigncountyil.gov>
Subject: RE: Follow up about Randox

Hi Kaitlyn,

Thank you so much for meeting with me regarding the Randox Analyzer. The Randox Evidence Multistat Analyzer is \$79,244. The invoice includes the analyzer, shipping, accessory package and 12 quantitative kits.

MultiSTAT Benefits to Champaign County Coroner's Office

- **Results in under 30 Minutes** – greatly reduces the wait time for results.
- **Semi-Quantitative Results** – the biochip allows for the identification of substances and metabolites present in a post-mortem sample.
- **Multiplexing Technology** – our test menu can detect over 600 drugs and drug metabolites
- **Reduced False Positives** – specific antibodies on the biochip enable the separation of drugs with the same parent type. Example, Amphetamines, Benzodiazepines, Oxycodone, fentanyl and 6-MAM.

The Savings for Champaign County Coroner's Office

- Champaign County has roughly 205,000 people in population.
- As per the most recent annual report, toxicology was performed on approximately 250 cases in 2023.
- As per the most recent annual report, autopsies were performed in approximately 30% of death investigations.
- The current toxicology process ranges from \$300 -\$600 for screen and confirmation results.

By utilizing the MultiSTAT, we would spend about \$40-50 per decedent. Plus, we would gain the benefit of a greatly reduced result time allowing us to provide faster answers to the families of our decedents and local law enforcement and public health agencies.

How can Champaign County use the MultiSTAT?

- Everyday use for any case where toxicology is warranted.
- Can be used for Drug Court.
- Testing in Blood, Urine, Oral Fluids and, Saliva samples.
- Employment Screening.
- Drug Testing for the Jails.
- Can be used to alert local authorities to the prevalence or rise in dangerous drugs in the community.

- Can decrease the need for full autopsies – saving the county money when performing Radox toxicology only is an alternative.
- Signing of death certificates more expeditiously in toxicology only cases.
- Assisting in expediting arrest warrants (prevention usage).

Having the positive quantitative results that Radox would provide in real time will also benefit the Overdose fatality review board. The overdose fatality review boards are multidisciplinary teams that are established on the state, city, or county level to examine and understand the circumstances surrounding fatal drug overdoses. These teams review fatal drug overdose cases via decedent reviews within their jurisdictions in order to determine what factors and characteristics may lead to a possible overdose, and to identify missed opportunities and system gaps in hopes of preventing future overdose deaths.

Please let me know if you have any other questions.



Laurie Brauer | Coroner
Champaign County Coroner's Office
p. (217) 384-3888 f. (217) 384-1209
lbrauer@champaigncountyil.gov

From: Kaitlyn M. Kuzio <kaitlyn.kuzio@champaigncountyil.gov>
Sent: Wednesday, March 5, 2025 08:23
To: Laurie A. Brauer <lbrauer@champaigncountyil.gov>
Subject: RE: Follow up about Radox

Hi Laurie,

Is this \$79,244 is the total you're requesting or are there additional related expenses. For instance, you'd talked about warranty, etc.

Best,
Kait

Good morning,

Yes the \$79,244 is the total, the warranty cost will be after the first year and each year after that so I didn't include it.



Laurie Brauer | Coroner
Champaign County Coroner's Office
p. (217) 384-3888 f. (217) 384-1209
lbrauer@champaigncountyil.gov

CONFIDENTIAL
DO NOT COPY OR DISTRIBUTE

RANDOX
TOXICOLOGY

Evidence MULTISTAT proposal

Our Reference: rdxtox/usa-IN10

Dear Laurie Brauer,


Randox Toxicology is pleased to offer this proposal for the purchase of the Multistat analyzer for toxicology drug screening and testing in the medical examiner's office. This analyzer is an excellent analyzer for fast and accurate screening of drugs in the postmortem workflow process.

The Evidence Multistat analyzer and Biochip Array Technology will allow for reliable analysis of toxicology specimen in blood, urine, or oral fluid.

Fully automated bench top analyzer

- 3 samples per hour
- Results in 17 minutes
- 1,000 patient data storage capability
- LIS compatible
- CV less than 10%
- Touch screen color monitor

We are excited at the possibility of the analyzer being considered for procurement in your lab and we look forward to working with the lab.



Randox Laboratories-US Limited, 515 Industrial Boulevard, Bardane Industrial Park, Kearneysville, WV, 25430
T +1 304 728 2890 Toll Free: 866 4 RANDOX F +304 728 1890 Toll Free: 866 RANDOX I

Randox Toxicology Limited is a company registered within Northern Ireland. Company number: NI 000013 VAT Registered Number: GB 351482706



FINANCIAL PROPOSAL

Name	Laurie Brauer
Organization	Champaign County Coroner Office
Address	202 Art Bartell Rd, Urbana, IL 61802

Ref. No. rdxtox/usa- ILCHMS1	Randox Contact Curtis Miller	Date January 31, 2025
Contract Type Outright Purchase	Contract Period N/A	Minimum Purchase none

Evidence Multistat Analyzer **\$60,000.00**

Cat. No. EV4115

Consisting of: Analyzer; Equipment Installation; Training of two operators; Operator's manual; One year's analyzer warranty

Shipping **\$ 2,500**

Accessory Package **\$ 5,500**

Consisting of: Roller mixer, MicroCentrifuge, 2ml centrifuge tubes, Tube rack, (20), 200ul pipette, (20) 300ul tip reloads, (100) 1000ul pipette, (50) 1250ul tip reloads

Evidence MultiSTAT – ToxPlex Quant Kit **\$937/kit**

Cat. No. EV4156 (Blood)

Expected Annual Testing Expense (1 ToxPlex per month) **\$11,244/yr**

*Consisting of: 24 Biochips x 29 tests per Biochip = 696 tests (two samples per cartridge)
Multi-analyte reagents and consumables.*

Total Purchase Order **\$79,244**

Order includes; Multistat analyzer, Shipping, Accessory package, 12 ToxPlex Quantitative kits



ToxPlex Quantitative Drug Panel
Cat. No. EV4156 (Blood)

1. Acetaminophen	16. Meprobamate
2. Amphetamines	17. Methamphetamine
3. Barbiturates	18. Methadone
4. Benzodiazepines I (Oxazepam)	19. Methaqualone
5. Benzodiazepines II (Clonazepam)	20. Opiate
6. Cocaine (Benzoylecgonine)	21. Oxycodone
7. Buprenorphine	22. Phencyclidine (PCP)
8. Cannabinoids (THC)	23. Pregabalin
9. Xylazine	24. Propoxyphene
10. Dextromethorphan	25. Salicylate
11. Ethyl Glucuronide (ETG)	26. Tramadol
12. Fentanyl	27. Tricyclic Antidepressants
13. Haloperidol	28. Zolpidem
14. Ketamine	29. 6-MAM(Heroin)
15. MDMA	

Accessory Package Components

VWR Item #	Item Description
75838-336	CENTRIFUGE MICRO 16100 X G 15000 RPM
76462-034	ROLLER-MIXER VACUUM TUBE 36RPM 1
20170-170	TUBE PP CAP NAT 2ML PK500
76337-380	RACK 96 PLACE ASSORTED W/O LID PK5
76627-798	UHP 1 CHANNEL 20-200 µL
76627-770	UHP 1 CHANNEL 100-1000 µL

QUOTATION TERMS AND CONDITIONS

Delivery

The analyzer and other products delivered within six (6) weeks of receipt of confirmed purchase order.

Installation and Training

Installation will take place at the customer premises as soon as requested after delivery of the analyzer. A technical specialist shall conduct the training course, which will take the form of a three-day course for as three operators.

Payment and Credit Terms

Credit terms of 30 days from product delivery.

Warranty Period and Service

The analyzer will be covered by a comprehensive warranty for the period of 12 months from the date of installation. This warranty covers all costs of parts, travel and labor.

Customer and Technical Support

Immediate technical support provided by telephone, with 48-hour turnaround onsite technical support.

ALL PRICES QUOTED ARE EXCLUSIVE OF TAX AND FREIGHT.

F.O.B. Kearneysville, WV



Evaluation of “Real-Time” Fatal Drug Overdose Surveillance by King County Medical Examiner's Office, Seattle, Washington

Richard Harruff, MD, PhD, Celia M. Simpson, BS, Amy L. Gifford, BS, Nicole Yaris, MD, William L. Barbour, BS, and Catherine Heidere, MSW

Abstract: To address the challenges in monitoring the continuously accelerating drug overdose epidemic, the King County Medical Examiner's Office in Seattle, Washington, instituted a “real-time” fatal drug overdose surveillance project, depending on scene investigations, autopsy findings, and in-house testing of blood, urine, and drug evidence collected from death scenes. Validation of the project's rapid death certification methodology from 2019 through 2021 was performed at the following 3 levels: blood testing, urine testing, and death certification, and for the following 4 drugs: fentanyl, opiate, methamphetamine, and cocaine. For blood testing, sensitivity ranged from 90% to 99%, and specificity ranged from 86% to 97%. For urine testing, sensitivity ranged from 91% to 92%, and specificity ranged from 87% to 97%. The positive predictive value for cocaine was poor for both blood testing (57%) and urine testing (72%). Of 1034 deaths, 807 were certified as overdose by rapid methodology, and 803 (99.5%) were confirmed by formal toxicology results. Manners of death were changed from accident to natural in 3 of 1034 cases (0.29%). Results of this study indicate that the rapid overdose surveillance methodology described in this study offers benefits to families and provides useful, timely information for responding law enforcement and public health agencies.

Key Words: forensic pathology, drug overdose surveillance, toxicology, drug evidence testing, validation

(*Am J Forensic Med Pathol* 2023;44: 11–16)

As the overdose epidemic continues to accelerate throughout the United States,^{1–4} the goal of achieving an effective surveillance strategy by rapidly identifying the appearance and identity of specific drugs has become increasingly important.^{5–12} National, regional, and local trends are all important for monitoring the impact on our communities as manifestations of the epidemic vary temporally and regionally, especially with respect to the appearance of novel synthetic drugs and seemingly limitless supplies of fentanyl and inexpensive methamphetamine.^{13–20} The COVID-19 pandemic superimposed further complications that remain largely uncharted.^{21,22} Monitoring the drug overdose epidemic is crucial to informing public health and criminal justice responses and guiding rational drug policies. Chief among the metrics for monitoring the crisis are mortality data derived from death certificates generated by medical examiner and coroner offices relying on analyses from toxicology laboratories. Because of the burgeoning caseload of overdose deaths relative to limited resources, crucial death investigation systems have been overwhelmed, resulting in long delays in completing death certificates.^{5–7,12,16,19,21}

As the escalating overdose epidemic overwhelmed resources in the Pacific Northwest, the King County Medical Examiner's Office (KCMEO) in Seattle, Washington, an agency of Public Health–Seattle and King County, created a rapid fatal overdose surveillance system with the goal of rapidly certifying drug overdose deaths and identifying the specific drugs involved.^{11,12} This project involved dedicated personnel, specialized testing instruments, development of methodologies, and multiagency collaborations. In many instances, rapid death certification (RDC) reduced delays in death certification from weeks or months to hours or days and provided information critical for timely law enforcement and public health responses. The purposes of this report are to evaluate RDC and to validate the methods employed.

METHODS AND MATERIALS

The KCMEO serves a population of approximately 2.3 million in a mixed urban and rural population in a geographic area of 2307 square miles. Seattle is the largest city with population of approximately 0.74 million. During the 3 years of this study, the KCMEO had from 10 to 12 medicolegal death investigators who responded to death scenes, gathered information, examined decedents for evidence relative to cause and manner of death, and collected items of suspicious drugs and paraphernalia. Items of drug evidence were transported along with decedents to the KCMEO facility. In-house testing was performed on deaths due to probable overdose, identified using an algorithm described, and validated previously.¹¹ This study found the algorithm alone to be accurate in identifying probable overdose deaths, with a sensitivity of 83% and a positive predictive value (PPV) of 89%. The median time between death and identification as a probable overdose was 1 day, and the interquartile range was 1 to 2 days.¹¹

In-house testing for RDC comprised the following 3 parts: (1) testing of urine collected at autopsy using BTNX Rapid Response fentanyl-specific dipsticks and 1-Step Detect MultiDrug Rapid Test Cups, which hold an array of 14 different drug test strips (Table 1); (2) testing of autopsy blood using Randox Evidence MultiSTAT chemiluminescence immunoanalyzer with an array of 20 different drugs (Table 1); and (3) testing of drug evidence collected at scenes such as pills, powders, crystals, pipes, straws, syringes, scorched foil, and other paraphernalia, using 2 Raman spectrometers (ThermoFisher TriNarc and Rigaku ResQ), MX908 high-pressure mass spectrometer, and BTNX Rapid Response fentanyl-specific urine dipsticks on evidence samples appropriately diluted into water. Blood samples were submitted to the Washington State Patrol (WSP) Toxicology Laboratory for comprehensive testing. The WSP Toxicology Laboratory, in turn, used NMS Labs (Horsesham, Pa) to manage backlogged cases. Both toxicology laboratories used immunoassay screening for the common drug categories, gas chromatography–mass spectrometry for confirmation and quantitation of cocaine, and liquid chromatography–tandem mass spectrometry for confirmation and quantitation of fentanyl, methamphetamine, and opiate. After in-house testing

Manuscript received July 27, 2022; accepted August 25, 2022.
From the King County Medical Examiner's Office, Seattle, WA.
The authors report no conflict of interest.
Reprints: Richard C. Harruff, MD, PhD, King County Medical Examiner's Office, 325 Ninth Ave, HMC Box 359792, Seattle, WA 98104.
E-mail: richard.harruff@kingcounty.gov.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
ISSN: 0195-7910/23/4401-0011
DOI: 10.1097/PAF.0000000000000798

TABLE 1. Analytes in Blood and Urine Testing Used for Rapid Death Certification

Analytes in Blood and Urine Screening Methods	
Randox Evidence MultiSTAT	1-Step Detect MultiDrug Rapid Test Cups
ABCHMINACA	Amphetamine
ABPINACA	Benzodiazepine
ALPHAPVP	Buprenorphine
Amphetamine	Carfentanyl
Barbiturate	Cocaine
Benzodiazepine	Ethyl glucuronide
Benzoylcegonine	Fentanyl
Buprenorphine	Methadone
Ethyl glucuronide	Methamphetamine
Fentanyl	Morphine
Methadone	Oxycodone
Methamphetamine	Synthetic marijuana
6-Monoacetylmorphine	Tetrahydrocannabinol
Opiate	Tramadol
Oxycodone	
PCP	
Pregabalin	
Tetrahydrocannabinol	
Tramadol	
Tricyclic antidepressants	

of drug evidence collected at scenes, using the instruments described previously, these items were submitted to the WSP Crime Laboratory, Materials Analysis Section, for confirmatory testing by gas chromatography–mass spectrometry and infrared spectroscopy.

Rapid death certification for individual deaths was based on concurrence of scene investigations, autopsy findings, and in-house testing. A specific drug was listed on the death certificate if at least 2 independent tests of the 3 (blood testing, urine testing, and drug evidence testing) were positive for the same drug. By these combined methodologies, overdose deaths were certified within hours or few days. For those certified by RDC, the cause of death used the wording, “Acute (combination) drug intoxication including <specific drug(s) identified>”; this wording carries the implication that additional drugs may be added to the death certificate after receiving results of formal toxicology analysis. At the time of certification, to indicate specific cases in which RDC methodology was used to certify the death, whether as an overdose or to exclude overdose, the certifying pathologist would “flag” the case in a special database field. After results from the WSP Toxicology Laboratory were received, the results were used to confirm the initial death certificates based on RDC methodology or to amend them by affidavit, if necessary, adding drugs that were not identified by in-house testing or removing drugs that were not identified by WSP results.

The KCMEO developed and maintains a surveillance database structure specific for the in-house testing and other activities generating data related to fatal overdose surveillance. The surveillance database is linked by case number to KCMEO's case management system (CME Case Management Software; VertiQ Software LLC, Morgan Hill, Calif). CME is likewise linked to the Washington Department of Health Electronic Death Registration System (EDRS). After the death certificate is filed with the Washington Department of Health, the EDRS record is permanent and remains unchanged, while the CME record is updated with results from the WSP Toxicology Laboratory.

Evaluation and validation of RDC were performed for the following 4 major drugs: opiate, fentanyl, methamphetamine, and cocaine. As described earlier²³ and used in this report, “opiate” in contrast to the general drug category, “opioid,” refers to heroin or probable heroin because morphine, with or without 6-monoacetylmorphine, is reported in toxicology analyses. With in-house urine and blood testing, “cocaine” refers to cocaine or benzoylcegonine. Validation was performed at the following 3 levels: blood testing, urine testing, and death certification. The WSP Toxicology Laboratory results served as the “criterion standard” for validation at all levels. Validation at the death certificate level was accomplished by comparing the initial death certificates filed in EDRS with the final death certificate in CME, identified by the RDC flag described previously. Data queries using tools of Microsoft SQL Server Management Studio, Visual Studio, Access, and Excel generated the tables for this report. Sensitivity, specificity, PPV and negative predictive value (NPV), and accuracy were computed using standard methods.²⁴ The Venn diagram in the Figure 1 was constructed using R/RStudio with the *VennDiagram* package. Because this study used only deidentified, aggregate data from decedents, institutional review by University of Washington, Human Subjects Division, were not required.

RESULTS

Over the 3 years of this study, 2019 through 2021, there were a total of 47,778 deaths in King County, of which KCMEO took jurisdiction in 11,080. A total of 1797 deaths (3.8% of all King County deaths and 16% of KCMEO jurisdictional cases) were certified as overdose deaths; 1710 were certified as overdose as a primary cause, and the others listed overdose as other significant condition (OSC). The RDC methods allowed rapid certification of 1005 overdose deaths (56% of all overdose deaths in the same period). In these 3 years, blood testing was performed on 1915 decedents, urine testing was performed in 1992, and drug evidence testing was done on 6047 items collected from 1213




FIGURE 1. Diagram showing extent of in-house testing. BT, blood testing; UT, urine testing; DT, drug evidence testing.

death scenes. A subset of these were used to calculate performance metrics of 1507 in-house blood testing results (Table 2) and 1172 in-house urine testing results (Table 3).

There were 1034 death certificate records that were initially certified by RDC methodology, flagged as described earlier, with which to compare the final death certificates completed after receiving WSP toxicology results. Table 4A shows that of the 1034 initial deaths certificates based on RDC methodology, 807 had overdose as the primary cause of death, 19 listed overdose as a contributing condition, 10 were certified with causes other than overdose, and 198 certificates remained pending, awaiting toxicology results from WSP. After the toxicology results were received, the pending cases were updated. In the final death certificates, shown in Table 4B, overdose as a primary cause accounted for 989; of these 652 (66%) were due to a combination of drugs. Of the 807 overdose deaths initially certified as the primary cause by RDC testing, 803 (99.5%) were confirmed as overdose after obtaining formal toxicology results. Table 5 compares initial death certification, based on

RDC methodology, with final certification, based on WSP toxicology results, and the agreement between the two, for each of the 4 drugs independently. In this analysis, the false-negative rates ranged from 2.9% for cocaine to 15% for methamphetamine, and the false-positive rates ranged from 0.29% for methamphetamine to 1.6% for cocaine. Death certificates were amended accordingly; that is, drugs were added to the amended death certificates for the false negatives and removed from the false positives. Tables 6 to 9 provide more extensive performance metrics of RDC relative to the extent of the individual in-house testing modalities: 991 cases of blood testing only, 730 cases of blood and urine testing, 656 cases of blood and drug evidence testing, and 504 cases having all 3 in-house testing modalities—blood, urine, and drug evidence. Overall, blood testing was most important, with 991 of the 1034 cases certified using blood testing in concurrence with urine and/or drug testing. The Venn diagram in the Figure 1 further illustrates the relative extent of testing among the 3 modalities. As expected, as the extent of testing increased, fewer cases were in each category.

TABLE 2. Sensitivity, PPV, Specificity, NPV, and Accuracy for In-House Blood Testing of 1507 Decedent Samples Compared With WSP Toxicology Results of Blood Testing

Drug	Sensitivity, %	PPV, %	Specificity, %	NPV, %	Accuracy, %
Fentanyl	97	90	94	98	95
Methamphetamine	90	95	97	93	94
Opiate/morphine	92	89	95	97	95
Cocaine	99	57	86	100	88

TABLE 3. Sensitivity, PPV, Specificity, NPV, and Accuracy for In-House Urine Testing of 1172 Decedent Samples Compared With WSP Toxicology Results of Blood Testing

Drug	Sensitivity, %	PPV, %	Specificity, %	NPV, %	Accuracy, %
Fentanyl	92	79	87	95	88
Methamphetamine	91	94	97	95	94
Opiate/morphine	91	75	92	97	92
Cocaine	92	72	95	99	94

In addition, specificity increased with the extent of testing while sensitivity decreased. With respect to manner of death, of the 813 deaths initially certified accident by RDC methodology (Table 4A), 5 were amended otherwise: 3 deaths initially certified accident (overdose) were amended to natural (2 heart disease and 1 alcoholic liver disease with an OSC of chronic drug use), one was amended to suicide (overdose), and one was amended to undetermined (overdose). Taking amendment from an unnatural manner to a natural manner as the most serious false positive, the overall error rate in manner certification was 0.29% (3/1034).

DISCUSSION

Guidelines for certification of overdose deaths published by the National Association of Medical Examiners²⁵ recommend against using screening methods to certify deaths because of the inherent false-positive rates of these tests.^{26,27} While this study certainly supports this recommendation, the results also indicate that RDC can be achieved in many cases by the RDC methodology described herein, adhering to a strict protocol relying on concurrence of information gathered from scene investigation, autopsy findings, screening autopsy blood and urine, and testing drug evidence collected from scenes. Over the 3-year period KCMEO certified 56% of 1797 overdose deaths within 1 to 3 days. Using formal toxicology testing as the "criterion standard" for comparison, both the sensitivities and negative predictive values of blood and urine screenings were greater than 90% for all 4 drugs, indicating that these screening tests were fairly good in detecting the presence or absence of drugs. The specificities and PPVs for 3 of the 4 were 89% or greater, indicating that the blood and urine screening tests

TABLE 5. Drugs Present in 1034 Death Certificates Based on RDC Methodology (Initial DC) Compared With Certification Following WSP Results (Final DC) and Agreement Between the Initial and Final Certification (Both) Along With Calculated FN and FP Rates

Drug	Initial DC, n	Final DC, n	Both, n	FN, %	FP, %
Fentanyl	406	493	393	8.4	1.3
Methamphetamine	363	514	360	15	0.29
Opiate/morphine	254	341	240	8.4	1.4
Cocaine	187	217	170	2.9	1.6

FN, false negative; FP, false positive.

were also fairly good in excluding the presence or absence of drugs. The exception was for cocaine because of a high false-positive rate; only 57% of positive blood screening tests were correct, and only 72% of urine screening tests were correct. Accuracy, the overall probability that the screening test gave a correct result, positive or negative, ranged from 88% to 95% for the 4 drugs evaluated.

For death certification, the most important considerations are correctly classifying overdose as the cause of death and, even more importantly, correctly classifying the manner of death. By RDC methodology, certification relied on a combination of the following 3 independent means: blood testing, urine testing, and drug evidence testing. The probability of error in certification was reduced by adhering to the "2-test" rule: a drug was listed on the death certificate only if 2 independent tests found the same drug. Comparing initial death certificates based on RDC methodology with final death certificates based on WSP toxicology results and taking the latter as the "criterion standard" for comparison found that adding an additional test to blood screening, although reducing sensitivity, substantially enhanced the specificity of certification for all drugs, even for cocaine; specificities ranged from 98% to 100% if all 3 tests were employed. Although certain death certificates were amended after receiving WSP results, either adding or removing drugs, as indicated in Table 5, this was considered a relatively minor error because the cause of death remained overdose and the manner remained accident. Because most overdose deaths (66%) in this study were due to a combination of drugs, the probability of

TABLE 4. (A) Death Certification Based on Rapid Death Certification Compared With (B) Certification Completed After Receiving WSP Toxicology Results

A. Death Certified by RDC Methodology	Manner of Death					Total
	Accident	Suicide	Natural	Undetermined	Pending/Blank	
Drug OD primary	791	10	0	6	0	807
Drug OD (OSC)*	19	0	0	0	0	19
Not drug OD	3	1	6	0	NA	10
Total	813	11	6	6	198	1034

B. Death Certified After WSP Results	Manner of Death					Total
	Accident	Suicide	Natural	Undetermined	Homicide	
Drug OD primary	965	14	0	9	1	989
Drug OD (OSC)*	21	0	0	0	0	21
Not drug OD	4	0	19	1	0	24
Total	990	14	19	10	1	1034

*Other significant conditions.

TABLE 6. Sensitivity, PPV, Specificity, NPV, and Accuracy of In-House Blood Testing of 991 Cases Compared With Final Death Certification

Drug	Sensitivity, %	PPV, %	Specificity, %	NPV, %	Accuracy, %
Fentanyl	99	93	93	99	96
Methamphetamine	92	98	98	92	95
Opiate/morphine	96	90	94	98	95
Cocaine	100	70	87	100	90

correctly classifying an overdose death was very high (essentially 100%) even if some of the drugs listed on the initial death certificate were not confirmed by the toxicology laboratory results. On the other hand, changing the manner of death from accident to natural constituted a major error; this occurred in 3 of 1034 cases. Nevertheless, the overall probability of correctly classifying the manner of death was very high (99.7%).

There are definite reasons to certify overdose deaths rapidly: to benefit families who want to understand the reason for their loved ones' deaths and need death certificates for settling insurance and other business matters; to facilitate timely responses by law enforcement and public health agencies; to quickly identify emergence of novel drugs in a community; and to expedite collection of mortality data. Testing of drug evidence offers another dimension of surveillance. Although testing of drug evidence is rarely performed by medical examiner and coroner offices, this added dimension of overdose surveillance allows rapid identification of novel drugs, formulations, and routes of administrations occurring in the local community.^{28,29} Furthermore, the collaboration in this project, between KCMEO and the WSP Crime Laboratory, represents a notable example of uniting resources of public health and criminal justice agencies in surveillance of illicit drugs.

There are disadvantages in RDC. It is resource intensive, requiring personnel, equipment, and funding not usually part of a medical examiner or coroner office. To deploy RDC methodology, the KCMEO made use of federal grants for purchase of instruments and supplies and to fund key positions; student interns from local colleges were found to be reliable and cost-effective. Data management was especially challenging in maintaining consistency and updating death certificates after receiving WSP toxicology results. Affidavits were often required to amend the official Certification of Death. However, another challenge was discovered when the Washington Department of Health compared data for entry into the State Unintentional Drug Overdose Reporting System; the death certificate affidavits were not making their way into the data stream for State Unintentional Drug Overdose Reporting System entry. This problem is currently being resolved and represents a growing need for data science in exploiting the valuable information collected by medical examiners and coroners.³⁰

TABLE 7. Sensitivity, PPV, Specificity, NPV, and Accuracy for In-House Blood Testing Combined With Urine Testing of 730 Cases, Compared With Final Death Certification

Drug	Sensitivity, %	PPV, %	Specificity, %	NPV, %	Accuracy, %
Fentanyl	93	97	97	92	95
Methamphetamine	88	99	99	90	94
Opiate/morphine	93	93	97	97	96
Cocaine	94	89	97	98	96

TABLE 8. Sensitivity, PPV, Specificity, NPV, and Accuracy for In-House Blood Testing Combined With Drug Evidence Testing of 656 Cases, Compared With Final Death Certification

Drug	Sensitivity, %	PPV, %	Specificity, %	NPV, %	Accuracy, %
Fentanyl	73	99	99	78	86
Methamphetamine	75	100	100	78	86
Opiate/morphine	75	95	98	97	89
Cocaine	58	82	96	88	87

Limitations of this study and RDC methodology were largely due to the separation of KCMEO from the testing laboratories and the length of time between postmortem examination and final certification. Although excellent collaboration existed between KCMEO and WSP for the period of study, the WSP toxicology laboratory depended heavily on NMS Labs to manage their backlog. Thus, there were long delays, weeks to months, between specimen collection and receipt of final toxicology results. Furthermore, discrepancies between RDC testing and final toxicology results were difficult to resolve, requiring communications with 2 different laboratories, both external to KCMEO. This limitation was especially challenging in resolving discrepancies in results for cocaine. Part of cocaine's discrepancy seemed to be due to higher levels of reporting positive results by the toxicology laboratories compared with in-house blood testing for RDC; the higher threshold of the toxicology laboratory may have resulted in false-negative results. For example, in certain cases, scene investigation, blood testing, urine testing, and drug evidence testing all indicated cocaine's involvement in the overdose in the absence of a positive toxicology laboratory result; communicating directly with the toxicology laboratory analysts confirmed the presence of cocaine or benzoylcegonine but at levels below their reporting limit. On the other hand, relying on RDC data in the face of conflicting toxicology laboratory results jeopardized the concept of the "criterion standard." This problem deserves further study. Another limitation was due to the way death certificates were identified for analysis in this study; this depended on the certifying pathologist remembering to flag the case as described earlier. Thus, some cases initially certified by RDC may have been missed in the present analysis. On the other hand, over the course of the 3 years encompassed by this study, KCMEO pathologists became more familiar and confident with the processes, leading to a gradual maturation in using RDC methodology.

In summary, this study shows that the methods described offer a reasonable means of rapidly issuing death certificates, for the benefit of families and facilitating responses by agencies of law enforcement and public health. Because of concerted efforts in "real-time" fatal drug overdose surveillance, the KCMEO has become the center of overdose information collection and dissemination

TABLE 9. Sensitivity, PPV, Specificity, NPV, and Accuracy for In-House Blood Testing Combined With Urine and Drug Evidence Testing of 504 Cases, Compared With Final Death Certification

Drug	Sensitivity, %	PPV, %	Specificity, %	NPV, %	Accuracy, %
Fentanyl	68	100	100	69	82
Methamphetamine	71	99	100	77	85
Opiate/morphine	70	97	99	87	89
Cocaine	52	91	98	87	88

Attachment B: List of Opioid Remediation Uses

Final Distributor Settlement Agreement – Exhibit E

Schedule A Core Strategies

Settling States and Exhibit G Participants may choose from among the abatement strategies listed in Schedule B. However, priority may be given to the following core abatement strategies (“*Core Strategies*”).¹

¹ As used in this Schedule A, words like “expand,” “fund,” “provide” or the like shall not indicate a preference for new or existing programs.

NALOXONE OR OTHER FDA-APPROVED DRUG TO REVERSE OPIOID OVERDOSES

Expand training for first responders, schools, community support groups and families; and

Increase distribution to individuals who are uninsured or whose insurance does not cover the needed service.

MEDICATION-ASSISTED TREATMENT (“MAT”) DISTRIBUTION AND OTHER OPIOID-RELATED TREATMENT

Increase distribution of MAT to individuals who are uninsured or whose insurance does not cover the needed service;

Provide education to school-based and youth-focused programs that discourage or prevent misuse;

Provide MAT education and awareness training to healthcare providers, EMTs, law enforcement, and other first responders; and

Provide treatment and recovery support services such as residential and inpatient treatment, intensive outpatient treatment, outpatient therapy or counseling, and recovery housing that allow or integrate medication and with other support services.

PREGNANT & POSTPARTUM WOMEN

Expand Screening, Brief Intervention, and Referral to Treatment (“*SBIRT*”) services to non-Medicaid eligible or uninsured pregnant women;

Expand comprehensive evidence-based treatment and recovery services, including MAT, for women with co- occurring Opioid Use Disorder (“*OUD*”) and other

Substance Use Disorder (“*SUD*”)/Mental Health disorders for uninsured individuals for up to 12 months postpartum; and

Provide comprehensive wrap-around services to individuals with OUD, including housing, transportation, job placement/training, and childcare.

EXPANDING TREATMENT FOR NEONATAL ABSTINENCE SYNDROME (“NAS”)

Expand comprehensive evidence-based and recovery support for NAS babies;

Expand services for better continuum of care with infant- need dyad; and

Expand long-term treatment and services for medical monitoring of NAS babies and their families.

EXPANSION OF WARM HAND-OFF PROGRAMS AND RECOVERY SERVICES

Expand services such as navigators and on-call teams to begin MAT in hospital emergency departments;

Expand warm hand-off services to transition to recovery services;

Broaden scope of recovery services to include co-occurring SUD or mental health conditions;

Provide comprehensive wrap-around services to individuals in recovery, including housing, transportation, job placement/training, and childcare; and

Hire additional social workers or other behavioral health workers to facilitate expansions above.

TREATMENT FOR INCARCERATED POPULATION

Provide evidence-based treatment and recovery support, including MAT for persons with OUD and co-occurring SUD/MH disorders within and transitioning out of the criminal justice system; and

Increase funding for jails to provide treatment to inmates with OUD.

PREVENTION PROGRAMS

Funding for media campaigns to prevent opioid use (similar to the FDA’s “Real Cost” campaign to prevent youth from misusing tobacco);

Funding for evidence-based prevention programs in schools;

Funding for medical provider education and outreach regarding best prescribing practices for opioids consistent with CDC guidelines, including providers at hospitals (academic detailing);

Funding for community drug disposal programs; and

Funding and training for first responders to participate in pre- arrest diversion programs, post-overdose response teams, or similar strategies that connect at-risk individuals to behavioral health services and supports.

EXPANDING SYRINGE SERVICE PROGRAMS

Provide comprehensive syringe services programs with more wrap-around services, including linkage to OUD treatment, access to sterile syringes and linkage to care and treatment of infectious diseases.

EVIDENCE-BASED DATA COLLECTION AND RESEARCH ANALYZING THE EFFECTIVENESS OF THE ABATEMENT STRATEGIES WITHIN THE STATE

Attachment C: Approved Uses of Opioid Settlement Funds

Final Distributor Settlement Agreement – Exhibit E

Schedule B Approved Uses

² As used in this Schedule B, words like “expand,” “fund,” “provide” or the like shall not indicate a preference for new or existing programs.

Support treatment of Opioid Use Disorder (OUD) and any co-occurring Substance Use Disorder or Mental Health (SUD/MH) conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

TREAT OPIOID USE DISORDER (OUD)

Support treatment of Opioid Use Disorder (“OUD”) and any co-occurring Substance Use Disorder or Mental Health (“SUD/MH”) conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, those that:²

Expand availability of treatment for OUD and any co-occurring SUD/MH conditions, including all forms of Medication-Assisted Treatment (“MAT”) approved by the U.S. Food and Drug Administration.

Support and reimburse evidence-based services that adhere to the American Society of Addiction Medicine (“ASAM”) continuum of care for OUD and any co-occurring SUD/MH conditions.

Expand telehealth to increase access to treatment for OUD and any co-occurring SUD/MH conditions, including MAT, as well as counseling, psychiatric support, and other treatment and recovery support services.

Improve oversight of Opioid Treatment Programs (“OTPs”) to assure evidence-based or evidence-informed practices such as adequate methadone dosing and low threshold approaches to treatment.

Support mobile intervention, treatment, and recovery services, offered by qualified professionals and service providers, such as peer recovery coaches, for persons with OUD and any co-occurring SUD/MH conditions and for persons who have experienced an opioid overdose.

Provide treatment of trauma for individuals with OUD (*e.g.*, violence, sexual assault, human trafficking, or adverse childhood experiences) and family members (*e.g.*, surviving family members after an overdose or overdose fatality), and training of health care personnel to identify and address such trauma.

Support evidence-based withdrawal management services for people with OUD and any co-occurring mental health conditions.

Provide training on MAT for health care providers, first responders, students, or other supporting professionals, such as peer recovery coaches or recovery outreach specialists, including telementoring to assist community-based providers in rural or underserved areas.

Support workforce development for addiction professionals who work with persons with OUD and any co-occurring SUD/MH conditions.

Offer fellowships for addiction medicine specialists for direct patient care, instructors, and clinical research for treatments.

Offer scholarships and supports for behavioral health practitioners or workers involved in addressing OUD and any co-occurring SUD/MH or mental health conditions, including, but not limited to, training, scholarships, fellowships, loan repayment programs, or other incentives for providers to work in rural or underserved areas.

Provide funding and training for clinicians to obtain a waiver under the federal Drug Addiction Treatment Act of 2000 (“*DATA 2000*”) to prescribe MAT for OUD, and provide technical assistance and professional support to clinicians who have obtained a DATA 2000 waiver.

Disseminate web-based training curricula, such as the American Academy of Addiction Psychiatry’s Provider Clinical Support Service–Opioids web-based training curriculum and motivational interviewing.

Develop and disseminate new curricula, such as the American Academy of Addiction Psychiatry’s Provider Clinical Support Service for Medication–Assisted Treatment.

SUPPORT PEOPLE IN TREATMENT AND RECOVERY

Support people in recovery from OUD and any co-occurring SUD/MH conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the programs or strategies that:

Provide comprehensive wrap-around services to individuals with OUD and any co-occurring SUD/MH conditions, including housing, transportation, education, job placement, job training, or childcare.

Provide the full continuum of care of treatment and recovery services for OUD and any co-occurring SUD/MH conditions, including supportive housing, peer support services and counseling, community navigators, case management, and connections to community-based services.

Provide counseling, peer-support, recovery case management and residential treatment with access to medications for those who need it to persons with OUD and any co-occurring SUD/MH conditions.

Provide access to housing for people with OUD and any co-occurring SUD/MH conditions, including supportive housing, recovery housing, housing assistance programs, training for housing providers, or recovery housing programs that allow or integrate FDA-approved medication with other support services.

Provide community support services, including social and legal services, to assist in deinstitutionalizing persons with OUD and any co-occurring SUD/MH conditions.

Support or expand peer-recovery centers, which may include support groups, social events, computer access, or other services for persons with OUD and any co-occurring SUD/MH conditions.

Provide or support transportation to treatment or recovery programs or services for persons with OUD and any co-occurring SUD/MH conditions.

Provide employment training or educational services for persons in treatment for or recovery from OUD and any co-occurring SUD/MH conditions.

Identify successful recovery programs such as physician, pilot, and college recovery programs, and provide support and technical assistance to increase the number and capacity of high-quality programs to help those in recovery.

Engage non-profits, faith-based communities, and community coalitions to support people in treatment and recovery and to support family members in their efforts to support the person with OUD in the family.

Provide training and development of procedures for government staff to appropriately interact and provide social and other services to individuals with or in recovery from OUD, including reducing stigma.

Support stigma reduction efforts regarding treatment and support for persons with OUD, including reducing the stigma on effective treatment.

Create or support culturally appropriate services and programs for persons with OUD and any co-occurring SUD/MH conditions, including new Americans.

Create and/or support recovery high schools.

Hire or train behavioral health workers to provide or expand any of the services or supports listed above.

CONNECT PEOPLE WHO NEED HELP TO THE HELP THEY NEED (CONNECTIONS TO CARE)

Provide connections to care for people who have—or are at risk of developing—OUD and any co-occurring SUD/MH conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, those that:

Ensure that health care providers are screening for OUD and other risk factors and know how to appropriately counsel and treat (or refer if necessary) a patient for OUD treatment.

Fund SBIRT programs to reduce the transition from use to disorders, including SBIRT services to pregnant women who are uninsured or not eligible for Medicaid.

Provide training and long-term implementation of SBIRT in key systems (health, schools, colleges, criminal justice, and probation), with a focus on youth and young adults when transition from misuse to opioid disorder is common.

Purchase automated versions of SBIRT and support ongoing costs of the technology.

Expand services such as navigators and on-call teams to begin MAT in hospital emergency departments.

Provide training for emergency room personnel treating opioid overdose patients on post-discharge planning, including community referrals for MAT, recovery case management or support services.

Support hospital programs that transition persons with OUD and any co-occurring SUD/MH conditions, or persons who have experienced an opioid overdose, into clinically appropriate follow-up care through a bridge clinic or similar approach.

Support crisis stabilization centers that serve as an alternative to hospital emergency departments for persons with OUD and any co-occurring SUD/MH conditions or persons that have experienced an opioid overdose.

Support the work of Emergency Medical Systems, including peer support specialists, to connect individuals to treatment or other appropriate services following an opioid overdose or other opioid-related adverse event.

Provide funding for peer support specialists or recovery coaches in emergency departments, detox facilities, recovery centers, recovery housing, or similar settings; offer services, supports, or connections to care to persons with OUD and any co-occurring SUD/MH conditions or to persons who have experienced an opioid overdose.

Expand warm hand-off services to transition to recovery services.

Create or support school-based contacts that parents can engage with to seek immediate treatment services for their child; and support prevention, intervention, treatment, and recovery programs focused on young people.

Develop and support best practices on addressing OUD in the workplace.

Support assistance programs for health care providers with OUD.

Engage non-profits and the faith community as a system to support outreach for treatment.

Support centralized call centers that provide information and connections to appropriate services and supports for persons with OUD and any co-occurring SUD/MH conditions.

ADDRESS THE NEEDS OF CRIMINAL JUSTICE-INVOLVED PERSONS

Address the needs of persons with OUD and any co-occurring SUD/MH conditions who are involved in, are at risk of becoming involved in, or are transitioning out of the criminal justice system through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, those that:

Support pre-arrest or pre-arraignment diversion and deflection strategies for persons with OUD and any co-occurring SUD/MH conditions, including established strategies such as:

Self-referral strategies such as the Angel Programs or the Police Assisted Addiction Recovery Initiative (“*PAARI*”);

Active outreach strategies such as the Drug Abuse Response Team (“*DART*”) model;

“Naloxone Plus” strategies, which work to ensure that individuals who have received naloxone to reverse the effects of an overdose are then linked to treatment programs or other appropriate services;

Officer prevention strategies, such as the Law Enforcement Assisted Diversion (“*LEAD*”) model;

Officer intervention strategies such as the Leon County, Florida Adult Civil Citation Network or the Chicago Westside Narcotics Diversion to Treatment Initiative; or

Co-responder and/or alternative responder models to address OUD-related 911 calls with greater SUD expertise.

Support pre-trial services that connect individuals with OUD and any co-occurring SUD/MH conditions to evidence-informed treatment, including MAT, and related services.

Support treatment and recovery courts that provide evidence-based options for persons with OUD and any co-occurring SUD/MH conditions.

Provide evidence-informed treatment, including MAT, recovery support, harm reduction, or other appropriate services to individuals with OUD and any co-occurring SUD/MH conditions who are incarcerated in jail or prison.

Provide evidence-informed treatment, including MAT, recovery support, harm reduction, or other appropriate services to individuals with OUD and any co-occurring SUD/MH conditions who are leaving jail or prison or have recently left jail or prison, are on probation or parole, are under community corrections supervision, or are in re-entry programs or facilities.

Support critical time interventions (“CTI”), particularly for individuals living with dual-diagnosis OUD/serious mental illness, and services for individuals who face immediate risks and service needs and risks upon release from correctional settings.

Provide training on best practices for addressing the needs of criminal justice-involved persons with OUD and any co-occurring SUD/MH conditions to law enforcement, correctional, or judicial personnel or to providers of treatment, recovery, harm reduction, case management, or other services offered in connection with any of the strategies described in this section.

ADDRESS THE NEEDS OF PREGNANT OR PARENTING WOMEN AND THEIR FAMILIES, INCLUDING BABIES WITH NEONATAL ABSTINENCE SYNDROME

Address the needs of pregnant or parenting women with OUD and any co-occurring SUD/MH conditions, and the needs of their families, including babies with neonatal

abstinence syndrome (“NAS”), through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, those that:

Support evidence-based or evidence-informed treatment, including MAT, recovery services and supports, and prevention services for pregnant women—or women who could become pregnant—who have OUD and any co-occurring SUD/MH conditions, and other measures to educate and provide support to families affected by Neonatal Abstinence Syndrome.

Expand comprehensive evidence-based treatment and recovery services, including MAT, for uninsured women with OUD and any co-occurring SUD/MH conditions for up to 12 months postpartum.

Provide training for obstetricians or other healthcare personnel who work with pregnant women and their families regarding treatment of OUD and any co-occurring SUD/MH conditions.

Expand comprehensive evidence-based treatment and recovery support for NAS babies; expand services for better continuum of care with infant-need dyad; and expand long-term treatment and services for medical monitoring of NAS babies and their families.

Provide training to health care providers who work with pregnant or parenting women on best practices for compliance with federal requirements that children born with NAS get referred to appropriate services and receive a plan of safe care.

Provide child and family supports for parenting women with OUD and any co-occurring SUD/MH conditions.

Provide enhanced family support and childcare services for parents with OUD and any co-occurring SUD/MH conditions.

Provide enhanced support for children and family members suffering trauma as a result of addiction in the family; and offer trauma-informed behavioral health treatment for adverse childhood events.

Offer home-based wrap-around services to persons with OUD and any co-occurring SUD/MH conditions, including, but not limited to, parent skills training.

Provide support for Children's Services—Fund additional positions and services, including supportive housing and other residential services, relating to children being removed from the home and/or placed in foster care due to custodial opioid use.

PREVENT OVER-PRESCRIBING AND ENSURE APPROPRIATE PRESCRIBING AND DISPENSING OF OPIOIDS

Support efforts to prevent over-prescribing and ensure appropriate prescribing and dispensing of opioids through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

Funding medical provider education and outreach regarding best prescribing practices for opioids consistent with the Guidelines for Prescribing Opioids for Chronic Pain from the U.S. Centers for Disease Control and Prevention, including providers at hospitals (academic detailing).

Training for health care providers regarding safe and responsible opioid prescribing, dosing, and tapering patients off opioids.

Continuing Medical Education (CME) on appropriate prescribing of opioids.

Providing Support for non-opioid pain treatment alternatives, including training providers to offer or refer to multi-modal, evidence-informed treatment of pain.

Supporting enhancements or improvements to Prescription Drug Monitoring Programs ("PDMPs"), including, but not limited to, improvements that:

Increase the number of prescribers using PDMPs;

Improve point-of-care decision-making by increasing the quantity, quality, or format of data available to prescribers using PDMPs, by improving the interface that prescribers use to access PDMP data, or both; or

Enable states to use PDMP data in support of surveillance or intervention strategies, including MAT referrals and follow-up for individuals identified within PDMP data as likely to experience OUD in a manner that complies with all relevant privacy and security laws and rules.

Ensuring PDMPs incorporate available overdose/naloxone deployment data, including the United States Department of Transportation's Emergency Medical Technician overdose database in a manner that complies with all relevant privacy and security laws and rules.

Increasing electronic prescribing to prevent diversion or forgery.

Educating dispensers on appropriate opioid dispensing.

PREVENT MISUSE OF OPIOIDS

Support efforts to discourage or prevent misuse of opioids through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

Funding media campaigns to prevent opioid misuse.

Corrective advertising or affirmative public education campaigns based on evidence.

Public education relating to drug disposal.

Drug take-back disposal or destruction programs.

Funding community anti-drug coalitions that engage in drug prevention efforts.

Supporting community coalitions in implementing evidence-informed prevention, such as reduced social access and physical access, stigma reduction—including staffing, educational campaigns, support for people in treatment or recovery, or training of coalitions in evidence-informed implementation, including the Strategic Prevention Framework developed by the U.S. Substance Abuse and Mental Health Services Administration (“SAMHSA”).

Engaging non-profits and faith-based communities as systems to support prevention.

Funding evidence-based prevention programs in schools or evidence-informed school and community education programs and campaigns for students, families, school employees, school athletic programs, parent-teacher and student associations, and others.

School-based or youth-focused programs or strategies that have demonstrated effectiveness in preventing drug misuse and seem likely to be effective in preventing the uptake and use of opioids.

Create or support community-based education or intervention services for families, youth, and adolescents at risk for OUD and any co-occurring SUD/MH conditions.

Support evidence-informed programs or curricula to address mental health needs of young people who may be at risk of misusing opioids or other drugs, including emotional modulation and resilience skills.

Support greater access to mental health services and supports for young people, including services and supports provided by school nurses, behavioral health workers or other school staff, to address mental health needs in young people that (when not properly addressed) increase the risk of opioid or another drug misuse.

PREVENT OVERDOSE DEATHS AND OTHER HARMS (HARM REDUCTION)

Support efforts to prevent or reduce overdose deaths or other opioid-related harms through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

Increased availability and distribution of naloxone and other drugs that treat overdoses for first responders, overdose patients, individuals with OUD and their friends and family members, schools, community navigators and outreach workers, persons being released from jail or prison, or other members of the general public.

Public health entities providing free naloxone to anyone in the community.

Training and education regarding naloxone and other drugs that treat overdoses for first responders, overdose patients, patients taking opioids, families, schools, community support groups, and other members of the general public.

Enabling school nurses and other school staff to respond to opioid overdoses, and provide them with naloxone, training, and support.

Expanding, improving, or developing data tracking software and applications for overdoses/naloxone revivals.

Public education relating to emergency responses to overdoses.

Public education relating to immunity and Good Samaritan laws.

Educating first responders regarding the existence and operation of immunity and Good Samaritan laws.

Syringe service programs and other evidence-informed programs to reduce harms associated with intravenous drug use, including supplies, staffing, space, peer support services, referrals to treatment, fentanyl checking, connections to care, and the full range of harm reduction and treatment services provided by these programs.

Expanding access to testing and treatment for infectious diseases such as HIV and Hepatitis C resulting from intravenous opioid use.

Supporting mobile units that offer or provide referrals to harm reduction services, treatment, recovery supports, health care, or other appropriate services to persons that use opioids or persons with OUD and any co-occurring SUD/MH conditions.

Providing training in harm reduction strategies to health care providers, students, peer recovery coaches, recovery outreach specialists, or other professionals that provide care to persons who use opioids or persons with OUD and any co-occurring SUD/MH conditions.

Supporting screening for fentanyl in routine clinical toxicology testing.

FIRST RESPONDERS

In addition to items in section C, D and H relating to first responders, support the following:

Education of law enforcement or other first responders regarding appropriate practices and precautions when dealing with fentanyl or other drugs.

Provision of wellness and support services for first responders and others who experience secondary trauma associated with opioid-related emergency events.

LEADERSHIP, PLANNING AND COORDINATION

Support efforts to provide leadership, planning, coordination, facilitations, training and technical assistance to abate the opioid epidemic through activities, programs, or strategies that may include, but are not limited to, the following:

Statewide, regional, local or community regional planning to identify root causes of addiction and overdose, goals for reducing harms related to the opioid epidemic, and areas and populations with the greatest needs for treatment intervention services, and to support training and technical assistance and other strategies to abate the opioid epidemic described in this opioid abatement strategy list.

A dashboard to (a) share reports, recommendations, or plans to spend opioid settlement funds; (b) to show how opioid settlement funds have been spent; (c) to report program or strategy outcomes; or (d) to track, share or visualize key opioid- or health-related indicators and supports as identified through collaborative statewide, regional, local or community processes.

Invest in infrastructure or staffing at government or not-for-profit agencies to support collaborative, cross-system coordination with the purpose of preventing overprescribing, opioid misuse, or opioid overdoses, treating those with OUD and any co-occurring SUD/MH conditions, supporting them in treatment or recovery, connecting them to care, or implementing other strategies to abate the opioid epidemic described in this opioid abatement strategy list.

Provide resources to staff government oversight and management of opioid abatement programs.

TRAINING

In addition to the training referred to throughout this document, support training to abate the opioid epidemic through activities, programs, or strategies that may include, but are not limited to, those that:

Provide funding for staff training or networking programs and services to improve the capability of government, community, and not-for-profit entities to abate the opioid crisis.

Support infrastructure and staffing for collaborative cross-system coordination to prevent opioid misuse, prevent overdoses, and treat those with OUD and any co-occurring SUD/MH conditions, or implement other strategies to abate the opioid epidemic described in this opioid abatement strategy list (*e.g.*, health care, primary care, pharmacies, PDMPs, etc.).

RESEARCH

Support opioid abatement research that may include, but is not limited to, the following:

Monitoring, surveillance, data collection and evaluation of programs and strategies described in this opioid abatement strategy list.

Research non-opioid treatment of chronic pain.

Research on improved service delivery for modalities such as SBIRT that demonstrate promising but mixed results in populations vulnerable to opioid use disorders.

Research on novel harm reduction and prevention efforts such as the provision of fentanyl test strips.

Research on innovative supply-side enforcement efforts such as improved detection of mail-based delivery of synthetic opioids.

Expanded research on swift/certain/fair models to reduce and deter opioid misuse within criminal justice populations that build upon promising approaches used to address other substances (*e.g.*, Hawaii HOPE and Dakota 24/7).

Epidemiological surveillance of OUD-related behaviors in critical populations, including individuals entering the criminal justice system, including, but not limited to approaches modeled on the Arrestee Drug Abuse Monitoring (“ADAM”) system.

Qualitative and quantitative research regarding public health risks and harm reduction opportunities within illicit drug markets, including surveys of market participants who sell or distribute illicit opioids.

Geospatial analysis of access barriers to MAT and their association with treatment engagement and treatment outcomes



OPIOID SETTLEMENT FUNDING APPLICATION

1. APPLICATION INFORMATION

Date Submitted	4/30/2025	Project Date Range	Jan - Dec 2025
Name of Project or Proposal	Harm Reduction 2025	Total Funding Requested	\$45,424
Purpose of Request for Funding	Service Expansion	Date Funding Requested by	Sept 2025

Organization

Name	Champaign-Urbana Public Health District
Address	201 W. Kenyon Rd, Champaign, IL 61820
Email Address	info@c-uphd.org
Phone Number	217-352-7961
Website	www.c-uphd.org
Legal Status of your Organization	Local Unit of Government

Point of Contact

Name	Joe Trotter
Address	201 W. Kenyon Rd, Champaign, IL 61820
Email Address	jtrotter@c-uphd.org
Phone Number	217-531-5370

2. PROPOSAL SUMMARY

(One paragraph maximum)

Provide a summary of the proposed project. Briefly describe why your organization or department is requesting this funding, what results you hope to achieve, how you will spend the funds and how the project contributes to Champaign County Opioid Settlement Task Force's overall mission to serve opioid-impacted individuals and communities.

3. NARRATIVE

(Preferred length not to exceed one page)

Please include the following information:

1. Background—Describe the work of your agency, addressing each of the following:
 - a. A brief description of the purpose and history of the organization
 - b. The organization’s mission and goals, especially highlighting those that specifically serve opioid-impacted individuals and communities
 - c. Board roster and the number of paid full-time staff and/or part-time staff
2. Funding Request— Please explain the specific project to be funded including:
 - a. A project description, including goals, objectives, timeline for implementation, specific activities to be funded and outcomes expected.
 - b. The population(s) that you plan to serve and how they will benefit from the project.
 - c. Approaches and methods and the activities planned for which this requested funding will be used.
 - d. The names, titles, qualifications and experience of key personnel.
 - e. Any plans for sustaining the project and for long-term sources/strategies for funding upon completion of the proposed grant.
 - f. Other organizations, if any, participating in the activity.
 - g. Evaluation—Please explain your expected results and how you will measure the effectiveness of your activities.

4. ATTACHMENTS

- Most recent annual statements (audited if available)
- Current operating budget
- Signed current W-9
- A detailed budget of this project
- A list of other sources of actual and expected funding, including amounts

5. APPROVED USES

Using the List of Opioid Remediation Uses and the Approved Uses of Opioid Settlement Funds, Attachments C and D of this application packet, identify which approved uses your proposal request will fulfill.

(Check or highlight ALL that apply from Attachments C AND D of this packet)

Attachment C: List of Opioid Remediation Uses

Final Distributor Settlement Agreement – Exhibit E
Schedule A Core Strategies

Settling States and Exhibit G Participants may choose from among the abatement strategies listed in Schedule B. However, priority may be given to the following core abatement strategies (“Core Strategies”).¹

¹ As used in this Schedule A, words like “expand,” “fund,” “provide” or the like shall not indicate a preference for new or existing programs.

NALOXONE OR OTHER FDA-APPROVED DRUG TO REVERSE OPIOID OVERDOSES

Expand training for first responders, schools, community support groups and families; and

Increase distribution to individuals who are uninsured or whose insurance does not cover the needed service.

MEDICATION-ASSISTED TREATMENT (“MAT”) DISTRIBUTION AND OTHER OPIOID-RELATED TREATMENT

Increase distribution of MAT to individuals who are uninsured or whose insurance does not cover the needed service;

Provide education to school-based and youth-focused programs that discourage or prevent misuse;

Provide MAT education and awareness training to healthcare providers, EMTs, law enforcement, and other first responders; and

Provide treatment and recovery support services such as residential and inpatient treatment, intensive outpatient treatment, outpatient therapy or counseling, and recovery housing that allow or integrate medication and with other support services.

PREGNANT & POSTPARTUM WOMEN

Expand Screening, Brief Intervention, and Referral to Treatment (“SBIRT”) services to non-Medicaid eligible or uninsured pregnant women;

Expand comprehensive evidence-based treatment and recovery services, including MAT, for women with co- occurring Opioid Use Disorder (“OUD”) and other

Substance Use Disorder (“SUD”)/Mental Health disorders for uninsured individuals for up to 12 months postpartum; and

Provide comprehensive wrap-around services to individuals with OUD, including housing, transportation, job placement/training, and childcare.

EXPANDING TREATMENT FOR NEONATAL ABSTINENCE SYNDROME (“NAS”)

Expand comprehensive evidence-based and recovery support for NAS babies;

Expand services for better continuum of care with infant- need dyad; and

Expand long-term treatment and services for medical monitoring of NAS babies and their families.

EXPANSION OF WARM HAND-OFF PROGRAMS AND RECOVERY SERVICES

Expand services such as navigators and on-call teams to begin MAT in hospital emergency departments;

Expand warm hand-off services to transition to recovery services;

Broaden scope of recovery services to include co-occurring SUD or mental health conditions;

Provide comprehensive wrap-around services to individuals in recovery, including housing, transportation, job placement/training, and childcare; and

Hire additional social workers or other behavioral health workers to facilitate expansions above.

TREATMENT FOR INCARCERATED POPULATION

Provide evidence-based treatment and recovery support, including MAT for persons with OUD and co-occurring SUD/MH disorders within and transitioning out of the criminal justice system; and

Increase funding for jails to provide treatment to inmates with OUD.

PREVENTION PROGRAMS

Funding for media campaigns to prevent opioid use (similar to the FDA's "Real Cost" campaign to prevent youth from misusing tobacco);

Funding for evidence-based prevention programs in schools;

Funding for medical provider education and outreach regarding best prescribing practices for opioids consistent with CDC guidelines, including providers at hospitals (academic detailing);

Funding for community drug disposal programs; and

Funding and training for first responders to participate in pre-arrest diversion programs, post-overdose response teams, or similar strategies that connect at-risk individuals to behavioral health services and supports.

EXPANDING SYRINGE SERVICE PROGRAMS

Provide comprehensive syringe services programs with more wrap-around services, including linkage to OUD treatment, access to sterile syringes and linkage to care and treatment of infectious diseases.

EVIDENCE-BASED DATA COLLECTION AND RESEARCH ANALYZING THE EFFECTIVENESS OF THE ABATEMENT STRATEGIES WITHIN THE STATE

Attachment D: Approved Uses of Opioid Settlement Funds

Final Distributor Settlement Agreement – Exhibit E Schedule B Approved Uses

² As used in this Schedule B, words like “expand,” “fund,” “provide” or the like shall not indicate a preference for new or existing programs.

Support treatment of Opioid Use Disorder (OUD) and any co-occurring Substance Use Disorder or Mental Health (SUD/MH) conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

TREAT OPIOID USE DISORDER (OUD)

Support treatment of Opioid Use Disorder (“OUD”) and any co-occurring Substance Use Disorder or Mental Health (“SUD/MH”) conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, those that:²

Expand availability of treatment for OUD and any co-occurring SUD/MH conditions, including all forms of Medication-Assisted Treatment (“MAT”) approved by the U.S. Food and Drug Administration.

Support and reimburse evidence-based services that adhere to the American Society of Addiction Medicine (“ASAM”) continuum of care for OUD and any co-occurring SUD/MH conditions.

Expand telehealth to increase access to treatment for OUD and any co-occurring SUD/MH conditions, including MAT, as well as counseling, psychiatric support, and other treatment and recovery support services.

Improve oversight of Opioid Treatment Programs (“OTPs”) to assure evidence-based or evidence-informed practices such as adequate methadone dosing and low threshold approaches to treatment.

Support mobile intervention, treatment, and recovery services, offered by qualified professionals and service providers, such as peer recovery coaches, for persons with OUD and any co-occurring SUD/MH conditions and for persons who have experienced an opioid overdose.

Provide treatment of trauma for individuals with OUD (*e.g.*, violence, sexual assault, human trafficking, or adverse childhood experiences) and family members (*e.g.*, surviving family members after an overdose or overdose fatality), and training of health care personnel to identify and address such trauma.

Support evidence-based withdrawal management services for people with OUD and any co-occurring mental health conditions.

Provide training on MAT for health care providers, first responders, students, or other supporting professionals, such as peer recovery coaches or recovery outreach specialists, including telementoring to assist community-based providers in rural or underserved areas.

Support workforce development for addiction professionals who work with persons with OUD and any co-occurring SUD/MH conditions.

Offer fellowships for addiction medicine specialists for direct patient care, instructors, and clinical research for treatments.

Offer scholarships and supports for behavioral health practitioners or workers involved in addressing OUD and any co-occurring SUD/MH or mental health conditions, including, but not limited to, training, scholarships, fellowships, loan repayment programs, or other incentives for providers to work in rural or underserved areas.

Provide funding and training for clinicians to obtain a waiver under the federal Drug Addiction Treatment Act of 2000 (“DATA 2000”) to prescribe MAT for OUD, and provide technical assistance and professional support to clinicians who have obtained a DATA 2000 waiver.

Disseminate web-based training curricula, such as the American Academy of Addiction Psychiatry’s Provider Clinical Support Service–Opioids web-based training curriculum and motivational interviewing.

Develop and disseminate new curricula, such as the American Academy of Addiction Psychiatry’s Provider Clinical Support Service for Medication–Assisted Treatment.

SUPPORT PEOPLE IN TREATMENT AND RECOVERY

Support people in recovery from OUD and any co-occurring SUD/MH conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the programs or strategies that:

Provide comprehensive wrap-around services to individuals with OUD and any co-occurring SUD/MH conditions, including housing, transportation, education, job placement, job training, or childcare.

Provide the full continuum of care of treatment and recovery services for OUD and any co-occurring SUD/MH conditions, including supportive housing, peer support services and counseling, community navigators, case management, and connections to community-based services.

Provide counseling, peer-support, recovery case management and residential treatment with access to medications for those who need it to persons with OUD and any co-occurring SUD/MH conditions.

Provide access to housing for people with OUD and any co-occurring SUD/MH conditions, including supportive housing, recovery housing, housing assistance programs, training for housing providers, or recovery housing programs that allow or integrate FDA-approved medication with other support services.

Provide community support services, including social and legal services, to assist in deinstitutionalizing persons with OUD and any co-occurring SUD/MH conditions.

Support or expand peer-recovery centers, which may include support groups, social events, computer access, or other services for persons with OUD and any co-occurring SUD/MH conditions.

Provide or support transportation to treatment or recovery programs or services for persons with OUD and any co-occurring SUD/MH conditions.

Provide employment training or educational services for persons in treatment for or recovery from OUD and any co-occurring SUD/MH conditions.

Identify successful recovery programs such as physician, pilot, and college recovery programs, and provide support and technical assistance to increase the number and capacity of high-quality programs to help those in recovery.

Engage non-profits, faith-based communities, and community coalitions to support people in treatment and recovery and to support family members in their efforts to support the person with OUD in the family.

Provide training and development of procedures for government staff to appropriately interact and provide social and other services to individuals with or in recovery from OUD, including reducing stigma.

Support stigma reduction efforts regarding treatment and support for persons with OUD, including reducing the stigma on effective treatment.

Create or support culturally appropriate services and programs for persons with OUD and any co-occurring SUD/MH conditions, including new Americans.

Create and/or support recovery high schools.

Hire or train behavioral health workers to provide or expand any of the services or supports listed above.

CONNECT PEOPLE WHO NEED HELP TO THE HELP THEY NEED (CONNECTIONS TO CARE)

Provide connections to care for people who have—or are at risk of developing—OUD and any co-occurring SUD/MH conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, those that:

Ensure that health care providers are screening for OUD and other risk factors and know how to appropriately counsel and treat (or refer if necessary) a patient for OUD treatment.

Fund SBIRT programs to reduce the transition from use to disorders, including SBIRT services to pregnant women who are uninsured or not eligible for Medicaid.

Provide training and long-term implementation of SBIRT in key systems (health, schools, colleges, criminal justice, and probation), with a focus on youth and young adults when transition from misuse to opioid disorder is common.

Purchase automated versions of SBIRT and support ongoing costs of the technology.

Expand services such as navigators and on-call teams to begin MAT in hospital emergency departments.

Provide training for emergency room personnel treating opioid overdose patients on post-discharge planning, including community referrals for MAT, recovery case management or support services.

Support hospital programs that transition persons with OUD and any co-occurring SUD/MH conditions, or persons who have experienced an opioid overdose, into clinically appropriate follow-up care through a bridge clinic or similar approach.

Support crisis stabilization centers that serve as an alternative to hospital emergency departments for persons with OUD and any co-occurring SUD/MH conditions or persons that have experienced an opioid overdose.

Support the work of Emergency Medical Systems, including peer support specialists, to connect individuals to treatment or other appropriate services following an opioid overdose or other opioid-related adverse event.

Provide funding for peer support specialists or recovery coaches in emergency departments, detox facilities, recovery centers, recovery housing, or similar settings; offer services, supports, or connections to care to persons with OUD and any co-occurring SUD/MH conditions or to persons who have experienced an opioid overdose.

Expand warm hand-off services to transition to recovery services.

Create or support school-based contacts that parents can engage with to seek immediate treatment services for their child; and support prevention, intervention, treatment, and recovery programs focused on young people.

Develop and support best practices on addressing OUD in the workplace.

Support assistance programs for health care providers with OUD.

Engage non-profits and the faith community as a system to support outreach for treatment.

Support centralized call centers that provide information and connections to appropriate services and supports for persons with OUD and any co-occurring SUD/MH conditions.

ADDRESS THE NEEDS OF CRIMINAL JUSTICE-INVOLVED PERSONS

Address the needs of persons with OUD and any co-occurring SUD/MH conditions who are involved in, are at risk of becoming involved in, or are transitioning out of the criminal justice system through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, those that:

Support pre-arrest or pre-arraignment diversion and deflection strategies for persons with OUD and any co-occurring SUD/MH conditions, including established strategies such as:

Self-referral strategies such as the Angel Programs or the Police Assisted Addiction Recovery Initiative (“PAARI”);

Active outreach strategies such as the Drug Abuse Response Team (“DART”) model;

“Naloxone Plus” strategies, which work to ensure that individuals who have received naloxone to reverse the effects of an overdose are then linked to treatment programs or other appropriate services;

Officer prevention strategies, such as the Law Enforcement Assisted Diversion (“LEAD”) model;

Officer intervention strategies such as the Leon County, Florida Adult Civil Citation Network or the Chicago Westside Narcotics Diversion to Treatment Initiative; or

Co-responder and/or alternative responder models to address OUD-related 911 calls with greater SUD expertise.

Support pre-trial services that connect individuals with OUD and any co-occurring SUD/MH conditions to evidence-informed treatment, including MAT, and related services.

Support treatment and recovery courts that provide evidence-based options for persons with OUD and any co-occurring SUD/MH conditions.

Provide evidence-informed treatment, including MAT, recovery support, harm reduction, or other appropriate services to individuals with OUD and any co-occurring SUD/MH conditions who are incarcerated in jail or prison.

Provide evidence-informed treatment, including MAT, recovery support, harm reduction, or other appropriate services to individuals with OUD and any co-occurring SUD/MH conditions who are leaving jail or prison or have recently left jail or prison, are on probation or parole, are under community corrections supervision, or are in re-entry programs or facilities.

Support critical time interventions (“CTI”), particularly for individuals living with dual-diagnosis OUD/serious mental illness, and services for individuals who face immediate risks and service needs and risks upon release from correctional settings.

Provide training on best practices for addressing the needs of criminal justice-involved persons with OUD and any co-occurring SUD/MH conditions to law enforcement, correctional, or judicial personnel or to providers of treatment, recovery, harm reduction, case management, or other services offered in connection with any of the strategies described in this section.

ADDRESS THE NEEDS OF PREGNANT OR PARENTING WOMEN AND THEIR FAMILIES, INCLUDING BABIES WITH NEONATAL ABSTINENCE SYNDROME

Address the needs of pregnant or parenting women with OUD and any co-occurring SUD/MH conditions, and the needs of their families, including babies with neonatal

abstinence syndrome (“NAS”), through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, those that:

Support evidence-based or evidence-informed treatment, including MAT, recovery services and supports, and prevention services for pregnant women—or women who could become pregnant—who have OUD and any co-occurring SUD/MH conditions, and other measures to educate and provide support to families affected by Neonatal Abstinence Syndrome.

Expand comprehensive evidence-based treatment and recovery services, including MAT, for uninsured women with OUD and any co-occurring SUD/MH conditions for up to 12 months postpartum.

Provide training for obstetricians or other healthcare personnel who work with pregnant women and their families regarding treatment of OUD and any co-occurring SUD/MH conditions.

Expand comprehensive evidence-based treatment and recovery support for NAS babies; expand services for better continuum of care with infant-need dyad; and expand long-term treatment and services for medical monitoring of NAS babies and their families.

Provide training to health care providers who work with pregnant or parenting women on best practices for compliance with federal requirements that children born with NAS get referred to appropriate services and receive a plan of safe care.

Provide child and family supports for parenting women with OUD and any co-occurring SUD/MH conditions.

Provide enhanced family support and childcare services for parents with OUD and any co-occurring SUD/MH conditions.

Provide enhanced support for children and family members suffering trauma as a result of addiction in the family; and offer trauma-informed behavioral health treatment for adverse childhood events.

Offer home-based wrap-around services to persons with OUD and any co-occurring SUD/MH conditions, including, but not limited to, parent skills training.

Provide support for Children's Services—Fund additional positions and services, including supportive housing and other residential services, relating to children being removed from the home and/or placed in foster care due to custodial opioid use.

PREVENT OVER-PRESCRIBING AND ENSURE APPROPRIATE PRESCRIBING AND DISPENSING OF OPIOIDS

Support efforts to prevent over-prescribing and ensure appropriate prescribing and dispensing of opioids through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

Funding medical provider education and outreach regarding best prescribing practices for opioids consistent with the Guidelines for Prescribing Opioids for Chronic Pain from the U.S. Centers for Disease Control and Prevention, including providers at hospitals (academic detailing).

Training for health care providers regarding safe and responsible opioid prescribing, dosing, and tapering patients off opioids.

Continuing Medical Education (CME) on appropriate prescribing of opioids.

Providing Support for non-opioid pain treatment alternatives, including training providers to offer or refer to multi-modal, evidence-informed treatment of pain.

Supporting enhancements or improvements to Prescription Drug Monitoring Programs ("PDMPs"), including, but not limited to, improvements that:

Increase the number of prescribers using PDMPs;

Improve point-of-care decision-making by increasing the quantity, quality, or format of data available to prescribers using PDMPs, by improving the interface that prescribers use to access PDMP data, or both; or

Enable states to use PDMP data in support of surveillance or intervention strategies, including MAT referrals and follow-up for individuals identified within PDMP data as likely to experience OUD in a manner that complies with all relevant privacy and security laws and rules.

Ensuring PDMPs incorporate available overdose/naloxone deployment data, including the United States Department of Transportation’s Emergency Medical Technician overdose database in a manner that complies with all relevant privacy and security laws and rules.

Increasing electronic prescribing to prevent diversion or forgery.

Educating dispensers on appropriate opioid dispensing.

PREVENT MISUSE OF OPIOIDS

Support efforts to discourage or prevent misuse of opioids through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

Funding media campaigns to prevent opioid misuse.

Corrective advertising or affirmative public education campaigns based on evidence.

Public education relating to drug disposal.

Drug take-back disposal or destruction programs.

Funding community anti-drug coalitions that engage in drug prevention efforts.

Supporting community coalitions in implementing evidence-informed prevention, such as reduced social access and physical access, stigma reduction—including staffing, educational campaigns, support for people in treatment or recovery, or training of coalitions in evidence-informed implementation, including the Strategic Prevention Framework developed by the U.S. Substance Abuse and Mental Health Services Administration (“SAMHSA”).

Engaging non-profits and faith-based communities as systems to support prevention.

Funding evidence-based prevention programs in schools or evidence-informed school and community education programs and campaigns for students, families, school employees, school athletic programs, parent-teacher and student associations, and others.

School-based or youth-focused programs or strategies that have demonstrated effectiveness in preventing drug misuse and seem likely to be effective in preventing the uptake and use of opioids.

Create or support community-based education or intervention services for families, youth, and adolescents at risk for OUD and any co-occurring SUD/MH conditions.

Support evidence-informed programs or curricula to address mental health needs of young people who may be at risk of misusing opioids or other drugs, including emotional modulation and resilience skills.

Support greater access to mental health services and supports for young people, including services and supports provided by school nurses, behavioral health workers or other school staff, to address mental health needs in young people that (when not properly addressed) increase the risk of opioid or another drug misuse.

PREVENT OVERDOSE DEATHS AND OTHER HARMS (HARM REDUCTION)

Support efforts to prevent or reduce overdose deaths or other opioid-related harms through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

Increased availability and distribution of naloxone and other drugs that treat overdoses for first responders, overdose patients, individuals with OUD and their friends and family members, schools, community navigators and outreach workers, persons being released from jail or prison, or other members of the general public.

Public health entities providing free naloxone to anyone in the community.

Training and education regarding naloxone and other drugs that treat overdoses for first responders, overdose patients, patients taking opioids, families, schools, community support groups, and other members of the general public.

Enabling school nurses and other school staff to respond to opioid overdoses, and provide them with naloxone, training, and support.

Expanding, improving, or developing data tracking software and applications for overdoses/naloxone revivals.

Public education relating to emergency responses to overdoses.

Public education relating to immunity and Good Samaritan laws.

Educating first responders regarding the existence and operation of immunity and Good Samaritan laws.

Syringe service programs and other evidence-informed programs to reduce harms associated with intravenous drug use, including supplies, staffing, space, peer support services, referrals to treatment, fentanyl checking, connections to care, and the full range of harm reduction and treatment services provided by these programs.

Expanding access to testing and treatment for infectious diseases such as HIV and Hepatitis C resulting from intravenous opioid use.

Supporting mobile units that offer or provide referrals to harm reduction services, treatment, recovery supports, health care, or other appropriate services to persons that use opioids or persons with OUD and any co-occurring SUD/MH conditions.

Providing training in harm reduction strategies to health care providers, students, peer recovery coaches, recovery outreach specialists, or other professionals that provide care to persons who use opioids or persons with OUD and any co-occurring SUD/MH conditions.

Supporting screening for fentanyl in routine clinical toxicology testing.

FIRST RESPONDERS

In addition to items in section C, D and H relating to first responders, support the following:

Education of law enforcement or other first responders regarding appropriate practices and precautions when dealing with fentanyl or other drugs.

Provision of wellness and support services for first responders and others who experience secondary trauma associated with opioid-related emergency events.

LEADERSHIP, PLANNING AND COORDINATION

Support efforts to provide leadership, planning, coordination, facilitations, training and technical assistance to abate the opioid epidemic through activities, programs, or strategies that may include, but are not limited to, the following:

Statewide, regional, local or community regional planning to identify root causes of addiction and overdose, goals for reducing harms related to the opioid epidemic, and areas and populations with the greatest needs for treatment intervention services, and to support training and technical assistance and other strategies to abate the opioid epidemic described in this opioid abatement strategy list.

A dashboard to (a) share reports, recommendations, or plans to spend opioid settlement funds; (b) to show how opioid settlement funds have been spent; (c) to report program or strategy outcomes; or (d) to track, share or visualize key opioid- or health-related indicators and supports as identified through collaborative statewide, regional, local or community processes.

Invest in infrastructure or staffing at government or not-for-profit agencies to support collaborative, cross-system coordination with the purpose of preventing overprescribing, opioid misuse, or opioid overdoses, treating those with OUD and any co-occurring SUD/MH conditions, supporting them in treatment or recovery, connecting them to care, or implementing other strategies to abate the opioid epidemic described in this opioid abatement strategy list.

Provide resources to staff government oversight and management of opioid abatement programs.

TRAINING

In addition to the training referred to throughout this document, support training to abate the opioid epidemic through activities, programs, or strategies that may include, but are not limited to, those that:

Provide funding for staff training or networking programs and services to improve the capability of government, community, and not-for-profit entities to abate the opioid crisis.

Support infrastructure and staffing for collaborative cross-system coordination to prevent opioid misuse, prevent overdoses, and treat those with OUD and any co-occurring SUD/MH conditions, or implement other strategies to abate the opioid epidemic described in this opioid abatement strategy list (*e.g.*, health care, primary care, pharmacies, PDMPs, etc.).

RESEARCH

Support opioid abatement research that may include, but is not limited to, the following:

Monitoring, surveillance, data collection and evaluation of programs and strategies described in this opioid abatement strategy list.

Research non-opioid treatment of chronic pain.

Research on improved service delivery for modalities such as SBIRT that demonstrate promising but mixed results in populations vulnerable to opioid use disorders.

Research on novel harm reduction and prevention efforts such as the provision of fentanyl test strips.

Research on innovative supply-side enforcement efforts such as improved detection of mail-based delivery of synthetic opioids.

Expanded research on swift/certain/fair models to reduce and deter opioid misuse within criminal justice populations that build upon promising approaches used to address other substances (*e.g.*, Hawaii HOPE and Dakota 24/7).

Epidemiological surveillance of OUD-related behaviors in critical populations, including individuals entering the criminal justice system, including, but not limited to approaches modeled on the Arrestee Drug Abuse Monitoring (“ADAM”) system.


Qualitative and quantitative research regarding public health risks and harm reduction opportunities within illicit drug markets, including surveys of market participants who sell or distribute illicit opioids.

Geospatial analysis of access barriers to MAT and their association with treatment engagement and treatment outcomes.

6. SIGNATURE/SUBMISSION/QUESTIONS

SIGNATURE

By signing below, I certify that the information provided in this document is true, accurate, and complete to the best of my knowledge.



Joe Trotter 4/29/25

PLEASE SUBMIT COMPLETED PACKETS AND QUESTIONS VIA EMAIL TO:

[INSERT CHAMPAIGN COUNTY CONTACT INFO]

4/30/2025

Subject: Funding Request for Harm Reduction Program

To the Opioid Settlement Task Force,

The Champaign-Urbana Public Health District is requesting funding for the Harm Reduction program, which aims to reduce risks associated with substance use in our community. Our evidence-based approach focuses on providing life-saving resources, including overdose prevention, safe use education, access to clean supplies, and connections to treatment and support services.

Our program utilizes an outdoor storage box to reach clients outside of normal business hours. This option started in 2020 during the COVID-19 pandemic and remains popular with our clients. In 2024, 60% of our total syringes distributed were from our storage box. We are seeking funding to modernize this storage box into a vending machine. This vending option would allow CUPHD to have improved data collection on the clients who are using our contactless services. This change would also allow our participants to join the statewide Harm Reduction Project, thereby giving them some legal protections under Illinois statutes to possess syringes. This model of vending harm reduction has become a more common practice nationwide with multiple other states utilizing this service. McKinley Health Center on the University of Illinois campus uses similar vending machines to provide health care resources and Narcan to the student population, and it's provided by the same vendor. We are seeking a one-time award of \$10,730 to purchase this vending machine. This total was quoted by CUPHD's vendor, IDS (see attached). This machine would be temperature-controlled and designed for outdoor settings.

Disposal of sharps and used supplies remains a standard of practice that we wish to improve. Our current sharps kiosk can only handle small amounts of syringes and is not secured. An improved kiosk would allow us to handle larger amounts of syringes and provide a secure location that cannot be tampered with. We are requesting a one-time award for \$2,600 for a sharp disposal kiosk. This total was quoted by CUPHD's vendor, NASEN, who specializes in harm reduction supplies (see attached). It would be bolted into a concrete pad at the side of our building. See photo of current disposal method below.

Between 2021 and 2024, Champaign Urbana Public Health District (CUPHD) distributed an average of 250,000 syringes annually to clients in our harm reduction program. In 2023 alone, 300,000 syringes were accessed through our services. To meet the demand, CUPHD is requesting \$32,094 for one to support these Champaign County residents.

Those supplies include:

- Syringes: \$26,488 (Current Price \$44/500 syringes)
- Cotton Pellets: \$657 (Current Price \$280/10,000 pellets)
- Band-Aids: \$560 (Current Price \$70/2400 band-aids)
- Tourniquets: \$2,036 (Current Price \$182/1,000 tourniquets)
- Cylindrical Metal Containers: \$500 (Current Price \$734/13,800 containers)
- Alcohol Prep Pad: \$133 (Current Price \$38/4,000 pad)
- Sterile Water Container: \$1,720 (Current Price \$99/1,000 containers)

With this additional funding, we will continue our syringe access, enhance service accessibility, and improve health outcomes for these vulnerable populations. Your support will directly contribute to reducing overdose rates, preventing the spread of infections, and promoting overall public health and safety.

We welcome the opportunity to discuss how your investment can make a meaningful impact. Thank you for your time and consideration.

1. Vending Machine for Narcan
2. Kiosk for Sharps Disposal
3. 1 Year Supply Funding

Sincerely,

Joe Trotter
Harm Reduction Program Coordinator
Champaign-Urbana Public Health District
201 W. Kenyon Rd.
Champaign, IL 61820
217-531-5370


Image of our current storage box and sharps disposal:



Harm Reduction Supply Dispenser




Securely dispense harm reduction supplies to minimize health risks associated with drug use. This machine is a great way health officials can promote safe injections, safe smoking and safe sex in their communities.



The Harm Reduction Supply Dispenser can be used to deliver clean needles, clean syringes and disposal containers for used needles.

Making important harm reduction supplies easily accessible to the public can reduce the spread of HIV, Hepatitis C and other infections from shared needles.




Easily Track Usage & Inventory

iQ Technology allows a unique code to be created for one time or multiple uses of the machine. These codes can be managed and tracked for use.

Harm Reduction Supply Dispenser



SD 5000



SD 3000



Re-configure trays to almost any package size in the field with no need for tools.



PUSH-IT (Optional)
With no coils, vend a variety of products with different size, weight and form factors.



iQ Technology
Easily manage your assets and inventory with iQ Technology's real-time analytics and reporting tools.



iVend® Guaranteed Delivery System
Every test kit is guaranteed to dispense and every kit dispensed is tracked through iQ Technology.

	SD5000	SD3000
Selections	Configurable up to 60 Items	Configurable up to 36 Items
Capacity	Typical capacity 350 items, Capacity varies with tray configurations.	Typical capacity 115 items, Capacity varies with tray configurations.
Communication	Web based	
Electrical Requirements	Domestic: 115 VAC/60Hz, 1.2 AMPS; International: 230 VAC/50Hz, 0.6 AMPS	
Height	72"(183 cm)	
Width	41" (104 cm)	29.3" (74.4 cm)
Depth	35.2" (89.4 cm)	
Shipping Weight	628 lbs, Varies with configuration and options	445 lbs, Varies with configuration and options
Standard Features	<ul style="list-style-type: none"> Keypad Point of Interface Guaranteed Delivery Sensor System LED Interior Lighting Software Monitoring 	
Options	<ul style="list-style-type: none"> Badge Reader (Bar Code ID Scanner; PROX Card Reader; Magnetic Strip Card Reader depending on your interface system) Custom Graphic Wrap Shipping Installation 10.1" Touch Screen 	

Users can access medical kits using a variety of access methods including: RFID badge, magnetic strip, Proximity card reader, barcode, personal PIN, Biometrics, credit card reader (retail applications) and more.



Bar Code ID Scanner



Proximity Card Reader



Pin Number



Mag Stripe Reader

NOTE: Models with coils can be easily changed as required for vending different size products.

In order to bring you the best products possible, we continue to improve product design and performance and as such specifications are subject to change without notice. The manufacturer makes no warranties or representations of compliance with any local, state, national or international requirements for the operation of the equipment in any application for which it is capable of being used beyond approvals listed on the product. Any purchaser is required to make an independent analysis of the fitness and legality of the product's usage before it is deployed and must continue to monitor the potential changing nature of compliance requirements. The manufacturer expressly disclaims responsibility for compliance with any laws and affirmatively requires any buyer to make an independent analysis of the fitness and legal basis of any use or application of the subject unit.



Intelligent Dispensing Solutions | 8040 University Blvd. | Des Moines, IA 50325
1-877-771-4446 | info@idsvending.com
www.idsvending.com

© 2021 Intelligent Dispensing Solutions, A Wittern Group Company.

IDS Intelligent Dispensing Solutions

KIOSK 3.0

(without feet)



- + Place Kiosk on the ground where you want it
- + Mark holes on the concrete pad
- + Move kiosk off of pad and pre drill holes with a 3/8" concrete drill bit
- + Line kiosk up with the holes and insert 1 – 3/8" x 3" concrete sleeve anchor into each hole
- + Tighten with a ratchet

If installing with the raised feet, additional assembly required. Ideal for locations exposed to heavy rain & snow

Request for Taxpayer Identification Number and Certification

Go to www.irs.gov/FormW9 for instructions and the latest information.

**Give form to the
 requester. Do not
 send to the IRS.**

Before you begin. For guidance related to the purpose of Form W-9, see *Purpose of Form*, below.

Print or type. See Specific Instructions on page 3.	1 Name of entity/individual. An entry is required. (For a sole proprietor or disregarded entity, enter the owner's name on line 1, and enter the business/disregarded entity's name on line 2.) Champaign-Urbana Public Health District	
	2 Business name/disregarded entity name, if different from above.	
	3a Check the appropriate box for federal tax classification of the entity/individual whose name is entered on line 1. Check only one of the following seven boxes. <input type="checkbox"/> Individual/sole proprietor <input type="checkbox"/> C corporation <input type="checkbox"/> S corporation <input type="checkbox"/> Partnership <input type="checkbox"/> Trust/estate <input type="checkbox"/> LLC. Enter the tax classification (C = C corporation, S = S corporation, P = Partnership) Note: Check the "LLC" box above and, in the entry space, enter the appropriate code (C, S, or P) for the tax classification of the LLC, unless it is a disregarded entity. A disregarded entity should instead check the appropriate box for the tax classification of its owner. <input type="checkbox"/> Other (see instructions) Unit of Local Government	
	4 Exemptions (codes apply only to certain entities, not individuals; see instructions on page 3): Exempt payee code (if any) <u> 3 </u> Exemption from Foreign Account Tax Compliance Act (FATCA) reporting code (if any) _____ (Applies to accounts maintained outside the United States.)	
	3b If on line 3a you checked "Partnership" or "Trust/estate," or checked "LLC" and entered "P" as its tax classification, and you are providing this form to a partnership, trust, or estate in which you have an ownership interest, check this box if you have any foreign partners, owners, or beneficiaries. See instructions <input type="checkbox"/>	
	5 Address (number, street, and apt. or suite no.). See instructions. 201 W. Kenyon Road	
	6 City, state, and ZIP code Champaign, IL 61820	
7 List account number(s) here (optional)		
Requester's name and address (optional)		

Part I Taxpayer Identification Number (TIN)

Enter your TIN in the appropriate box. The TIN provided must match the name given on line 1 to avoid backup withholding. For individuals, this is generally your social security number (SSN). However, for a resident alien, sole proprietor, or disregarded entity, see the instructions for Part I, later. For other entities, it is your employer identification number (EIN). If you do not have a number, see *How to get a TIN*, later.

Note: If the account is in more than one name, see the instructions for line 1. See also *What Name and Number To Give the Requester* for guidelines on whose number to enter.

Social security number										
or										
Employer identification number										
3	7		-	6	0	0	5	4	3	5

Part II Certification

Under penalties of perjury, I certify that:

1. The number shown on this form is my correct taxpayer identification number (or I am waiting for a number to be issued to me); and
2. I am not subject to backup withholding because (a) I am exempt from backup withholding, or (b) I have not been notified by the Internal Revenue Service (IRS) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding; and
3. I am a U.S. citizen or other U.S. person (defined below); and
4. The FATCA code(s) entered on this form (if any) indicating that I am exempt from FATCA reporting is correct.

Certification instructions. You must cross out item 2 above if you have been notified by the IRS that you are currently subject to backup withholding because you have failed to report all interest and dividends on your tax return. For real estate transactions, item 2 does not apply. For mortgage interest paid, acquisition or abandonment of secured property, cancellation of debt, contributions to an individual retirement arrangement (IRA), and, generally, payments other than interest and dividends, you are not required to sign the certification, but you must provide your correct TIN. See the instructions for Part II, later.

Sign Here	Signature of U.S. person 	Date 3-27-25
------------------	------------------------------	---------------------

General Instructions

Section references are to the Internal Revenue Code unless otherwise noted.

Future developments. For the latest information about developments related to Form W-9 and its instructions, such as legislation enacted after they were published, go to www.irs.gov/FormW9.

What's New

Line 3a has been modified to clarify how a disregarded entity completes this line. An LLC that is a disregarded entity should check the appropriate box for the tax classification of its owner. Otherwise, it should check the "LLC" box and enter its appropriate tax classification.

New line 3b has been added to this form. A flow-through entity is required to complete this line to indicate that it has direct or indirect foreign partners, owners, or beneficiaries when it provides the Form W-9 to another flow-through entity in which it has an ownership interest. This change is intended to provide a flow-through entity with information regarding the status of its indirect foreign partners, owners, or beneficiaries, so that it can satisfy any applicable reporting requirements. For example, a partnership that has any indirect foreign partners may be required to complete Schedules K-2 and K-3. See the Partnership Instructions for Schedules K-2 and K-3 (Form 1065).

Purpose of Form

An individual or entity (Form W-9 requester) who is required to file an information return with the IRS is giving you this form because they

**AGREEMENT BY AND BETWEEN THE COUNTY OF CHAMPAIGN, ILLINOIS AND CHAMPAIGN
URBANA PUBLIC HEALTH DISTRICT REGARDING THE USE OF OPIOID SETTLEMENT
FUNDS FOR THE PURCHASE OF HARM REDUCTION EQUIPMENT AND SUPPLIES**

This **AGREEMENT** is entered into by and between the County of Champaign, Illinois ("County"); and Champaign Urbana Public Health District ("CUPHD") hereinafter collectively referred to as "the Parties", regarding funding for harm reduction supplies effective on the last date signed by a Party hereto.

Witnesseth:

WHEREAS, units of local government had conferred upon them the following powers by Article VII, Section 10, of the 1970 Illinois Constitution:

"(A) Units of local government and school districts may contract or otherwise associate themselves, with the State, with other States and their units of local government and school districts, and with the United States to obtain or share services and to exercise, combine or transfer any power or function, in any manner not prohibited by law or ordinance. Units of local government and school districts may contract and otherwise associate with individuals, associations, and corporations in any manner not prohibited by law or by ordinance. Participating units of government may use their credit, revenues and other resources to pay costs and to service debt related to intergovernmental activities"; and

WHEREAS, the County is a unit of local government within the meaning of Article VII, Section 1 of the Illinois Constitution of 1970 and is authorized to enter into contracts with individuals, associations, and corporations in any manner not prohibited by law or by ordinance; and

WHEREAS, the County wishes to utilize opioid settlement funding to address the opioid crisis and support evidence-based strategies for prevention, treatment, and harm reduction; and

WHEREAS, CUPHD operates a harm reduction program aimed at reducing the spread of infectious diseases and preventing overdoses through the distribution of sterile syringes and other resources; and

WHEREAS, harm reduction, especially syringe exchange programs, help to reduce the spread of diseases such as Hepatitis C, HIV and AIDS that are highly communicable and expensive to treat by providing sterile syringes, therefore reducing shared materials; and

WHEREAS, CUPHD desires to replace its current sharps disposal with a larger piece of equipment with a higher capacity that can be installed safely in the ground outside of their facility, add a temperature controlled vending machine for Narcan on its property, and purchase harm reduction supplies to fill the gaps; and

WHEREAS, the County recognizes the importance of harm reduction as a public health strategy and wishes to allocate a portion of its opioid settlement funds to support CUPHD's program; and

WHEREAS, both Parties agree that this funding will enhance community health outcomes and align with the intended use of Opioid Settlement Funds per Attachments C and D, List of Opioid Remediation Uses and Approved Uses of Opioid Settlement Funds; and

WHEREAS, such provision of Opioid Settlement funding shall be construed as a subaward, with CUPHD as the subrecipient, and this Agreement construed as a subrecipient agreement; and

NOW, THEREFORE, in consideration of the premises and the mutual covenants hereafter set forth, the Parties agree as follows:

Section 1. PREAMBLE

The foregoing preambles are hereby incorporated into this Agreement as if fully restated in this Section 1.

Section 2. COUNTY agrees to the following:

- a. COUNTY shall provide CUPHD a one-time payment of \$45,424.00 in opioid settlement funding to assist with purchasing harm reduction supplies for Champaign County opioid-impacted individuals. CUPHD acknowledges that this is a one-time payment and that future funding must be formally requested.
- b. COUNTY shall provide CUPHD a copy of Final Distributor Settlement Agreement (Schedules A and B of Exhibit E of the Opioid Settlement Agreement, attached hereto and) incorporated by reference herein as Attachment C and/or D, and shall provide CUPHD with updates as to any additional terms, conditions, or related communications from the Illinois Department of Human Services and by the Illinois Office of Opioid Settlement Administration within.

Section 3. CUPHD agrees to the following:

- a. CUPHD agrees to utilize the \$45,424.00 in opioid settlement funding from the County to purchase harm reduction equipment and supplies, specifically a vending machine for Narcan, a kiosk for sharps disposal, and a 1-year supply of sterile syringes, cotton pellets, band-aids, tourniquets, cylindrical metal containers, alcohol prep pads, and sterile water containers, to meet their anticipated need.

- b. CUPHD agrees to use the funds exclusively for the purchase of harm reduction supplies and programming support, including but not limited to sterile syringes, cotton pellets, band-aids, tourniquets, cylindrical metal containers, alcohol prep pads, and sterile water containers fentanyl test strips, naloxone, wound care materials, and other harm reduction tools that align with public health best practices to serve opioid-impacted individuals. Funds shall not be used for administrative expenses, salaries, lobbying activities, or any other purpose outside the scope of harm reduction services and the approved uses outlined in Attachment D of this agreement.
- c. CUPHD agrees to comply with all applicable federal, state, and local statutes, rules, regulations, and guidelines governing the use, management, and reporting of opioid settlement funds, including all requirements set forth in Attachments C and D by the Illinois Department of Human Services and by the Illinois Office of Opioid Settlement Administration within.
- d. CUPHD agrees to complete the reporting form attached as Attachment B on a quarterly basis for one year from the date the funds are disbursed and provide it to the Opioid Settlement Task Force; should the Task Force cease to exist the reporting form shall be provided to the Champaign County Board Justice and Social Services Committee. The Champaign County Board or any of its committees may request an in-person review of the reporting form and services provides by CUPHD at any point during the year.
- e. CUPHD certifies that it is not debarred, suspended, proposed for debarment or permanent inclusion on the Illinois Stop Payment List, declared ineligible, or voluntarily excluded from participation in the award as set forth in Attachments C and D or in this Agreement by any federal department or agency, or by the State of Illinois.

Section 4. Terms & Conditions:

a) Compliance

CUPHD shall comply with all applicable federal, state, and local laws and regulations related to harm reduction services, including the lawful distribution of syringes and naloxone.

b) Record-Keeping

CUPHD shall maintain records of all purchases made with the provided funds for a minimum of 3 years and shall make such records available to the County upon request. The County may conduct a financial or programmatic review to verify the appropriate use of provided funds.

c) Independent Status

CUPHD acknowledges that it is acting as an independent entity and not as an agent, employee, or representative of Champaign County Government. This AGREEMENT does not create any legal partnership or joint venture between the parties.

d) Amendments

This AGREEMENT may be amended only by writing signed by both parties.

e) Duration; Termination

The AGREEMENT shall remain in effect for one year from the date of payment. The County reserves the right to terminate this Agreement if CUPHD fails to meet its obligations.

f) Repayment and Misuse of Funds

If CUPHD is found to have used funds for unauthorized purposes, fails to provide the required report, or ceases to provide harm reduction services during the AGREEMENT period, the County reserves the right to request repayment of funds in whole or in part.

g) Indemnification

Each Party agrees to indemnify and hold harmless the other Party and its affiliates, officers, agents, employees, and permitted successors and assigns against any and all claims, losses, damages, liabilities, penalties, punitive damages, expenses, reasonable legal fees and costs of any kind or amount whatsoever, to the extent they result from the negligence of the Indemnifying Party or its permitted successors and assigns in connection with the services provided under this Agreement, or to the extent they result from the breach of this Agreement by the Indemnifying Party. This indemnification and hold harmless obligation shall remain in full force and effect even after termination of the Agreement by its natural termination or the early termination by either party.

SIGNATURE PAGE

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly authorized officers on the date(s) below.

The County of Champaign, Illinois

Approved: _____

Steve Summers
County Executive
Champaign County

Date: _____

Approved: _____

Jennifer Locke
Board Chair
Champaign County

Date: _____

Champaign-Urbana Public Health District

Approved: _____

Julie Pryde
Public Health Administrator

Date: _____

Attachment A: CUPHD's Request



OPIOID SETTLEMENT FUNDING APPLICATION

1. APPLICATION INFORMATION

Date Submitted	4/30/2025	Project Date Range	Jan - Dec 2025
Name of Project or Proposal	Harm Reduction 2025	Total Funding Requested	\$45,424
Purpose of Request for Funding	Service Expansion	Date Funding Requested by	Sept 2025

Organization

Name	Champaign-Urbana Public Health District
Address	201 W. Kenyon Rd, Champaign, IL 61820
Email Address	info@c-uphd.org
Phone Number	217-352-7961
Website	www.c-uphd.org
Legal Status of your Organization	Local Unit of Government

Point of Contact

Name	Joe Trotter
Address	201 W. Kenyon Rd, Champaign, IL 61820
Email Address	jtrotter@c-uphd.org
Phone Number	217-531-5370

3/27/2025

Subject: Funding Request for Harm Reduction Program

To the Opioid Settlement Task Force,

The Champaign-Urbana Public Health District is requesting funding for the Harm Reduction program, which aims to reduce risks associated with substance use in our community. Our evidence-based approach focuses on providing life-saving resources, including overdose prevention, safe use education, access to clean supplies, and connections to treatment and support services.

Our program utilizes an outdoor storage box to reach clients outside of normal business hours. This option started in 2020 during the COVID-19 pandemic and remains popular with our clients. In 2024, 60% of our total syringes distributed were from our storage box. We are seeking funding to modernize this storage box into a vending machine. This vending option would allow CUPHD to have improved data collection on the clients who are using our contactless services. This change would also allow our participants to join the statewide Harm Reduction Project, thereby giving them some legal protections under Illinois statutes to possess syringes. This model of vending harm reduction has become a more common practice nationwide with multiple other states utilizing this service. McKinley Health Center on the University of Illinois campus uses similar vending machines to provide health care resources and Narcan to the student population. We are seeking a one-time award of \$10,730 to purchase this vending machine.

Disposal of sharps and used supplies remains a standard of practice that we wish to improve. Our current sharps kiosk can only handle small amounts of syringes and is not secured. An improved kiosk would allow us to handle larger amounts of syringes and provide a secure location that cannot be tampered with. We are requesting a one-time award for \$2,600 for a sharp disposal kiosk.

Between 2021 and 2024, Champaign Urbana Public Health District (CUPHD) distributed an average of 250,000 syringes annually to clients in our harm reduction program. In 2023 alone, 300,000 syringes were accessed through our services. To meet the demand, CUPHD is requesting \$32,094 for each year of the Settlement Term to support these Champaign County residents.

Those supplies include:

- Syringes: \$26,488 (Current Price \$44/500 syringes)
- Cotton Pellets: \$657 (Current Price \$280/10,000 pellets)
- Band-Aids: \$560 (Current Price \$70/2400 band-aids)
- Tourniquets: \$2,036 (Current Price \$182/1,000 tourniquets)
- Cylindrical Metal Containers: \$500 (Current Price \$734/13,800 containers)
- Alcohol Prep Pad: \$133 (Current Price \$38/4,000 pad)
- Sterile Water Container: \$1,720 (Current Price \$99/1,000 containers)

With this additional funding, we will continue our syringe access, enhance service accessibility, and improve health outcomes for these vulnerable populations. Your support will directly contribute to reducing overdose rates, preventing the spread of infections, and promoting overall public health and safety.

We welcome the opportunity to discuss how your investment can make a meaningful impact. Thank you for your time and consideration.

Image of our current storage box and sharps disposal:



KIOSK 3.0
(without feet)



- + Place Kiosk on the ground where you want it
- + Mark holes on the concrete pad
- + Move kiosk off of pad and pre drill holes with a 3/8" concrete drill bit
- + Line kiosk up with the holes and insert 1 – 3/8" x 3" concrete sleeve anchor into each hole
- + Tighten with a ratchet


If installing with the raised feet, additional assembly required. Ideal for locations exposed to heavy rain & snow

Harm Reduction Supply Dispenser



SD 5000

SD 3000



Re-configure trays to almost any package size in the field with no need for tools.



PUSH-IT (Optional)
With no coils, vend a variety of products with different size, weight and form factors.



iQ Technology
Easily manage your assets and inventory with iQ Technology's real-time analytics and reporting tools.



iVend® Guaranteed Delivery System
Every test kit is guaranteed to dispense and every kit dispensed is tracked through iQ Technology.

	SD5000	SD3000
Selections	Configurable up to 60 Items	Configurable up to 36 Items
Capacity	Typical capacity 350 items, Capacity varies with tray configurations.	Typical capacity 115 items, Capacity varies with tray configurations.
Communication	Web based	
Electrical Requirements	Domestic: 115 VAC/60Hz, 1.2 AMPS; International: 230 VAC/50Hz, 0.6 AMPS	
Height	72" (183 cm)	
Width	41" (104 cm)	29.3" (74.4 cm)
Depth	35.2" (89.4 cm)	
Shipping Weight	628 lbs. Varies with configuration and options	445 lbs. Varies with configuration and options
Standard Features	<ul style="list-style-type: none"> Keypad Point of Interface Guaranteed Delivery Sensor System LED Interior Lighting Software Monitoring 	
Options	<ul style="list-style-type: none"> Badge Reader (Bar Code ID Scanner; PROX Card Reader; Magnetic Strip Card Reader depending on your interface system) Custom Graphic Wrap Shipping Installation 10.1" Touch Screen 	

Users can access medical kits using a variety of access methods including: RFID badge, magnetic strip, Proximity card reader, barcode, personal PIN, Biometrics, credit card reader (retail applications) and more.



Bar Code ID Scanner



Proximity Card Reader



Pin Number



Mag Stripe Reader

NOTE: Models with coils can be easily changed as required for vending different size products.

In order to bring you the best products possible, we continue to improve product design and performance and as such specifications are subject to change without notice. The manufacturer makes no warranties or representations of compliance with any local, state, national or international requirements for the operation of the equipment in any application for which it is capable of being used beyond approval based on the product. Any purchaser is required to make an independent analysis of the fitness and legality of the product's usage before it is deployed and must continue to monitor the potential changing nature of compliance requirements. The manufacturer expressly disclaims responsibility for compliance with any laws and affirmatively requires any buyer to make an independent analysis of the fitness and legal basis of any use or application of the subject unit.



Intelligent Dispensing Solutions | 8040 University Blvd. | Des Moines, IA 50325
1-877-771-4446 | info@idsvending.com
www.idsvending.com

© 2021 Intelligent Dispensing Solutions, A Wittern Group Company.



Attachment B: Reporting Form

Reporting form for harm reduction supplies distributed in Champaign County from May 01, 2025 through April 30, 2026 per use of opioid settlement funds.

Reporting Period 2/1/26 to 4/30/26

Submission Date: May 16, 2025

Contact Person:

Phone Number:

Email Address:

1. Total Distribution Data:
 - a. The total number of harm reduction materials purchased with County-provided opioid settlement funds.
 - b. The total number of syringes and other applicable harm reduction materials distributed to Champaign County program participants.
 - i. The total number of syringes and other applicable harm reduction materials distributed to CUPHD program participants (not limited to Champaign County).
2. Geographic Distribution Analysis
 - a. A ranking of zip codes served, based on highest number of requests and distribution.
 - b. A breakdown of distribution by zip code, including the numbers of individuals served in each area in Champaign County.
3. Program Insights:
 - a. Any notable trends in service demand.
 - b. Challenges or barriers encountered in implementing the program.
 - c. Any relevant participant feedback or observed outcomes.

By signing, I certify that the information provided in this report is accurate to the best of my knowledge.

X

May 16, 2025

Name, Title

Attachment C: List of Opioid Remediation Uses

Final Distributor Settlement Agreement – Exhibit E

Schedule A Core Strategies

Settling States and Exhibit G Participants may choose from among the abatement strategies listed in Schedule B. However, priority may be given to the following core abatement strategies (“*Core Strategies*”).¹

¹ As used in this Schedule A, words like “expand,” “fund,” “provide” or the like shall not indicate a preference for new or existing programs.

NALOXONE OR OTHER FDA-APPROVED DRUG TO REVERSE OPIOID OVERDOSES

Expand training for first responders, schools, community support groups and families; and

Increase distribution to individuals who are uninsured or whose insurance does not cover the needed service.

MEDICATION-ASSISTED TREATMENT (“MAT”) DISTRIBUTION AND OTHER OPIOID-RELATED TREATMENT

Increase distribution of MAT to individuals who are uninsured or whose insurance does not cover the needed service;

Provide education to school-based and youth-focused programs that discourage or prevent misuse;

Provide MAT education and awareness training to healthcare providers, EMTs, law enforcement, and other first responders; and

Provide treatment and recovery support services such as residential and inpatient treatment, intensive outpatient treatment, outpatient therapy or counseling, and recovery housing that allow or integrate medication and with other support services.

PREGNANT & POSTPARTUM WOMEN

Expand Screening, Brief Intervention, and Referral to Treatment (“*SBIRT*”) services to non-Medicaid eligible or uninsured pregnant women;

Expand comprehensive evidence-based treatment and recovery services, including MAT, for women with co- occurring Opioid Use Disorder (“*OUD*”) and other

Substance Use Disorder (“*SUD*”)/Mental Health disorders for uninsured individuals for up to 12 months postpartum; and

Provide comprehensive wrap-around services to individuals with OUD, including housing, transportation, job placement/training, and childcare.

EXPANDING TREATMENT FOR NEONATAL ABSTINENCE SYNDROME (“NAS”)

Expand comprehensive evidence-based and recovery support for NAS babies;

Expand services for better continuum of care with infant- need dyad; and

Expand long-term treatment and services for medical monitoring of NAS babies and their families.

EXPANSION OF WARM HAND-OFF PROGRAMS AND RECOVERY SERVICES

Expand services such as navigators and on-call teams to begin MAT in hospital emergency departments;

Expand warm hand-off services to transition to recovery services;

Broaden scope of recovery services to include co-occurring SUD or mental health conditions;

Provide comprehensive wrap-around services to individuals in recovery, including housing, transportation, job placement/training, and childcare; and

Hire additional social workers or other behavioral health workers to facilitate expansions above.

TREATMENT FOR INCARCERATED POPULATION

Provide evidence-based treatment and recovery support, including MAT for persons with OUD and co-occurring SUD/MH disorders within and transitioning out of the criminal justice system; and

Increase funding for jails to provide treatment to inmates with OUD.

PREVENTION PROGRAMS

Funding for media campaigns to prevent opioid use (similar to the FDA’s “Real Cost” campaign to prevent youth from misusing tobacco);

Funding for evidence-based prevention programs in schools;

Funding for medical provider education and outreach regarding best prescribing practices for opioids consistent with CDC guidelines, including providers at hospitals (academic detailing);

Funding for community drug disposal programs; and

Funding and training for first responders to participate in pre- arrest diversion programs, post-overdose response teams, or similar strategies that connect at-risk individuals to behavioral health services and supports.

EXPANDING SYRINGE SERVICE PROGRAMS

Provide comprehensive syringe services programs with more wrap-around services, including linkage to OUD treatment, access to sterile syringes and linkage to care and treatment of infectious diseases.

EVIDENCE-BASED DATA COLLECTION AND RESEARCH ANALYZING THE EFFECTIVENESS OF THE ABATEMENT STRATEGIES WITHIN THE STATE

Attachment D: Approved Uses of Opioid Settlement Funds

Final Distributor Settlement Agreement – Exhibit E

Schedule B Approved Uses

² As used in this Schedule B, words like “expand,” “fund,” “provide” or the like shall not indicate a preference for new or existing programs.

Support treatment of Opioid Use Disorder (OUD) and any co-occurring Substance Use Disorder or Mental Health (SUD/MH) conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

TREAT OPIOID USE DISORDER (OUD)

Support treatment of Opioid Use Disorder (“OUD”) and any co-occurring Substance Use Disorder or Mental Health (“SUD/MH”) conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, those that:²

Expand availability of treatment for OUD and any co-occurring SUD/MH conditions, including all forms of Medication-Assisted Treatment (“MAT”) approved by the U.S. Food and Drug Administration.

Support and reimburse evidence-based services that adhere to the American Society of Addiction Medicine (“ASAM”) continuum of care for OUD and any co-occurring SUD/MH conditions.

Expand telehealth to increase access to treatment for OUD and any co-occurring SUD/MH conditions, including MAT, as well as counseling, psychiatric support, and other treatment and recovery support services.

Improve oversight of Opioid Treatment Programs (“OTPs”) to assure evidence-based or evidence-informed practices such as adequate methadone dosing and low threshold approaches to treatment.

Support mobile intervention, treatment, and recovery services, offered by qualified professionals and service providers, such as peer recovery coaches, for persons with OUD and any co-occurring SUD/MH conditions and for persons who have experienced an opioid overdose.

Provide treatment of trauma for individuals with OUD (*e.g.*, violence, sexual assault, human trafficking, or adverse childhood experiences) and family members (*e.g.*, surviving family members after an overdose or overdose fatality), and training of health care personnel to identify and address such trauma.

Support evidence-based withdrawal management services for people with OUD and any co-occurring mental health conditions.

Provide training on MAT for health care providers, first responders, students, or other supporting professionals, such as peer recovery coaches or recovery outreach specialists, including telementoring to assist community-based providers in rural or underserved areas.

Support workforce development for addiction professionals who work with persons with OUD and any co-occurring SUD/MH conditions.

Offer fellowships for addiction medicine specialists for direct patient care, instructors, and clinical research for treatments.

Offer scholarships and supports for behavioral health practitioners or workers involved in addressing OUD and any co-occurring SUD/MH or mental health conditions, including, but not limited to, training, scholarships, fellowships, loan repayment programs, or other incentives for providers to work in rural or underserved areas.

Provide funding and training for clinicians to obtain a waiver under the federal Drug Addiction Treatment Act of 2000 (“*DATA 2000*”) to prescribe MAT for OUD, and provide technical assistance and professional support to clinicians who have obtained a DATA 2000 waiver.

Disseminate web-based training curricula, such as the American Academy of Addiction Psychiatry’s Provider Clinical Support Service–Opioids web-based training curriculum and motivational interviewing.

Develop and disseminate new curricula, such as the American Academy of Addiction Psychiatry’s Provider Clinical Support Service for Medication–Assisted Treatment.

SUPPORT PEOPLE IN TREATMENT AND RECOVERY

Support people in recovery from OUD and any co-occurring SUD/MH conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the programs or strategies that:

Provide comprehensive wrap-around services to individuals with OUD and any co-occurring SUD/MH conditions, including housing, transportation, education, job placement, job training, or childcare.

Provide the full continuum of care of treatment and recovery services for OUD and any co-occurring SUD/MH conditions, including supportive housing, peer support services and counseling, community navigators, case management, and connections to community-based services.

Provide counseling, peer-support, recovery case management and residential treatment with access to medications for those who need it to persons with OUD and any co-occurring SUD/MH conditions.

Provide access to housing for people with OUD and any co-occurring SUD/MH conditions, including supportive housing, recovery housing, housing assistance programs, training for housing providers, or recovery housing programs that allow or integrate FDA-approved medication with other support services.

Provide community support services, including social and legal services, to assist in deinstitutionalizing persons with OUD and any co-occurring SUD/MH conditions.

Support or expand peer-recovery centers, which may include support groups, social events, computer access, or other services for persons with OUD and any co-occurring SUD/MH conditions.

Provide or support transportation to treatment or recovery programs or services for persons with OUD and any co-occurring SUD/MH conditions.

Provide employment training or educational services for persons in treatment for or recovery from OUD and any co-occurring SUD/MH conditions.

Identify successful recovery programs such as physician, pilot, and college recovery programs, and provide support and technical assistance to increase the number and capacity of high-quality programs to help those in recovery.

Engage non-profits, faith-based communities, and community coalitions to support people in treatment and recovery and to support family members in their efforts to support the person with OUD in the family.

Provide training and development of procedures for government staff to appropriately interact and provide social and other services to individuals with or in recovery from OUD, including reducing stigma.

Support stigma reduction efforts regarding treatment and support for persons with OUD, including reducing the stigma on effective treatment.

Create or support culturally appropriate services and programs for persons with OUD and any co-occurring SUD/MH conditions, including new Americans.

Create and/or support recovery high schools.

Hire or train behavioral health workers to provide or expand any of the services or supports listed above.

CONNECT PEOPLE WHO NEED HELP TO THE HELP THEY NEED (CONNECTIONS TO CARE)

Provide connections to care for people who have—or are at risk of developing—OUD and any co-occurring SUD/MH conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, those that:

Ensure that health care providers are screening for OUD and other risk factors and know how to appropriately counsel and treat (or refer if necessary) a patient for OUD treatment.

Fund SBIRT programs to reduce the transition from use to disorders, including SBIRT services to pregnant women who are uninsured or not eligible for Medicaid.

Provide training and long-term implementation of SBIRT in key systems (health, schools, colleges, criminal justice, and probation), with a focus on youth and young adults when transition from misuse to opioid disorder is common.

Purchase automated versions of SBIRT and support ongoing costs of the technology.

Expand services such as navigators and on-call teams to begin MAT in hospital emergency departments.

Provide training for emergency room personnel treating opioid overdose patients on post-discharge planning, including community referrals for MAT, recovery case management or support services.

Support hospital programs that transition persons with OUD and any co-occurring SUD/MH conditions, or persons who have experienced an opioid overdose, into clinically appropriate follow-up care through a bridge clinic or similar approach.

Support crisis stabilization centers that serve as an alternative to hospital emergency departments for persons with OUD and any co-occurring SUD/MH conditions or persons that have experienced an opioid overdose.

Support the work of Emergency Medical Systems, including peer support specialists, to connect individuals to treatment or other appropriate services following an opioid overdose or other opioid-related adverse event.

Provide funding for peer support specialists or recovery coaches in emergency departments, detox facilities, recovery centers, recovery housing, or similar settings; offer services, supports, or connections to care to persons with OUD and any co-occurring SUD/MH conditions or to persons who have experienced an opioid overdose.

Expand warm hand-off services to transition to recovery services.

Create or support school-based contacts that parents can engage with to seek immediate treatment services for their child; and support prevention, intervention, treatment, and recovery programs focused on young people.

Develop and support best practices on addressing OUD in the workplace.

Support assistance programs for health care providers with OUD.

Engage non-profits and the faith community as a system to support outreach for treatment.

Support centralized call centers that provide information and connections to appropriate services and supports for persons with OUD and any co-occurring SUD/MH conditions.

ADDRESS THE NEEDS OF CRIMINAL JUSTICE-INVOLVED PERSONS

Address the needs of persons with OUD and any co-occurring SUD/MH conditions who are involved in, are at risk of becoming involved in, or are transitioning out of the criminal justice system through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, those that:

Support pre-arrest or pre-arraignment diversion and deflection strategies for persons with OUD and any co-occurring SUD/MH conditions, including established strategies such as:

Self-referral strategies such as the Angel Programs or the Police Assisted Addiction Recovery Initiative (“*PAARI*”);

Active outreach strategies such as the Drug Abuse Response Team (“*DART*”) model;

“Naloxone Plus” strategies, which work to ensure that individuals who have received naloxone to reverse the effects of an overdose are then linked to treatment programs or other appropriate services;

Officer prevention strategies, such as the Law Enforcement Assisted Diversion (“*LEAD*”) model;

Officer intervention strategies such as the Leon County, Florida Adult Civil Citation Network or the Chicago Westside Narcotics Diversion to Treatment Initiative; or

Co-responder and/or alternative responder models to address OUD-related 911 calls with greater SUD expertise.

Support pre-trial services that connect individuals with OUD and any co-occurring SUD/MH conditions to evidence-informed treatment, including MAT, and related services.

Support treatment and recovery courts that provide evidence-based options for persons with OUD and any co-occurring SUD/MH conditions.

Provide evidence-informed treatment, including MAT, recovery support, harm reduction, or other appropriate services to individuals with OUD and any co-occurring SUD/MH conditions who are incarcerated in jail or prison.

Provide evidence-informed treatment, including MAT, recovery support, harm reduction, or other appropriate services to individuals with OUD and any co-occurring SUD/MH conditions who are leaving jail or prison or have recently left jail or prison, are on probation or parole, are under community corrections supervision, or are in re-entry programs or facilities.

Support critical time interventions (“CTI”), particularly for individuals living with dual-diagnosis OUD/serious mental illness, and services for individuals who face immediate risks and service needs and risks upon release from correctional settings.

Provide training on best practices for addressing the needs of criminal justice-involved persons with OUD and any co-occurring SUD/MH conditions to law enforcement, correctional, or judicial personnel or to providers of treatment, recovery, harm reduction, case management, or other services offered in connection with any of the strategies described in this section.

ADDRESS THE NEEDS OF PREGNANT OR PARENTING WOMEN AND THEIR FAMILIES, INCLUDING BABIES WITH NEONATAL ABSTINENCE SYNDROME

Address the needs of pregnant or parenting women with OUD and any co-occurring SUD/MH conditions, and the needs of their families, including babies with neonatal

abstinence syndrome (“NAS”), through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, those that:

Support evidence-based or evidence-informed treatment, including MAT, recovery services and supports, and prevention services for pregnant women—or women who could become pregnant—who have OUD and any co-occurring SUD/MH conditions, and other measures to educate and provide support to families affected by Neonatal Abstinence Syndrome.

Expand comprehensive evidence-based treatment and recovery services, including MAT, for uninsured women with OUD and any co-occurring SUD/MH conditions for up to 12 months postpartum.

Provide training for obstetricians or other healthcare personnel who work with pregnant women and their families regarding treatment of OUD and any co-occurring SUD/MH conditions.

Expand comprehensive evidence-based treatment and recovery support for NAS babies; expand services for better continuum of care with infant-need dyad; and expand long-term treatment and services for medical monitoring of NAS babies and their families.

Provide training to health care providers who work with pregnant or parenting women on best practices for compliance with federal requirements that children born with NAS get referred to appropriate services and receive a plan of safe care.

Provide child and family supports for parenting women with OUD and any co-occurring SUD/MH conditions.

Provide enhanced family support and childcare services for parents with OUD and any co-occurring SUD/MH conditions.

Provide enhanced support for children and family members suffering trauma as a result of addiction in the family; and offer trauma-informed behavioral health treatment for adverse childhood events.

Offer home-based wrap-around services to persons with OUD and any co-occurring SUD/MH conditions, including, but not limited to, parent skills training.

Provide support for Children's Services—Fund additional positions and services, including supportive housing and other residential services, relating to children being removed from the home and/or placed in foster care due to custodial opioid use.

PREVENT OVER-PRESCRIBING AND ENSURE APPROPRIATE PRESCRIBING AND DISPENSING OF OPIOIDS

Support efforts to prevent over-prescribing and ensure appropriate prescribing and dispensing of opioids through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

Funding medical provider education and outreach regarding best prescribing practices for opioids consistent with the Guidelines for Prescribing Opioids for Chronic Pain from the U.S. Centers for Disease Control and Prevention, including providers at hospitals (academic detailing).

Training for health care providers regarding safe and responsible opioid prescribing, dosing, and tapering patients off opioids.

Continuing Medical Education (CME) on appropriate prescribing of opioids.

Providing Support for non-opioid pain treatment alternatives, including training providers to offer or refer to multi-modal, evidence-informed treatment of pain.

Supporting enhancements or improvements to Prescription Drug Monitoring Programs ("PDMPs"), including, but not limited to, improvements that:

Increase the number of prescribers using PDMPs;

Improve point-of-care decision-making by increasing the quantity, quality, or format of data available to prescribers using PDMPs, by improving the interface that prescribers use to access PDMP data, or both; or

Enable states to use PDMP data in support of surveillance or intervention strategies, including MAT referrals and follow-up for individuals identified within PDMP data as likely to experience OUD in a manner that complies with all relevant privacy and security laws and rules.

Ensuring PDMPs incorporate available overdose/naloxone deployment data, including the United States Department of Transportation's Emergency Medical Technician overdose database in a manner that complies with all relevant privacy and security laws and rules.

Increasing electronic prescribing to prevent diversion or forgery.

Educating dispensers on appropriate opioid dispensing.

PREVENT MISUSE OF OPIOIDS

Support efforts to discourage or prevent misuse of opioids through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

Funding media campaigns to prevent opioid misuse.

Corrective advertising or affirmative public education campaigns based on evidence.

Public education relating to drug disposal.

Drug take-back disposal or destruction programs.

Funding community anti-drug coalitions that engage in drug prevention efforts.

Supporting community coalitions in implementing evidence-informed prevention, such as reduced social access and physical access, stigma reduction—including staffing, educational campaigns, support for people in treatment or recovery, or training of coalitions in evidence-informed implementation, including the Strategic Prevention Framework developed by the U.S. Substance Abuse and Mental Health Services Administration (“SAMHSA”).

Engaging non-profits and faith-based communities as systems to support prevention.

Funding evidence-based prevention programs in schools or evidence-informed school and community education programs and campaigns for students, families, school employees, school athletic programs, parent-teacher and student associations, and others.

School-based or youth-focused programs or strategies that have demonstrated effectiveness in preventing drug misuse and seem likely to be effective in preventing the uptake and use of opioids.

Create or support community-based education or intervention services for families, youth, and adolescents at risk for OUD and any co-occurring SUD/MH conditions.

Support evidence-informed programs or curricula to address mental health needs of young people who may be at risk of misusing opioids or other drugs, including emotional modulation and resilience skills.

Support greater access to mental health services and supports for young people, including services and supports provided by school nurses, behavioral health workers or other school staff, to address mental health needs in young people that (when not properly addressed) increase the risk of opioid or another drug misuse.

PREVENT OVERDOSE DEATHS AND OTHER HARMS (HARM REDUCTION)

Support efforts to prevent or reduce overdose deaths or other opioid-related harms through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

Increased availability and distribution of naloxone and other drugs that treat overdoses for first responders, overdose patients, individuals with OUD and their friends and family members, schools, community navigators and outreach workers, persons being released from jail or prison, or other members of the general public.

Public health entities providing free naloxone to anyone in the community.

Training and education regarding naloxone and other drugs that treat overdoses for first responders, overdose patients, patients taking opioids, families, schools, community support groups, and other members of the general public.

Enabling school nurses and other school staff to respond to opioid overdoses, and provide them with naloxone, training, and support.

Expanding, improving, or developing data tracking software and applications for overdoses/naloxone revivals.

Public education relating to emergency responses to overdoses.

Public education relating to immunity and Good Samaritan laws.

Educating first responders regarding the existence and operation of immunity and Good Samaritan laws.

Syringe service programs and other evidence-informed programs to reduce harms associated with intravenous drug use, including supplies, staffing, space, peer support services, referrals to treatment, fentanyl checking, connections to care, and the full range of harm reduction and treatment services provided by these programs.

Expanding access to testing and treatment for infectious diseases such as HIV and Hepatitis C resulting from intravenous opioid use.

Supporting mobile units that offer or provide referrals to harm reduction services, treatment, recovery supports, health care, or other appropriate services to persons that use opioids or persons with OUD and any co-occurring SUD/MH conditions.

Providing training in harm reduction strategies to health care providers, students, peer recovery coaches, recovery outreach specialists, or other professionals that provide care to persons who use opioids or persons with OUD and any co-occurring SUD/MH conditions.

Supporting screening for fentanyl in routine clinical toxicology testing.

FIRST RESPONDERS

In addition to items in section C, D and H relating to first responders, support the following:

Education of law enforcement or other first responders regarding appropriate practices and precautions when dealing with fentanyl or other drugs.

Provision of wellness and support services for first responders and others who experience secondary trauma associated with opioid-related emergency events.

LEADERSHIP, PLANNING AND COORDINATION

Support efforts to provide leadership, planning, coordination, facilitations, training and technical assistance to abate the opioid epidemic through activities, programs, or strategies that may include, but are not limited to, the following:

Statewide, regional, local or community regional planning to identify root causes of addiction and overdose, goals for reducing harms related to the opioid epidemic, and areas and populations with the greatest needs for treatment intervention services, and to support training and technical assistance and other strategies to abate the opioid epidemic described in this opioid abatement strategy list.

A dashboard to (a) share reports, recommendations, or plans to spend opioid settlement funds; (b) to show how opioid settlement funds have been spent; (c) to report program or strategy outcomes; or (d) to track, share or visualize key opioid- or health-related indicators and supports as identified through collaborative statewide, regional, local or community processes.

Invest in infrastructure or staffing at government or not-for-profit agencies to support collaborative, cross-system coordination with the purpose of preventing overprescribing, opioid misuse, or opioid overdoses, treating those with OUD and any co-occurring SUD/MH conditions, supporting them in treatment or recovery, connecting them to care, or implementing other strategies to abate the opioid epidemic described in this opioid abatement strategy list.

Provide resources to staff government oversight and management of opioid abatement programs.

TRAINING

In addition to the training referred to throughout this document, support training to abate the opioid epidemic through activities, programs, or strategies that may include, but are not limited to, those that:

Provide funding for staff training or networking programs and services to improve the capability of government, community, and not-for-profit entities to abate the opioid crisis.

Support infrastructure and staffing for collaborative cross-system coordination to prevent opioid misuse, prevent overdoses, and treat those with OUD and any co-occurring SUD/MH conditions, or implement other strategies to abate the opioid epidemic described in this opioid abatement strategy list (*e.g.*, health care, primary care, pharmacies, PDMPs, etc.).

RESEARCH

Support opioid abatement research that may include, but is not limited to, the following:

Monitoring, surveillance, data collection and evaluation of programs and strategies described in this opioid abatement strategy list.

Research non-opioid treatment of chronic pain.

Research on improved service delivery for modalities such as SBIRT that demonstrate promising but mixed results in populations vulnerable to opioid use disorders.

Research on novel harm reduction and prevention efforts such as the provision of fentanyl test strips.

Research on innovative supply-side enforcement efforts such as improved detection of mail-based delivery of synthetic opioids.

Expanded research on swift/certain/fair models to reduce and deter opioid misuse within criminal justice populations that build upon promising approaches used to address other substances (*e.g.*, Hawaii HOPE and Dakota 24/7).

Epidemiological surveillance of OUD-related behaviors in critical populations, including individuals entering the criminal justice system, including, but not limited to approaches modeled on the Arrestee Drug Abuse Monitoring (“ADAM”) system.

Qualitative and quantitative research regarding public health risks and harm reduction opportunities within illicit drug markets, including surveys of market participants who sell or distribute illicit opioids.

Geospatial analysis of access barriers to MAT and their association with treatment engagement and treatment outcomes